var title_f4_48_4864="Paintball purpura";
var content_f4_48_4864=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Purpura due to a paintball injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An annular purpuric lesion developed on this patient after getting struck by a paintball.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4864=[""].join("\n");
var outline_f4_48_4864=null;
var title_f4_48_4865="Nail excision en bloc";
var content_f4_48_4865=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F85736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F85736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Margins for en bloc nail excision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4865=[""].join("\n");
var outline_f4_48_4865=null;
var title_f4_48_4866="India ink marking a flat lesion";
var content_f4_48_4866=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    India ink staining",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A flat lesion is visible at the three o'clock position during colonoscopy (left panel). The lesion has been stained circumferentially for later identification of the site (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome D Waye, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4866=[""].join("\n");
var outline_f4_48_4866=null;
var title_f4_48_4867="Polyneuropathy systemic disease";
var content_f4_48_4867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54853%7ENEURO%2F69751%7EPC%2F58391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54853%7ENEURO%2F69751%7EPC%2F58391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Polyneuropathy associated with systemic diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Systemic disease",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Axonal",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Demyelinating",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Sensory versus motor",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Autonomic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        A",
"       </td>",
"       <td class=\"subtitle2\">",
"        SA",
"       </td>",
"       <td class=\"subtitle2\">",
"        C",
"       </td>",
"       <td class=\"subtitle2\">",
"        A",
"       </td>",
"       <td class=\"subtitle2\">",
"        SA",
"       </td>",
"       <td class=\"subtitle2\">",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes mellitus",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        S, SM, rarely M",
"       </td>",
"       <td>",
"        &plusmn; to +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Critical illness (sepsis)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        M &gt; S",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carcinoma (late)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S &gt; M",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Less common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uremia",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin deficiency (excluding B12)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B12 deficiency",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic liver disease",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        S or SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malabsorption (sprue, celiac disease)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S or SM",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carcinoma (sensorimotor)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carcinoma (demyelinating)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        _",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HIV infection",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S &gt;&gt; M",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lyme disease",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S &gt; M",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphoma, including Hodgkin's",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        See above",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple myeloma, osteosclerotic or solitary plasmacytoma type*",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"9\">",
"        Benign monoclonal gammopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist2\">",
"        IgA",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        &plusmn;",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        SM",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist2\">",
"        IgG",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        &plusmn;",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        SM",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist2\">",
"        IgM",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        &plusmn;",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        SM or S",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Porphyria (3 types)",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        M or SM",
"       </td>",
"       <td>",
"        &plusmn; to +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypoglycemia",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        M",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary biliary cirrhosis",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary systemic amyloidosis",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypothyroidism",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic obstructive lung disease",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S or SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acromegaly",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carcinoma (sensory)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Pure S",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polycythemia vera",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryoglobulinemia",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: usually; &plusmn;: sometimes; -: rare if ever; A: acute; SA: subacute; C: chronic; S: sensory; M: motor; SM: sensorimotor.",
"     <br>",
"      * Some cases associated with POEMS syndrome.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with data from: Fauci AS, Braunwald E, Isselbacher KJ, et al (Eds). Harrison's Principles of Internal Medicine, 14th ed, McGraw-Hill Company, Inc., New York 1998. p.2460.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Polyneuropathy associated with drugs and environmental toxins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Systemic disease",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Axonal",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Demyelinating",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Sensory versus motor",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Autonomic",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        CNS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        A",
"       </td>",
"       <td class=\"subtitle2\">",
"        SA",
"       </td>",
"       <td class=\"subtitle2\">",
"        C",
"       </td>",
"       <td class=\"subtitle2\">",
"        A",
"       </td>",
"       <td class=\"subtitle2\">",
"        SA",
"       </td>",
"       <td class=\"subtitle2\">",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\" rowspan=\"1\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amiodarone",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aurothioglucose",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cisplatin",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dapsone",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        M",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Disulfiram",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydralazine",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S &gt; M",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isoniazid",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leflunomide",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S, or SM",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Linezolid",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metronidazole",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S or SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Misonidazole",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S or SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nitrofurantoin",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nucleoside analogues (ddC, ddI, d4T)",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S &gt;&gt; M",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oxaliplatin",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phenytoin",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S &gt; M",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pyridoxine",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suramin",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        M &gt; S",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Taxol",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        S &gt; M",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vincristine",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S &gt; M",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"10\" rowspan=\"1\">",
"        Toxins*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acrylamide",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        S &gt; M",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arsenic",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"        <br/>",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diphtheria toxin",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gamma-Diketone hexacarbons",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inorganic lead",
"       </td>",
"       <td>",
"        &nbsp;-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        M &gt; S, or M",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Organophosphates",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thallium",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        SM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: usually; &plusmn;: sometimes; -: rare if ever; A: Acute; SA: Subacute; C: Chronic; S: sensory; M: Motor; SM: Sensorimotor; CNS: Central nervous system.",
"     <br>",
"      * The following drugs and environmental toxins are also neurotoxic, mainly affecting the peripheral nervous system: Drugs - Amitriptyline, chloramphenicol, colchicine, ethambutol, nitrous oxide, perhexiline maleate, sodium cyanate, thalidomide, L-tryptophan. Environmental toxins - Allyl chloride; buckthorn berry, carbon disulfide, dimethylaminopropionitrile (DMAPN), ethylene oxide, metallic mercury, methyl bromide, polychlorinated biphenyls, styrene, trichloroethylene, vacor.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with data from: Asbury, A. Approach to the patient with peripheral neuropathy. In: Harrison's Principles of Internal Medicine, 15th ed, Braunwald, E, Fauci, AS, Isselbacher, KJ, et al (Eds), McGraw- Hill Company, Inc., New York 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetically determined neuropathies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Genetic disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Basic process",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other systems involved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Charcot-Marie-Tooth (CMT) disease type 1A",
"       </td>",
"       <td>",
"        Demyelinating",
"       </td>",
"       <td>",
"        Hypertrophic change with onion bulbs; marked l NCV",
"       </td>",
"       <td>",
"        Rare; bony defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CMT disease type 1B",
"       </td>",
"       <td>",
"        Demyelinating",
"       </td>",
"       <td>",
"        Hypertrophic change with onion bulbs; marked l NCV",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CMT disease type 2",
"       </td>",
"       <td>",
"        Axonal",
"       </td>",
"       <td>",
"        Marked l NAP; slight l NCV",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary amyloid polyneuropathies",
"       </td>",
"       <td>",
"        Axonal",
"       </td>",
"       <td>",
"        Small-fiber involvement; endoneurial amyloid deposition",
"       </td>",
"       <td>",
"        In some families: cornea, kidneys, heart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary sensory neuropathy type I (HSN-I)",
"       </td>",
"       <td>",
"        Neuronopathic",
"       </td>",
"       <td>",
"        Dorsal root ganglia neurons selectively involved",
"       </td>",
"       <td>",
"        Sensorineural deafness (some families)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Porphyric neuropathy",
"       </td>",
"       <td>",
"        Axonal",
"       </td>",
"       <td>",
"        Neuropathy part of attacks; may be recurrent",
"       </td>",
"       <td>",
"        Widespread cellular abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary liability to pressure palsy",
"       </td>",
"       <td>",
"        Demyelinating",
"       </td>",
"       <td>",
"        Tomaculous changes in myelin",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fabry's disease",
"       </td>",
"       <td>",
"        Neuronopathic",
"       </td>",
"       <td>",
"        Sensory neuropathy, small dorsal root ganglia neurons",
"       </td>",
"       <td>",
"        Kidney, skin, lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CMT disease type 1, x-linked",
"       </td>",
"       <td>",
"        Demyelinating",
"       </td>",
"       <td>",
"        Heterozygote females have symptoms",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenomyeloneuropathy",
"       </td>",
"       <td>",
"        ?Axonal",
"       </td>",
"       <td>",
"        Mild neuropathy, spastic paraparesis, baldness, hypogonadism",
"       </td>",
"       <td>",
"        Adrenal cortex, cerebral white matter, spinal cord",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary sensory neuropathy type II (HSN-II)",
"       </td>",
"       <td>",
"        Neuronopathic",
"       </td>",
"       <td>",
"        Dorsal root ganglia neurons selectively involved",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D&eacute;jerine-Sottas neuropathy, types A and B (HMSN-III)",
"       </td>",
"       <td>",
"        Demyelinating",
"       </td>",
"       <td>",
"        Hypertrophic change with onion bulb formation",
"       </td>",
"       <td>",
"        May be mentally retarded",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CMT disease type 4A",
"       </td>",
"       <td>",
"        Demyelinating",
"       </td>",
"       <td>",
"        Hypomyelination; marked l NCV",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refsum's disease",
"       </td>",
"       <td>",
"        Demyelinating",
"       </td>",
"       <td>",
"        Hypertrophic change with onion bulb formation",
"       </td>",
"       <td>",
"        Retinitis pigmentosa, ichthyosis, sensorineural deafness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ataxia telangiectasia",
"       </td>",
"       <td>",
"        Axonal",
"       </td>",
"       <td>",
"        Neuropathy moderate",
"       </td>",
"       <td>",
"        Cell nuclear aneuploidy, skin and scleral telangiectasia, cerebellar atrophy, immunopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abetalipoproteinemia",
"       </td>",
"       <td>",
"        Neuronopathic",
"       </td>",
"       <td>",
"        Large dorsal root ganglia neurons",
"       </td>",
"       <td>",
"        Retinitis pigmentosa, acanthocytosis of red blood cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giant axonal neuropathy",
"       </td>",
"       <td>",
"        Axonal",
"       </td>",
"       <td>",
"        Massive segmented accumulation of neurofilaments in axons",
"       </td>",
"       <td>",
"        Slowly progressive encephalopathy with Rosenthal fibers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metachromatic leukodystrophy",
"       </td>",
"       <td>",
"        Demyelinating",
"       </td>",
"       <td>",
"        Schwannopathy with cerebroside accumulation",
"       </td>",
"       <td>",
"        Cerebral white matter disease predominates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Friedrich's ataxia",
"       </td>",
"       <td>",
"        Axonal",
"       </td>",
"       <td>",
"        Spinocerebellar and corticospinal tracts involved; also primary sensory neurons",
"       </td>",
"       <td>",
"        Cardiomyopathy (usual cause of death)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NAP: nerve action potential; NCV: nerve conduction velocity; HMSN: hereditary motor-sensory neuropathy.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with data from: Fauci AS, Braunwald E, Isselbacher KJ, et al (Eds). Harrison's Principles of Internal Medicine, 14th ed, McGraw-Hill Company, Inc., New York, 1998, p.2460.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4867=[""].join("\n");
var outline_f4_48_4867=null;
var title_f4_48_4868="Vena cava filter models";
var content_f4_48_4868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inferior vena caval filter models",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Stainless steel Greenfield filter. B) Modified-hook titanium Greenfield filter. C) Bird's nest filter. D) Simon nitinol filter. E) Vena Tech filter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Streiff, MB. Vena caval filters: a comprehensive review. Blood 2000 Jun 15;95(12):3669-77. (Copyright 2000 by American Society of Hematology",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4868=[""].join("\n");
var outline_f4_48_4868=null;
var title_f4_48_4869="Pimozide: Patient drug information";
var content_f4_48_4869=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pimozide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     see \"Pimozide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/22/34151?source=see_link\">",
"     see \"Pimozide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Orap&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F209994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pimozide&reg;;",
"     </li>",
"     <li>",
"      Orap&reg;;",
"     </li>",
"     <li>",
"      PMS-Pimozide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10016257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691357",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the number of tics in patients with Tourette's syndrome.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pimozide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10975 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4869=[""].join("\n");
var outline_f4_48_4869=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209993\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209994\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016257\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016259\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016258\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016263\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016264\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016266\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016261\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016262\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016267\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016268\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=related_link\">",
"      Pimozide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/22/34151?source=related_link\">",
"      Pimozide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_48_4870="Follicular cyst ultrasound";
var content_f4_48_4870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76189%7EOBGYN%2F79845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76189%7EOBGYN%2F79845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Follicular ovarian cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pelvic ultrasonography shows a follicular cyst. Follicular cysts are usually less than 10 cm in size and appear purely cystic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jorge Londono, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Follicular ovarian cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal ultrasound of the left adnexa. Normal left ovary with two follicles that are shown by the arrows. The follicles are circular anechoic structures within the substance of the hypoechoic ovarian tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4870=[""].join("\n");
var outline_f4_48_4870=null;
var title_f4_48_4871="Acute respiratory distress syndrome: Prognosis and outcomes";
var content_f4_48_4871=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute respiratory distress syndrome: Prognosis and outcomes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/48/4871/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/48/4871/contributors\">",
"     Mark D Siegel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/48/4871/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/48/4871/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/48/4871/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/48/4871/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/48/4871/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A distinct type of hypoxemic respiratory failure characterized by acute abnormality of both lungs was first recognized during the 1960s. Military clinicians working in surgical hospitals in Vietnam called it shock lung, while civilian clinicians referred to it as adult respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent recognition that individuals of any age could be afflicted led to the current term, acute respiratory distress syndrome (ARDS).",
"   </p>",
"   <p>",
"    The Berlin Definition of ARDS (published in 2012) has replaced the American-European Consensus Conference&rsquo;s definition of ARDS (published in 1994) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, it should be recognized that most evidence is based upon prior definitions. The current diagnostic criteria for ARDS are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link&amp;anchor=H10171195#H10171195\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis of ARDS is reviewed here. Other issues related to ARDS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=see_link\">",
"     \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link\">",
"     \"Novel therapies for the acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARDS is associated with appreciable mortality, with estimates ranging from 26 to 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. The underlying cause of the ARDS is the most common cause of death among patients who die early [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/7,8,10,11\">",
"     7,8,10,11",
"    </a>",
"    ]. In contrast, nosocomial pneumonia and sepsis are the most common causes of death among patients who die later in their clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients uncommonly die from respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous studies suggest that survival has improved over time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. As an example, an observational study of 2451 patients who had enrolled in ARDSNet randomized trials found a fall in mortality from 35 to 26 percent between 1996 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/12\">",
"     12",
"    </a>",
"    ]. Although encouraging, several issues should be considered with respect to trends in ARDS-related mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is not known if mortality has decreased among patients who received their care outside of a specialized center or a clinical trial.",
"     </li>",
"     <li>",
"      The improved mortality may be attributable to patients who have ARDS related to risk factors other than sepsis, such as trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To the extent that mortality has decreased, the reasons are uncertain. Likely causes include better supportive care and improved ventilatory strategies, such as low tidal volume ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/3,12,14\">",
"       3,12,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H2#H2\">",
"       \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Low tidal volume ventilation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have sought to identify factors during the acute illness that predict mortality. Such factors can be categorized as patient-, disease-, or treatment-related. No single factor has proven to be superior to the others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Patient-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older patients appear to be at an increased risk for death [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/5,15\">",
"     5,15",
"    </a>",
"    ]. This was illustrated by a multicenter cohort study that followed 1113 patients with ARDS for 15 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/5\">",
"     5",
"    </a>",
"    ]. The mortality rate increased progressively with age, ranging from 24 percent among patients 15 to 19 years of age to 60 percent among patients 85 years of age or older. The overall mortality rate was 41 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Disease-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease-related predictors of mortality include severe hypoxemia, failure of oxygenation to improve, pulmonary vascular dysfunction, increased dead space, infection, a high severity of illness score, a non-traumatic cause of the ARDS, and certain biomarkers and gene polymorphisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygenation &ndash; The severity of hypoxemia determines whether the patient has mild ARDS",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &gt;200 but &le;300 mmHg), moderate ARDS",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &gt;100 but &le;200 mmHg), or severe ARDS",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &le;100 mmHg). Mortality appears to increase as ARDS becomes more severe, according to an observational study of 3670 patients with ARDS that found that patients with mild, moderate, and severe ARDS had mortality rates of 27, 32, and 45 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/16\">",
"       16",
"      </a>",
"      ]. Similarly, there is general agreement that improvement of oxygenation during the early ICU course correlates with survival [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary vascular dysfunction &ndash; Pulmonary vascular dysfunction is indicated by an elevated transpulmonary gradient (ie, &ge;12 mmHg) or pulmonary vascular resistance index (ie, &gt;285 dyne",
"      <span class=\"nowrap\">",
"       s/cm).",
"      </span>",
"      The transpulmonary gradient is the difference between the mean pulmonary artery pressure and the pulmonary artery occlusion pressure, while the pulmonary vascular resistance index is the transpulmonary gradient divided by the cardiac index. Pulmonary vascular dysfunction appears to be an independent risk factor for 60-day mortality and fewer ventilator-free, ICU-free, and hypotension- or vasopressor-free days [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dead space &ndash; Dead space ventilation early in the course of ARDS appears to correlate with mortality. This was illustrated by a series of 179 patients with early ARDS who had their ratio of dead space to tidal volume (ie, the dead space fraction or",
"      <span class=\"nowrap\">",
"       Vd/Vt)",
"      </span>",
"      determined by measuring exhaled carbon dioxide (CO",
"      <sub>",
"       2",
"      </sub>",
"      ) levels [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/19\">",
"       19",
"      </a>",
"      ]. The dead space fraction was markedly elevated (mean 0.58, normal &lt;0.30) and there was a linear correlation between the degree of dead space ventilation and mortality. For every 0.05 increase in dead space fraction, the odds of death increased by 45 percent.",
"     </li>",
"     <li>",
"      Infection &ndash; Infection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      multiorgan dysfunction are better predictors of mortality than respiratory parameters [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/11,20-25\">",
"       11,20-25",
"      </a>",
"      ]. This is probably because they predict death from a nonrespiratory cause, which is more common than death due to respiratory failure.",
"     </li>",
"     <li>",
"      Severity of illness score &ndash; Severity of illness scores appear to correlate with mortality. As an example, patients with a higher APACHE III score have an increased likelihood of death (odds ratio 1.78 per 25-point increase, 95% CI 1.16-2.73) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=see_link&amp;anchor=H5#H5\">",
"       \"Predictive scoring systems in the intensive care unit\", section on 'Acute Physiologic and Chronic Health Evaluation (APACHE)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Underlying cause of the ARDS &ndash; Patients with trauma-related ARDS appear to have a lower likelihood of death at 90 days than patients with ARDS that is unrelated to trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Laboratory &ndash; Routine laboratory parameters are not helpful for predicting the outcome of ARDS. However, a large body of emerging evidence suggests that many biomarkers and gene polymorphisms are associated with both susceptibility to ARDS and outcome from ARDS [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/27\">",
"       27",
"      </a>",
"      ]. The practical utility of these observations is uncertain, but the research may lead to new preventative and therapeutic strategies in the future.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Treatment-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment-related predictors of mortality include a positive fluid balance, glucocorticoid therapy prior to the onset of ARDS, packed red blood cell transfusions, and being in an ICU that does not mandate care by an intensivist.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid balance &ndash; A positive fluid balance may be associated with higher mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. This was demonstrated by the ARDSNet low tidal volume trial, which found that a negative fluid balance at day 4 was associated with decreased mortality compared to a positive fluid balance, after adjustment for factors such as age, severity of illness, and ventilator strategy (adjusted odds ratio 0.50, 95% CI 0.28-0.89) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link&amp;anchor=H15#H15\">",
"       \"Supportive care and oxygenation in acute respiratory distress syndrome\", section on 'Fluid management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment with glucocorticoids &ndash; Patients who received glucocorticoids prior to the onset of ARDS may have an increased likelihood of death (odds ratio 4.65, 95% CI 1.47-14.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link&amp;anchor=H16#H16\">",
"       \"Novel therapies for the acute respiratory distress syndrome\", section on 'Glucocorticoids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Packed red blood cell transfusion &ndash; Patients who receive packed red blood cell transfusions may have an increased likelihood of death (odds ratio 1.10 per unit transfused, 95% CI 1.04-1.17) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/15,30\">",
"       15,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Organization of the ICU &ndash; Patients cared for in an ICU that mandates transfer to an intensivist or co-management by an intensivist may have a decreased likelihood of death (odds ratio 0.68, 95% CI 0.53-0.89) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MORBIDITY AMONG SURVIVORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of ARDS frequently have persistent, abnormal exercise endurance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/32-38\">",
"     32-38",
"    </a>",
"    ]. The persistent nature of this abnormality was demonstrated by a prospective cohort study that followed 109 survivors of ARDS for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/38\">",
"     38",
"    </a>",
"    ]. The six minute walking distance at one, three, and five years was 66, 67, and 76 percent of predicted, respectively. Whether this abnormal exercise endurance is due, in part, to decreased lung function is uncertain due to conflicting data. Numerous studies have suggested that there is persistent impairment of lung function following the acute illness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/32-37\">",
"     32-37",
"    </a>",
"    ], while others have found little or no impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A constellation of other physical and psychological problems also occur after the acute illness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/34,37-42\">",
"     34,37-42",
"    </a>",
"    ], many as long as five years after ICU discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/38\">",
"     38",
"    </a>",
"    ]. Examples include new physical disabilities, impaired neurocognitive function, depression, anxiety, pervasive memories of critical care, and changes to relationships, particularly with caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/38,43-45\">",
"     38,43-45",
"    </a>",
"    ]. Such problems appear to be common, with one prospective cohort study estimating that the incidences of depressive symptoms and impaired physical function were 40 and 66 percent, respectively, during the two years following acute lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these abnormalities, most survivors are able to return to work. In the prospective cohort study described above, 77 percent of those who were working at the time of their acute illness returned to work, while 17 percent did unpaid work within the home and six percent became full-time students [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/38\">",
"     38",
"    </a>",
"    ]. Most of those who returned to work did so within two years after ICU discharge, although many required a gradual transition back to work.",
"   </p>",
"   <p>",
"    Several studies have sought factors during the acute illness that predict long-term sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/35,39,46,47\">",
"     35,39,46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent symptoms one year after recovery correlate with the duration of mechanical ventilation and the lowest static thoracic compliance during the acute illness [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal lung function one year after recovery correlates with the following factors measured during the acute illness: lowest static thoracic compliance, mean pulmonary artery pressure, positive end-expiratory pressure (PEEP), initial intrapulmonary shunt fraction, and requirement of an FiO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;0.6 for more than 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A better functional outcome at one year correlates with the absence of steroid treatment, absence of illness acquired during the ICU stay, and rapid resolution of multiple organ failure and lung injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is no known correlation between ventilatory strategies and either long-term pulmonary function or health-related quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4871/abstract/34,48\">",
"       34,48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=see_link\">",
"       \"Patient information: Adult respiratory distress syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the acute onset of bilateral alveolar infiltrates and hypoxemia. Diagnostic criteria for ARDS are provided separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link&amp;anchor=H10171195#H10171195\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\", section on 'Diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The underlying cause of the ARDS is the usual cause of death among patients who die early. In contrast, sepsis due to nosocomial pulmonary infection is the most common cause of death among patients who die later in their clinical course. Patients seldom die from respiratory failure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are numerous factors that can be assessed during the acute illness that may predict mortality. However, no single factor appears to be superior to the others. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies suggest that survival has improved for patients with ARDS. Among long-term survivors, many have abnormalities in pulmonary function that are generally mild, as well as reduced quality of life for at least two years following the acute illness. There is growing recognition that survivors of ARDS struggle with physical, cognitive, and psychological disorders that may last for months or years following their acute illness. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Morbidity among survivors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/1\">",
"      Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967; 2:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/2\">",
"      Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/3\">",
"      Artigas A, Bernard GR, Carlet J, et al. The American-European Consensus Conference on ARDS, part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/4\">",
"      MacCallum NS, Evans TW. Epidemiology of acute lung injury. Curr Opin Crit Care 2005; 11:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/5\">",
"      Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/6\">",
"      Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/7\">",
"      Estenssoro E, Dubin A, Laffaire E, et al. Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome. Crit Care Med 2002; 30:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/8\">",
"      Bersten AD, Edibam C, Hunt T, et al. Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States. Am J Respir Crit Care Med 2002; 165:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/9\">",
"      Villar J, Blanco J, A&ntilde;&oacute;n JM, et al. The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med 2011; 37:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/10\">",
"      Montgomery AB, Stager MA, Carrico CJ, Hudson LD. Causes of mortality in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1985; 132:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/11\">",
"      Stapleton RD, Wang BM, Hudson LD, et al. Causes and timing of death in patients with ARDS. Chest 2005; 128:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/12\">",
"      Erickson SE, Martin GS, Davis JL, et al. Recent trends in acute lung injury mortality: 1996-2005. Crit Care Med 2009; 37:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/13\">",
"      Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest 2008; 133:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/14\">",
"      Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/15\">",
"      Gong MN, Thompson BT, Williams P, et al. Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 2005; 33:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/16\">",
"      The ARDS Definition Task Force. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA 2012; May 21:Epub ahead of print.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/17\">",
"      Bone RC, Maunder R, Slotman G, et al. An early test of survival in patients with the adult respiratory distress syndrome. The PaO2/FIo2 ratio and its differential response to conventional therapy. Prostaglandin E1 Study Group. Chest 1989; 96:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/18\">",
"      Bull TM, Clark B, McFann K, et al. Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury. Am J Respir Crit Care Med 2010; 182:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/19\">",
"      Nuckton TJ, Alonso JA, Kallet RH, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med 2002; 346:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/20\">",
"      Doyle RL, Szaflarski N, Modin GW, et al. Identification of patients with acute lung injury. Predictors of mortality. Am J Respir Crit Care Med 1995; 152:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/21\">",
"      Bone RC, Balk R, Slotman G, et al. Adult respiratory distress syndrome. Sequence and importance of development of multiple organ failure. The Prostaglandin E1 Study Group. Chest 1992; 101:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/22\">",
"      Suchyta MR, Clemmer TP, Elliott CG, et al. The adult respiratory distress syndrome. A report of survival and modifying factors. Chest 1992; 101:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/23\">",
"      Sloane PJ, Gee MH, Gottlieb JE, et al. A multicenter registry of patients with acute respiratory distress syndrome. Physiology and outcome. Am Rev Respir Dis 1992; 146:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/24\">",
"      Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 1997; 111:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/25\">",
"      Ely EW, Wheeler AP, Thompson BT, et al. Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome. Ann Intern Med 2002; 136:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/26\">",
"      Calfee CS, Eisner MD, Ware LB, et al. Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med 2007; 35:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/27\">",
"      Levitt JE, Gould MK, Ware LB, Matthay MA. The pathogenetic and prognostic value of biologic markers in acute lung injury. J Intensive Care Med 2009; 24:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/28\">",
"      Sakr Y, Vincent JL, Reinhart K, et al. High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest 2005; 128:3098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/29\">",
"      Rosenberg AL, Dechert RE, Park PK, et al. Review of a large clinical series: association of cumulative fluid balance on outcome in acute lung injury: a retrospective review of the ARDSnet tidal volume study cohort. J Intensive Care Med 2009; 24:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/30\">",
"      Netzer G, Shah CV, Iwashyna TJ, et al. Association of RBC transfusion with mortality in patients with acute lung injury. Chest 2007; 132:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/31\">",
"      Treggiari MM, Martin DP, Yanez ND, et al. Effect of intensive care unit organizational model and structure on outcomes in patients with acute lung injury. Am J Respir Crit Care Med 2007; 176:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/32\">",
"      Elliott CG, Morris AH, Cengiz M. Pulmonary function and exercise gas exchange in survivors of adult respiratory distress syndrome. Am Rev Respir Dis 1981; 123:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/33\">",
"      Neff TA, Stocker R, Frey HR, et al. Long-term assessment of lung function in survivors of severe ARDS. Chest 2003; 123:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/34\">",
"      Orme J Jr, Romney JS, Hopkins RO, et al. Pulmonary function and health-related quality of life in survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 2003; 167:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/35\">",
"      Suchyta MR, Elliott CG, Jensen RL, Crapo RO. Predicting the presence of pulmonary function impairment in adult respiratory distress syndrome survivors. Respiration 1993; 60:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/36\">",
"      McHugh LG, Milberg JA, Whitcomb ME, et al. Recovery of function in survivors of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1994; 150:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/37\">",
"      Cheung AM, Tansey CM, Tomlinson G, et al. Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 2006; 174:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/38\">",
"      Herridge MS, Tansey CM, Matt&eacute; A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011; 364:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/39\">",
"      Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003; 348:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/40\">",
"      Angus DC, Musthafa AA, Clermont G, et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/41\">",
"      Hopkins RO, Weaver LK, Collingridge D, et al. Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. Am J Respir Crit Care Med 2005; 171:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/42\">",
"      Hopkins RO, Weaver LK, Pope D, et al. Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/43\">",
"      Cox CE, Docherty SL, Brandon DH, et al. Surviving critical illness: acute respiratory distress syndrome as experienced by patients and their caregivers. Crit Care Med 2009; 37:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/44\">",
"      Bienvenu OJ, Colantuoni E, Mendez-Tellez PA, et al. Depressive symptoms and impaired physical function after acute lung injury: a 2-year longitudinal study. Am J Respir Crit Care Med 2012; 185:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/45\">",
"      Mikkelsen ME, Christie JD, Lanken PN, et al. The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury. Am J Respir Crit Care Med 2012; 185:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/46\">",
"      Elliott CG, Rasmusson BY, Crapo RO, et al. Prediction of pulmonary function abnormalities after adult respiratory distress syndrome (ARDS). Am Rev Respir Dis 1987; 135:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/47\">",
"      Ghio AJ, Elliott CG, Crapo RO, et al. Impairment after adult respiratory distress syndrome. An evaluation based on American Thoracic Society recommendations. Am Rev Respir Dis 1989; 139:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4871/abstract/48\">",
"      Cooper AB, Ferguson ND, Hanly PJ, et al. Long-term follow-up of survivors of acute lung injury: lack of effect of a ventilation strategy to prevent barotrauma. Crit Care Med 1999; 27:2616.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1601 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4871=[""].join("\n");
var outline_f4_48_4871=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predictors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Patient-related",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Disease-related",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Treatment-related",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MORBIDITY AMONG SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=related_link\">",
"      Patient information: Adult respiratory distress syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=related_link\">",
"      Predictive scoring systems in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_48_4872="Ketorolac (nasal): Drug information";
var content_f4_48_4872=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketorolac (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/59/41909?source=see_link\">",
"    see \"Ketorolac (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F12826405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12824194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sprix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10288897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Nasal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12826461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pain management (acute; moderate-to-moderately-severe):  Note:",
"     </b>",
"     The maximum combined duration of treatment (for nasal spray or other ketorolac formulations) is 5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intranasal: Adults&lt;65 years and &ge;50 kg: One spray (15.75 mg) in each nostril (total dose: 31.5 mg) every 6-8 hours; maximum dose: 4 doses (126 mg)/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustments in adults with low body weight (&lt;50 kg):",
"     </i>",
"     One spray (15.75 mg) in 1 nostril (total dose: 15.75 mg) every 6-8 hours; maximum dose: 4 doses (63 mg)/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F12826462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elderly (&ge;65 years): Intranasal: One spray (15.75 mg) in 1 nostril (total dose: 15.75 mg) every 6-8 hours; maximum dose: 4 doses (63 mg)/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12826464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Renal insufficiency: Intranasal: One spray (15.75 mg) in 1 nostril (total dose: 15.75 mg) every 6-8 hours; maximum dose: 4 doses (63 mg)/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Advanced renal impairment (or at risk for renal failure due to volume depletion): Use is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12826463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution with hepatic impairment or history of hepatic disease; use may cause elevation of liver enzymes; discontinue if clinical signs and symptoms of liver disease develop.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12824195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as tromethamine [spray, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sprix&reg;: 15.75 mg/spray (1.7 g) [delivers 8 metered sprays]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12826409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F12826408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089165.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089165.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12826465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each nasal spray contains medication for 1 day of therapy. Before first use of a nasal spray container, prime by pressing pump 5 times. There is no need to prime the pump again if more doses are administered during the next 24 hours using the same nasal container. Repeat priming each day prior to first use of each new nasal spray. Blow nose to clear nostrils. Sit up straight or stand; tilt head slightly forward. Insert tip of container into nostril, keeping bottle upright, and point container away from the center of nose. Spray once, pressing down evenly on both sides of container.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Discard container within 24 hours of priming even if there is unused medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10288898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (&le;5 days) management of moderate-to-moderately-severe acute pain requiring analgesia at the opioid level",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F12826406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ketorolac may be confused with Ketalar&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12826437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Events reported with intranasal use; refer to Ketorolac (Systemic) monograph for other potential ketorolac-related adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Respiratory: Nasal discomfort (15%), rhinalgia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Bradycardia (2%), hypertension (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Throat irritation (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urine output decreased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT/AST increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Lacrimation increased (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Rhinitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Oliguria (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1%, postmarketing, and/or case reports (limited to important or life-threatening): Anemia, bleeding, hematoma",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12826414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketorolac, aspirin, other NSAIDs, or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions following aspirin or other NSAID use; active or history of peptic ulcer disease; recent or history of GI bleeding or perforation; patients with advanced renal disease or risk of renal failure (due to volume depletion); prophylaxis before major surgery; suspected or confirmed cerebrovascular bleeding; hemorrhagic diathesis, incomplete hemostasis, or high risk of bleeding; concomitant probenecid or pentoxifylline; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; labor and delivery; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12826415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding:",
"     <b>",
"      [U.S. Boxed Warning]: May inhibit platelet function; contraindicated in patients with cerebrovascular bleeding (suspected or confirmed), hemorrhagic diathesis, incomplete hemostasis and patients at high risk for bleeding.",
"     </b>",
"     Effects on platelet adhesion and aggregation may prolong bleeding time. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding, ulcers, inflammatory bowel disease), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly, or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Even in patients without prior exposure, hypersensitivity including bronchospasm and anaphylactic shock, may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy. Ketorolac nasal spray is contraindicated in patients with prior hypersensitivity reaction to aspirin or NSAIDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery/major surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery. Use is also contraindicated as prophylactic analgesic before any major surgery. Wound bleeding and postoperative hematomas have been associated with ketorolac use in the perioperative setting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment or a history of liver disease. Closely monitor patients with any abnormal LFT. Rarely, severe hepatic reactions (eg, fulminant hepatitis, hepatic necrosis, liver failure) have occurred with NSAID use; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Ketorolac is contraindicated in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion.",
"     </b>",
"     NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Use with caution in patients with impaired renal function or history of kidney disease. Dosage adjustment is required in patients with moderate elevation in serum creatinine. Acute renal failure, interstitial nephritis, and nephrotic syndrome have been reported with ketorolac use; papillary necrosis and renal injury have been reported with the use of NSAIDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin/other NSAIDs: Ketorolac should not be used concomitantly with other forms of ketorolac, aspirin, or other NSAIDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Dosage adjustment is required for patients &ge;65 years of age. Avoid use in older adults; nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Low body weight: Dosage adjustment is required for patients weighing &lt;50 kg (&lt;110 pounds).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Nasal ketorolac is not indicated for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edetate sodium (EDTA): Preparation contains EDTA; do not use in patients with hypersensitivity to EDTA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nasal spray: Avoid contact with the eyes. If eye exposure occurs, wash eye with water or saline; consult physician if irritation continues &gt;1 hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Limitations of use:",
"     <b>",
"      [U.S. Boxed Warning]: Ketorolac nasal spray is indicated for short term (&le;5 days) use in adults for treatment of moderate- to moderately-severe acute pain requiring opioid-level analgesia. The combined therapy duration (nasal and other ketorolac formulations) should not exceed 5 days.",
"     </b>",
"     Therapy is not appropriate for minor or chronic pain therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12858788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants: Ketorolac (Nasal) may diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Ketorolac (Nasal) may enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Ketorolac (Nasal) may enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Ketorolac (Nasal) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: Ketorolac (Nasal) may enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Ketorolac (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F12826441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, and white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12826410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D &ge;30 weeks gestation (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12826411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies ketorolac (nasal) as pregnancy category C (category D: &ge;30 weeks gestation).When administered I.M., ketorolac crosses the placenta. The amount of ketorolac available systemically following intranasal administration is 60% to 70% in comparison to I.M. doses. Adverse fetal effects have been observed following maternal use of NSAIDs. Maternal use &ge;30 weeks gestation increases the risk of premature closure of the ductus arteriosus. When used during labor and delivery, ketorolac may cause adverse effects on the fetal circulation, inhibit uterine contractions and increase the risk of uterine hemorrhage. Use during labor and delivery is contraindicated. Refer to the Ketorolac (Systemic) monograph for details.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12826412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated (per manufacturer's labeling)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12826413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low concentrations of ketorolac are found in breast milk. Inhibition of prostaglandin synthesis may adversely affect neonates; use of nasal ketorolac is contraindicated in breast-feeding women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sprix Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15.75 mg/spray (1): $39.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12826474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for weight gain/edema; renal function (serum creatinine, BUN, urine output); observe for bleeding, bruising; evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia); CBC and platelets, liver function tests",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F12826446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum concentration: Therapeutic: 0.3-5 mcg/mL; Toxic: &gt;5 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12826444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity, inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12826447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of analgesia: Within 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and well absorbed; C",
"     <sub>",
"      max",
"     </sub>",
"     , t",
"     <sub>",
"      max",
"     </sub>",
"     and AUC values were similar following multiple administrations for 5 days compared to the single-dose study in healthy volunteers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: ~13 L following complete distribution; following intranasal administration, ketorolac is deposited primarily in the nasal cavity and pharynx; &lt;20% deposited in the esophagus and stomach; &lt;0.5% in the lungs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to hydroxylated and conjugated forms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~60% to 70% relative to I.M. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~5-6 hours (similar to I.M. administration); prolonged ~35% in elderly; up to 19 hours in renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 0.5-0.75 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~92%, ~60% as unchanged drug); feces ~6%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/48/4872/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singla N, Singla S, Minkowitz HS, et al, &ldquo;Intranasal Ketorolac for Acute Postoperative Pain,&rdquo;",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 2010, 26(8): 1915-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/48/4872/abstract-text/20557145/pubmed\" id=\"20557145\" target=\"_blank\">",
"        20557145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McAleer SD, Majid O, Venables E, et al, &ldquo;Pharmacokinetics and Safety of Ketorolac Following Single Intranasal and Intramuscular Administration in Healthy Volunteers,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2007; 47(1):13-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/48/4872/abstract-text/17192497/pubmed\" id=\"17192497\" target=\"_blank\">",
"        17192497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moodie JE, Brown CR, Bisley EJ, et al, &ldquo;The Safety and Analgesic Efficacy of Intranasal Ketorolac in Patients With Postoperative Pain,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2008, 107(6):2025-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/48/4872/abstract-text/19020154/pubmed\" id=\"19020154\" target=\"_blank\">",
"        19020154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15556 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4872=[""].join("\n");
var outline_f4_48_4872=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826405\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12824194\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10288897\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826461\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826462\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826464\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826463\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12824195\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826409\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826408\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826465\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10288898\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826406\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826437\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826414\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826415\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299556\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858788\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826441\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826410\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826411\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826412\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826413\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322855\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826474\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826446\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826444\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12826447\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15556\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15556|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/59/41909?source=related_link\">",
"      Ketorolac (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/32/35332?source=related_link\">",
"      Ketorolac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/0/19460?source=related_link\">",
"      Ketorolac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/51/43827?source=related_link\">",
"      Ketorolac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/1/21529?source=related_link\">",
"      Ketorolac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/33/3606?source=related_link\">",
"      Ketorolac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/22/1385?source=related_link\">",
"      Ketorolac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_48_4873="Overview of HIV drug resistance testing assays";
var content_f4_48_4873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of HIV drug resistance testing assays",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/48/4873/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/48/4873/contributors\">",
"     Michael J Kozal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/48/4873/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/48/4873/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/48/4873/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/48/4873/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/48/4873/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of drug resistance testing has become an integral part of HIV clinical care. The first clinical description of HIV resistance to antiretroviral drugs was published in 1989 about patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    monotherapy; accumulation of mutations within the reverse transcriptase gene resulted in a marked increase in drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequently, HIV variants resistant to every available antiretroviral agent have been identified in viral culture in the presence of drug and in treated HIV-infected patients. The evolution of drug resistance has significant clinical implications for choosing effective antiretroviral regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resistance assays can be categorized as either phenotypic or genotypic. These assays detect resistance in fundamentally different ways, although the results generally correlate with each other. There may be clinical settings in which one or the other assay could offer theoretical advantages or in which each assay would provide complementary information. However, the optimal specific use of these assays has not been definitively established.",
"   </p>",
"   <p>",
"    The clinically available antiretroviral drug resistance assays will be discussed here, including the benefits and limitations of each type. Clinical trials evaluating these assays and the clinical use of these drug resistance assays in various patient populations are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/46/3814?source=see_link\">",
"     \"Clinical trials of HIV drug resistance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHENOTYPIC RESISTANCE ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenotypic resistance assays measure the extent to which an antiretroviral drug inhibits virus replication in vitro. Similar to bacteriologic methods, this is typically performed by demonstrating an increase in the inhibitory concentration (IC) that is required to inhibit in vitro growth by 50 percent (IC50) compared with virus replication in the absence of drug. Results are reported as a fold-change in drug susceptibility of the patient sample compared with a laboratory reference strain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recombinant virus assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, phenotypic resistance assays were performed using virus cultured from patient peripheral blood mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/3\">",
"     3",
"    </a>",
"    ]. These assays, which required culturing virus in primary human peripheral blood mononuclear cells, were plagued by significant variability and lengthy turnaround times. They required approximately two to four weeks for initial HIV isolation, one week to titer the virus inoculum, and an additional one to two weeks to assay virus replication in the presence of different drug concentrations.",
"   </p>",
"   <p>",
"    The introduction of recombinant virus assays (RVAs) has been a major advance in streamlining phenotypic resistance assays [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/4\">",
"     4",
"    </a>",
"    ]. RVAs use recombinant (chimeric) viruses composed of protease, reverse transcriptase, and integrase gene sequences from viruses circulating in a patient's plasma, which are inserted into the genetic backbone of a laboratory reference strain of HIV. The resulting chimeric DNA clone is transfected into mammalian cells to produce an infectious virus that expresses the protease and reverse transcriptase enzymes from the patient HIV strain. The drug susceptibility of this chimeric virus can then be measured in a phenotypic resistance assay.",
"   </p>",
"   <p>",
"    RVAs accurately reflect the drug susceptibility of the original clinical isolate only if the region of the viral genome being amplified contains the genetic determinants (mutant sequences) of drug resistance. Modifications of the RVA have now been developed for fusion inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Commercial assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two reference laboratories currently offer HIV phenotypic resistance testing in the United States: the Antivirogram (Virco NV, Belgium) and PhenoSense assay (LabCorp, Burlington, NC). These assays use different methods to create laboratory-generated recombinant viruses (Virco) or pseudoviruses (LabCorp) that incorporate viral genes (eg, protease, reverse transcriptase, or integrase) from a patient's HIV isolate. These laboratory-generated test vectors or viruses are dependent on the activity of the viral genes from the patient's virus and are used to assess replication in the presence and absence of antiretroviral drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both assays compare the test strain IC50 with that of a reference strain, and express resistance as a fold-change in IC50 relative to the reference. Each assay uses somewhat different thresholds for defining resistance.",
"   </p>",
"   <p>",
"    Both assays are highly reproducible [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. A study that directly compared the agreement between the two assays in samples from 70 patients found relatively good concordance (86.9 percent). Agreement was highest for protease inhibitors, and lowest for nucleoside inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/10\">",
"     10",
"    </a>",
"    ]. Another study, in which the performance of each phenotypic assay was compared with genotypic interpretation, also found more discordance for nucleoside inhibitors, compared with protease inhibitors or NNRTIs. A third study found that discordant results between the two phenotypic assays primarily occurred at IC50 fold-change values near the threshold for resistance, suggesting that caution should be used when interpreting values near these cutoffs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenotypic assays can measure drug susceptibility directly. Furthermore, the susceptibility that is measured is the aggregate of the acquired drug mutations in a patient's viral strain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/12\">",
"     12",
"    </a>",
"    ]. This includes mutations that may not have been recognized to date as causing resistance or combinations of mutations, which may have a different effect on susceptibility compared with each individual mutation alone.",
"   </p>",
"   <p>",
"    In addition, phenotypic testing uses language infectious disease clinicians are accustomed to (inhibitory concentration); the results, expressed as IC50 fold-change, are more familiar to clinicians.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limitations of phenotypic assays, compared with genotypic assays, include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Longer turnaround time",
"     </li>",
"     <li>",
"      Expense",
"     </li>",
"     <li>",
"      Biological cutoffs for clinical resistance have not been developed for all antiretroviral agents. In addition, if biologic cutoffs are used, they do not take into account achievable drug levels (eg, pharmacokinetic boosting of protease inhibitors with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link&amp;anchor=H32#H32\">",
"       \"HIV protease inhibitors\", section on 'Pharmacokinetic boosting'",
"      </a>",
"      ). Biological cutoffs are being supplanted by clinical cutoffs, which correlate fold-change in IC50 with treatment responses.",
"     </li>",
"     <li>",
"      Insensitive to drug-resistant variants when present at low levels within the circulating viral population",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both phenotypic and genotypic assays are limited by insensitivity to minority variants when present at levels comprising less than 5 to 20 percent of the virus population. This limitation is important because once ART is discontinued, a wild-type virus often reemerges to replace the drug-resistant virus as soon as four to six weeks after therapy is stopped. Thus, absence of a detectable resistance mutation must be interpreted with caution in a patient who has recently discontinued ART.",
"   </p>",
"   <p>",
"    The ability of a phenotypic assay to detect a particular mutant virus has also been shown to vary by mutation and drug. For example, in one study, &gt;75 percent of",
"    <span class=\"nowrap\">",
"     K65R/M184V",
"    </span>",
"    double-mutant virus was needed to reach the clinical cutoff for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    , and &gt;80 percent of K65R was needed to reach the clinical cutoff for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ; in contrast &gt;50 percent of M184V sufficed to reach the clinical cutoff for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENOTYPIC RESISTANCE ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotypic resistance assays detect the presence of specific drug resistance mutations in the regions of the HIV genome encoding protease, reverse transcriptase, and integrase. Results are reported as the individual mutations (eg, M184V, the signature mutation for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance) with comments such as \"susceptible,\" \"possibly resistant,\" or \"resistant\" for each antiretroviral agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Available assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercially available tests include two FDA-approved kits as well as a variety of in-house assays performed by reference laboratories. These assays sequence regions of the HIV protease and reverse transcriptase genes that have been PCR-amplified from the viral quasispecies circulating in a patient's plasma.",
"   </p>",
"   <p>",
"    These assays differ somewhat in the region of protease, reverse transcriptase, and the integrase that is sequenced and in some technical aspects of sequencing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Sequence data are analyzed by an assay-specific computer program that compares the viral mutations present in the clinical strain to a list of reference drug resistance mutations. In addition, each software mutation algorithm provides an interpretation of the viral genotype, using algorithms established by a panel of experts.",
"   </p>",
"   <p>",
"    Two studies compared the performance of the two FDA-approved kits in clinical samples [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The two methods generally provided concordant results, and there was no evidence that either method was consistently more or less sensitive in detecting drug resistance mutations. However, these two assays do differ in the way in which resistance mutations are defined, and thus, differences in genotypic reports may result. Therefore, it is suggested that the same genotypic assay be used in serial follow-up of a patient's previous results to improve comparability.",
"   </p>",
"   <p>",
"    Other potential sources of variability in genotypic resistance testing are differences in the ability to detect mixtures of mutant and wild-type sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/18\">",
"     18",
"    </a>",
"    ], laboratory performance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/19\">",
"     19",
"    </a>",
"    ], and clinician interpretation of laboratory reports [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/20\">",
"     20",
"    </a>",
"    ]. The detection of insertions, which have been associated with multinucleoside resistance in reverse transcriptase, can be problematic using either assay [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to these two HIV sequencing kits, genotypic resistance testing is also available from several reference laboratories, which have developed their own internal sequencing methods.",
"   </p>",
"   <p>",
"    Modifications of these assays to detect resistance to the fusion inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    , CCR5 inhibitors, and the integrase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    are now offered by some reference laboratories, although the performance and interpretation of these tests is not as well standardized as those for protease and reverse transcriptase inhibitors. The specific details of the sequencing methods and resistance testing interpretation provided by these laboratories are beyond the scope of this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages of genotypic testing, relative to phenotypic testing include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower cost",
"     </li>",
"     <li>",
"      Shorter turnaround time",
"     </li>",
"     <li>",
"      More data from prospective clinical trials on the clinical utility of these assays (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/46/3814?source=see_link\">",
"       \"Clinical trials of HIV drug resistance testing\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disadvantages of genotypic testing, compared with phenotypic testing, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genotypic testing only interrogates known mutations",
"     </li>",
"     <li>",
"      Combinations of individual mutations may have a differential effect on resistance that differs from the individual mutation alone",
"     </li>",
"     <li>",
"      Difficulty in interpretation when many mutations are present",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some mutations cause resistance to certain drugs, but increase susceptibility to others; some mutations impact viral fitness; others may be important contributors to major pathways of resistance. Consequently, genotypic testing in itself is subject to diverse interpretation by various experts and over 20 rules-based genotypic interpretation systems (GIS) have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/22\">",
"     22",
"    </a>",
"    ]. However, several studies have shown good correlation among the various interpretation systems. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Interpreting resistance assays'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Both phenotypic and genotypic assays are also technically limited by insensitivity to minority variants comprising 5 to 20 percent of the virus population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     VircoTypeTM (Virco NV, Belgium)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An additional resistance assay is the VircoType (Virco NV, Belgium). This test provides a resistance interpretation for a patient's virus by: a) analyzing all of the mutations in a patient's genotype and b) comparing the mutations in the patient sample to a reference list of resistance mutations. These well-studied mutations have been assessed a \"weight factor\" for each antiretroviral drug [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A fold-change resistance score is then generated by calculating the sum of the values for all resistance weight factors identified. The weight factor of a mutation is determined by analyzing the relationship between specific genotypes and the paired phenotype in the Virco correlative database. These types of tests are limited both by the number of samples within the correlative database and the number of samples with a specific mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INTERPRETING RESISTANCE ASSAYS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Phenotypic definitions of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance thresholds for phenotypic assays can be defined based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assay variability",
"     </li>",
"     <li>",
"      Biologic variability",
"     </li>",
"     <li>",
"      Virologic response in patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Assay variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Earlier definitions of resistance for both the ViroLogic and Virco phenotypic assays were based on the technical reproducibility of the assay and did not necessarily reflect clinically relevant definitions of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Biologic variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance thresholds based upon biologic variability are usually defined as a level that exceeds the mean fold-change in IC(50) of HIV isolates obtained from treatment-naive patients by a certain factor. This definition of resistance is dependent upon the population chosen for study and assumes that all treatment-naive patients will respond equally well to that drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Virologic outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance thresholds based upon virologic outcome are considered to be a \"gold standard,\" but can be difficult to define. There is no consensus yet on the appropriate magnitude or timing of the virologic response that should be used to define these thresholds",
"    <strong>",
"     ;",
"    </strong>",
"    such thresholds can be influenced by the activity of the background regimen (other antiretroviral agents used in the combination). Studies performed to date suggest that virologic response may vary continuously with baseline resistance. For example, in one study (JAGUAR study), ddI or placebo was added to a failing ART regimen and virologic outcomes at four weeks were compared with phenotypic testing results using the PhenoSense assay [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/28\">",
"     28",
"    </a>",
"    ]. The proportion of virologic responders was 83 percent (15 of 18) for patients with a ddI fold-change &lt;1.3, 50 percent (33 of 66) for patients with a fold-change of 1.3 to 2.2, and 29 percent (4 of 14) for patients with a fold-change of &gt;2.2. Although these data need to be validated in larger populations, they suggest that a single resistance cutoff that sensitively and specifically predicts virologic failure in all patients may be difficult to define. Both the PhenoSense phenotype assay and VircoType virtual phenotype assay now incorporate clinical cutoffs based on virologic response for most antiretroviral drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, current phenotypic resistance thresholds are generally based upon either assay or biologic variability. However, defining clinically relevant phenotypic resistance thresholds that correlate with virologic outcome is an active area of research, and it is anticipated that phenotypic definitions of resistance will continue to evolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Genotypic definitions of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defining resistance using genotypic assays is generally more complex than for phenotypic assays. A mutation is generally identified as playing a role in resistance to a given drug if one or more of the following conditions are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mutation confers phenotypic resistance when introduced into a drug-sensitive laboratory strain of HIV.",
"     </li>",
"     <li>",
"      The mutation is selected for during serial in vitro passage of virus in the presence of drug.",
"     </li>",
"     <li>",
"      The mutation is selected for during clinical therapy with that drug.",
"     </li>",
"     <li>",
"      The presence of the mutation in clinical isolates is associated with phenotypic resistance and virologic failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Interpreting genotypic assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently two general approaches to interpreting genotypic resistance testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expert interpretation, in which data concerning the association of a mutation with drug resistance are evaluated and synthesized",
"     </li>",
"     <li>",
"      Databases, in which genotype is correlated with phenotype",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, there are not sufficient data to recommend one type of interpretation over the other. However, evidence suggests that many of these systems have a similar ability to predict virologic outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The following summarize some of the specific genotypic resistance testing interpretations that are available to clinicians and investigators. This summary provides only a few examples and is",
"    <strong>",
"     not",
"    </strong>",
"    intended to be a comprehensive list of the different approaches that are available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both the FDA-approved genotypic resistance assay reports list the specific drug resistance mutations detected in the test sample, compared with a reference sequence. In addition, each report summarizes which drugs may have reduced activity based upon the viral sequence. These interpretations are made using algorithms defined by experts in the field of resistance testing, based upon a synthesis of in vitro and clinical data. No direct comparisons of the genotypic interpretations using these two methods have been made.",
"     </li>",
"     <li>",
"      The International AIDS Society-USA provides an updated list of mutations associated with HIV drug resistance to all FDA-approved drugs, based on evaluations by a panel of experts (",
"      <a class=\"external\" href=\"file://www.iasusa.org/\">",
"       www.iasusa.org",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The Stanford drug resistance database (",
"      <a class=\"external\" href=\"file://hivdb.stanford.edu/\">",
"       hivdb.stanford.edu",
"      </a>",
"      ) provides access to a genotypic resistance algorithm, which assigns a drug penalty score for each resistance mutation, based on published studies of clinical outcome and expert opinion. Some information on expected fold-change in IC50 can be obtained by searching the database, which is drawn from published studies and some unpublished clinical trials data.",
"     </li>",
"     <li>",
"      ANRS [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/32\">",
"       32",
"      </a>",
"      ], Stanford HIVdb [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/30,33\">",
"       30,33",
"      </a>",
"      ], and Rega [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/34\">",
"       34",
"      </a>",
"      ] are three publicly available drug resistance interpretation systems that are most commonly used by HIV providers. The algorithms for these systems are transparent, updated regularly, and are free to the clinician. These systems are comparable in their ability to predict virologic outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The VircoTypeTM (Virco NV, Belgium) assay provides a resistance interpretation for a patient's virus by analyzing the mutations in a sample genotype and assigning a weight factor. The weight factor of each mutation for a specific drug is determined by using linear regression modeling to analyze the relationship between genotypes and phenotypes in the Virco correlative database. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'VircoTypeTM (Virco NV, Belgium)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Resistance testing and new drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since clinical data on the development of resistance to a drug are often limited at the time the drug is first introduced into routine clinical practice, there is usually a delay between access to a new agent and a full understanding of genotypic and phenotypic definitions of resistance to that drug. Thus, particular caution should be used when interpreting resistance testing to investigational or recently approved antiretroviral agents. Consideration should be given to reinterpreting older genotypes as algorithms are updated with new information and resistance interpretations can change over time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LOW-ABUNDANCE DRUG-RESISTANT VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotypic testing is unable to detect low-abundance drug-resistant variants that are present at less than 20 percent of the viral quasispecies in a given sample. Other techniques have been developed to improve the detection of these minority species compared with standard drug resistance assays [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/24,36\">",
"     24,36",
"    </a>",
"    ]. The presence of low frequency-resistant variants can be associated with inferior treatment responses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/24,37-39\">",
"     24,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Point mutation assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Point mutation assays depend on the differential hybridization of oligonucleotide probes to the wild-type virus and mutant variants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/40\">",
"     40",
"    </a>",
"    ]. These assays must be individually tailored for each mutation they are designed to detect. False positive or false negative test results can occur due to binding site variability [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/36\">",
"     36",
"    </a>",
"    ]. However, the low cost of this type of assay makes it a good candidate for drug resistance epidemiology studies, where information may be needed only on the most common resistance mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clonal sequencing assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clonal sequencing assays can detect minority species, but are labor intensive; approximately 100 to 300 clones must be sequenced in order to identify a viral variant present in only 1 or 2 percent of the viral quasispecies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ultradeep pyrosequencing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultradeep pyrosequencing (UDPS) can detect minority species present at &ge;1 percent using a technique whereby hundreds of thousands of individual molecules are sequenced in a single assay run [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/24\">",
"     24",
"    </a>",
"    ]. The clonal sequences are aligned and analyzed to evaluate the prevalence of low-abundance drug-resistant HIV strains.",
"   </p>",
"   <p>",
"    UDPS techniques were retrospectively applied to a subset of treatment-naive patients within a large clinical trial on baseline samples prior to initiating ART [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/24\">",
"     24",
"    </a>",
"    ]. A significantly higher proportion of mutations were detected by UDPS than by standard genotypic sequencing (28 versus 14 percent, respectively). Among patients who initiated treatment with an ART regimen that combined nucleoside and nonnucleoside reverse-transcriptase inhibitors (NNRTI), all individuals who had an NNRTI-resistance mutation identified by UDPS experienced virologic failure over a prolonged follow-up period.",
"   </p>",
"   <p>",
"    Subsequent data have shown that low-level variants with isolated PI mutations were not predictive of virologic failure; this is likely due to the higher genetic barrier to resistance for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PI-based regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/42\">",
"     42",
"    </a>",
"    ]. In contrast, subjects with low-level resistant variants with extensive nucleoside analog mutations had a high rate of virologic failure, as would be expected. Thus, the impact of finding low-level resistant variants also depends on the specific medication and its genetic barrier to resistance.",
"   </p>",
"   <p>",
"    One study of UDPS found that the detection of low-level resistant variants was more closely correlated with the patient&rsquo;s prior treatment history than with results of UDPS; these results confirm the importance of obtaining a thorough medical history [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that UDPS may lead to a lower risk of virologic failure due to improved detection of minority species, which may be missed by standard genotypic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/24,36\">",
"     24,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     TROPISM ASSAYS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     General background",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV requires both the CD4 receptor and a coreceptor in order to enter CD4+ T-cells. This coreceptor can be CCR5 or CXCR4. Viruses that use CCR5 as their coreceptor are referred to as R5 viruses; those that use CXCR4 are X4 viruses. An individual may have R5 viruses, X4 viruses, or a combination of both [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/44\">",
"     44",
"    </a>",
"    ]. Most transmitted viruses are R5 viruses; X4 viruses usually emerge later in infection.",
"   </p>",
"   <p>",
"    The frequency of exclusive R5 virus varies depending on the patient's treatment history; in treatment-naive patients, exclusive R5 virus is found in approximately 80 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]; in treatment-experienced patients with late-stage disease it is found in only 50 to 56 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testing for viral tropism is recommended when considering the use of a CCR5 antagonist, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , which only inhibits R5 virus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/50\">",
"     50",
"    </a>",
"    ]. Coreceptor tropism testing may also be helpful for patients who demonstrate virologic failure on a CCR5 inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Types of tropism assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both phenotypic and genotypic based assays have been developed to determine viral tropism, although there is much more clinical trial data regarding the use of phenotypic tropism assays [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. The United States Department of Health and Human Services (DHHS) HIV treatment guidelines recommend phenotypic assays as the preferred method for tropism testing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Phenotypic assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of phenotypic assays (Trofile assay, LabCorp, Burlington, NC; Phenoscript assay, VIRalliance, Paris, France) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/50,51,53-58\">",
"     50,51,53-58",
"    </a>",
"    ]. Similar to the previously mentioned phenotypic resistance methods, these assays use laboratory viruses that express patient-derived viral envelope proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/51\">",
"     51",
"    </a>",
"    ]. The laboratory-generated pseudovirus is used to infect cell lines that express either CCR5 or CXCR4; results of these infectivity assays determine the tropism of the patient's isolate.",
"   </p>",
"   <p>",
"    Although there were problems with the sensitivity of earlier assays, newer generation tropism assays are able to detect CXCR4-utilizing viruses at very low levels (ie, 0.3 percent of the viral population) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/17,57\">",
"     17,57",
"    </a>",
"    ]. These new phenotypic tropism assays compare well to older established methods that used cell lines (eg, MT-2 cells) that do not express CCR5 to determine tropism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/51,56\">",
"     51,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main limitation of these assays is the turnaround time needed for results (approximately two weeks) and the requirement for a plasma HIV RNA level &ge;1000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    Even with adequate viremia, tropism cannot be determined on a small number of patient samples. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\", section on 'Tropism assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Genotypic assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotypic assays are also under development to determine coreceptor usage, and there is a commercially available genotypic tropism test in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/50,52\">",
"     50,52",
"    </a>",
"    ]. These assays sequence specific regions in the env gene. Env, a major protein of HIV, determines HIV tropism. As with other genotypic methods, sequence algorithms are used to predict tropism.",
"   </p>",
"   <p>",
"    When compared with early generation phenotypic assays, population based genotypic assays are specific, but have lower sensitivity for the detection of CXCR-4 using viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/59\">",
"     59",
"    </a>",
"    ]. However, when used retrospectively to determine tropism in patients enrolled in clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , newer genotypic assays performed as well as or better than the original Trofile assay in predicting virologic response and clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of deep sequencing of the envelope protein can detect and quantify low prevalence subpopulations of CXCR-4-using HIV within a large set of clinical isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. This method surpassed the ability of the original Trofile assay to predict viral suppression and the likelihood of switching tropism after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    exposure.",
"   </p>",
"   <p>",
"    Current European guidelines favor genotypic testing for determining coreceptor usage. In the United States, DHHS HIV treatment guidelines still recommend that a phenotype be used to determine coreceptor tropism. Although there are more data correlating phenotypic tropism results to outcome than with genotypes, the latter are less expensive and results return much more rapidly. As a result, genotype tropism testing is now an alternative option for clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?4/48/4873/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenotypic testing and genotypic testing are the two available methods for assessing drug resistance in HIV-infected patients. Both assays are limited by their decreased sensitivity in assessing low-level minority variants that comprise 5 to 20 percent of the virus population. The choice between these assays is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/46/3814?source=see_link\">",
"     \"Clinical trials of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Phenotypic resistance assays",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phenotypic resistance assays measure the extent to which an antiretroviral drug inhibits virus replication.",
"     </li>",
"     <li>",
"      Advantages of phenotypic testing include the direct measure of drug susceptibility and the more familiar reporting of the test interpretation.",
"     </li>",
"     <li>",
"      Limitations of phenotypic assays, compared with genotypic assays, include a longer turnaround time, expense, and biologic cut-offs that do not account for achievable drug levels.",
"     </li>",
"     <li>",
"      Definitions of resistance are evolving to reflect thresholds based upon virologic outcome.",
"     </li>",
"     <li>",
"      Phenotypic resistance assays may be helpful when evaluating HIV strains with known or suspected complex drug resistance mutation patterns. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"       \"Drug resistance testing in the clinical management of HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Genotypic resistance assays",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genotypic resistance assays detect the presence of specific drug resistance mutations in the regions of the HIV genome encoding protease, reverse transcriptase, and integrase.",
"     </li>",
"     <li>",
"      The advantages of genotypic testing, relative to phenotypic testing, include lower cost, shorter turnaround times, and more prospective clinical trial data on the clinical utility of such assays.",
"     </li>",
"     <li>",
"      Genotypic testing is the preferred resistance testing method for treatment-naive patients and among those with a history of virologic failure during first or second ART regimens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"       \"Drug resistance testing in the clinical management of HIV infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/46/3814?source=see_link\">",
"       \"Clinical trials of HIV drug resistance testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disadvantages of genotypic testing, compared with phenotypic testing, include the interpretations of only known mutations and difficulty in interpretation of test results when large numbers of mutations are present. Also, combinations of individual mutations may have a different effect on resistance than individual mutations alone.",
"     </li>",
"     <li>",
"      Two general approaches to interpreting genotypic resistance testing include expert interpretation and the use of databases. At present there are not sufficient data to recommend one type of interpretation over the other.",
"     </li>",
"     <li>",
"      Phenotypic tropism testing for viral coreceptor usage is only necessary when therapy with a CCR5 inhibitor is being considered. Although studies are evaluating the genotypic correlates of viral tropism, further studies are needed before genotypic assays can be recommended for this purpose.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/1\">",
"      Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/2\">",
"      Hirsch MS, G&uuml;nthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/3\">",
"      Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother 1993; 37:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/4\">",
"      Kellam P, Larder BA. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994; 38:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/5\">",
"      Abstracts of the 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 23-26 October 2001. Athens, Greece. Antivir Ther 2001; 6 Suppl 4:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/6\">",
"      Wrin T, Huang W, Yap J, et al. Evaluating HIV-1 co-receptor usage and inhibitors of virus entry using recombinant virus assays. Antivir Ther 2001; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     Limoli K, Huang W, Toma S, et al. Validation and performance characteristics of the PhenoSense HIV fusion inhibitor susceptibility assay. 45th Annual ICAAC, Washington DC, 2005. Abstract H-1076.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/8\">",
"      Hertogs K, de B&eacute;thune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/9\">",
"      Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/10\">",
"      Ross L, Boulm&eacute; R, Fisher R, et al. A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms. AIDS Res Hum Retroviruses 2005; 21:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/11\">",
"      Zhang J, Rhee SY, Taylor J, Shafer RW. Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays. J Acquir Immune Defic Syndr 2005; 38:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/12\">",
"      Kuritzkes DR. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDS 2004; 18:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/13\">",
"      Daar ES. Antiretroviral resistance in clinical practice. J Int Assoc Physicians AIDS Care (Chic) 2003; 2 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/14\">",
"      Underwood MR, Ross LL, Irlbeck DM, et al. Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1. J Infect Dis 2009; 199:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/15\">",
"      Cunningham S, Ank B, Lewis D, et al. Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol 2001; 39:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/16\">",
"      Erali M, Page S, Reimer LG, Hillyard DR. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J Clin Microbiol 2001; 39:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/17\">",
"      Collin G, Descamps D, Telles F, et al. Differences in protease and reverse transcriptase sequences between the TruGene HIV-1 genotyping kit (Visible Genetics) and the ViroSeq genotyping system (PE Applied biosystems). Antivir Ther 2000; 5:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/18\">",
"      Demeter LM, D'Aquila R, Weislow O, et al. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. J Virol Methods 1998; 75:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/19\">",
"      Schuurman R, Demeter L, Reichelderfer P, et al. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999; 37:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/20\">",
"      Robert J, Fontaine E, Lambert C, et al. Inter-person variability in interpreting sequencing results for HIV-1 resistance testing. Antivir Ther 2000; 5:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/21\">",
"      Koch N, Tamalet C, Tivoli N, et al. Comparison of two commercial assays for the detection of insertion mutations of HIV-1 reverse transcriptase. J Clin Virol 2001; 21:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/22\">",
"      Fox ZV, Geretti AM, Kjaer J, et al. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS 2007; 21:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/23\">",
"      Metzner KJ, Giulieri SG, Knoepfel SA, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 2009; 48:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/24\">",
"      Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/25\">",
"      Bellosillo NA, Bacheler L, Villacian J. HIV drug resistance tests: an update on methods for calculating phenotypic fold change from a viral genotype. Clin Infect Dis 2009; 48:687; author reply 687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/26\">",
"      Vermeiren H, Van Craenenbroeck E, Alen P, et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 2007; 145:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/27\">",
"      Demeter L, Haubrich R. International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations. J Acquir Immune Defic Syndr 2001; 26 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/28\">",
"      Flandre P, Chappey C, Marcelin AG, et al. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection. J Infect Dis 2007; 195:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/29\">",
"      Harrigan PR, Montaner JS, Wegner SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/30\">",
"      Rhee SY, Fessel WJ, Liu TF, et al. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis 2009; 200:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/31\">",
"      Frentz D, Boucher CA, Assel M, et al. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One 2010; 5:e11505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/32\">",
"      De Luca A, Cingolani A, Di Giambenedetto S, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003; 187:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/33\">",
"      Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/34\">",
"      Van Laethem K, De Luca A, Antinori A, et al. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 2002; 7:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/35\">",
"      Desai S, Kyriakides T, Holodniy M, et al. Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy. HIV Clin Trials 2007; 8:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/36\">",
"      Shafer RW. Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options. J Infect Dis 2009; 199:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/37\">",
"      Halvas EK, Wiegand A, Boltz VF, et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis 2010; 201:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/38\">",
"      Paredes R, Lalama CM, Ribaudo HJ, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/39\">",
"      Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/40\">",
"      Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-na&iuml;ve populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:e158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/41\">",
"      Garcia-Diaz A, Lok CB, Blok C, et al. Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. J Antimicrob Chemother 2008; 62:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/42\">",
"      Lataillade M, Chiarella J, Yang R, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-na&iuml;ve subjects in the CASTLE study. PLoS One 2010; 5:e10952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/43\">",
"      Le T, Chiarella J, Simen BB, et al. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 2009; 4:e6079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/44\">",
"      Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/45\">",
"      Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/46\">",
"      Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/47\">",
"      Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/48\">",
"      Coakley E. HIV tropism testing in the clinic. J Viral Entry 2007; 3:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/49\">",
"      Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681.",
"     </a>",
"    </li>",
"    <li>",
"     Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. file://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. (Accessed on February 13, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/51\">",
"      Hosoya N, Su Z, Wilkin T, et al. Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions. J Clin Microbiol 2009; 47:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/52\">",
"      Lin NH, Kuritzkes DR. Tropism testing in the clinical management of HIV-1 infection. Curr Opin HIV AIDS 2009; 4:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/53\">",
"      Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/54\">",
"      Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM. An enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry 2009; 3:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/55\">",
"      Raymond S, Delobel P, Mavigner M, et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008; 22:F11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/56\">",
"      Coakley E, Reeves JD, Huang W, et al. Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays. Antimicrob Agents Chemother 2009; 53:4686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/57\">",
"      Su Z, Gulick RM, Krambrink A, et al. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009; 200:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/58\">",
"      Trouplin V, Salvatori F, Cappello F, et al. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001; 75:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/59\">",
"      McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/60\">",
"      McGovern RA, Thielen A, Portsmouth S, et al. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J Acquir Immune Defic Syndr 2012; 61:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/61\">",
"      Swenson LC, Mo T, Dong WW, et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011; 203:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/48/4873/abstract/62\">",
"      Swenson LC, Mo T, Dong WW, et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 2011; 53:732.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3769 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-D91D1357DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4873=[""].join("\n");
var outline_f4_48_4873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHENOTYPIC RESISTANCE ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recombinant virus assay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Commercial assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENOTYPIC RESISTANCE ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Available assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      VircoTypeTM (Virco NV, Belgium)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INTERPRETING RESISTANCE ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Phenotypic definitions of resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Assay variability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Biologic variability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Virologic outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Genotypic definitions of resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Interpreting genotypic assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Resistance testing and new drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LOW-ABUNDANCE DRUG-RESISTANT VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Point mutation assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clonal sequencing assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ultradeep pyrosequencing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      TROPISM ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      General background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Types of tropism assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Phenotypic assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Genotypic assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Phenotypic resistance assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Genotypic resistance assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/46/3814?source=related_link\">",
"      Clinical trials of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_48_4874="Lateral view of the internal carotid artery";
var content_f4_48_4874=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Lateral view of the internal carotid artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 651px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKLAk4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5q98caBY6++j3V3NHexyxQyE2cxhjeUDy1aYJ5alsjALDJOOtAHS0UUUAFFFFABRVLTdUs9Sa8Wym802dw1rP8AKV2SKASvI54YcjjmrNzMtvbyzOCVjQuQOuAM0ASUVn+HtVg17QNM1e0SVLbULWK7iWUAOqSIGAYAkZwRnBNaFABRVLRtUs9a0y31HTZvOs513RybSu4Zx0IBHTuKu0AFFFFAHkHxH8SeJLPx9d6X4dvdT86PRre7srC009LiK4uXuJkIncxsY4yqKCd6AYJBzWrZ/Eq/ulSWHw4s8V5DeyadFb34e4uGtiQUeMoBHuxwQz4OAcE4r0MWdqL970W0IvXjELXAjHmGMEkIW67QWYgdMk+tZv8Awivh77Rfz/2DpPn6grJeSfY491yrHLCQ4y4PcHOaAPOrP4h6/qPi7RILez02K1MN8b+zF1OJF8r7M2WWW0SRZFWUlU2gOH5YcGl034wXl5okmqHwnerbOtrJauTOiSia4jhCmSWBE3gShsIzqQD83evQYfCHhqGC0gh8PaPHDaTfaLaNLKILDLx+8QbcK3A5HPAotvCHhq1luJLXw9o8MlwyvM8dlEplZXDqWIXkhwGBPQgHrQByMnjnVbXxHc6M2mQTaxNew2kMD6gFtIybYzsRKIA4G1TwVYljxgdLfhPx/deJ9Yt7Gw0aJE+xpeXM0l7xGDcTwMqBUO8hoCVPAYHquBnrNS8P6NqkVzHqekadeR3LK86XFskglZRhSwIO4gcAnpU9npen2MiyWVja28iwrbhooVQiJSSseQPugsxA6DJ9aAOJ8W+NrvQvGT6ZZ2TX0kkFgsUMl0sMIe4nnj3ZETOCPLGTkgjGFBBLZEPj7xBfeLNDgg06zt7YDVIdStTeFgXtZoUZ43EO5sBiVGE3byG27QT6ZcaTp1zeLd3NhaTXS7MTSQqzjYxZPmIz8rMxHoWJHWq9x4c0O5eF7jRtNleC4a7iL2qMY52O4yrkcOTyWHOaAPNtK+MF7f2NtdjwleLb3klotrIWnjjcTzpEAZJYETePMDYRnUgH5+M1rn4g6tb6/NYX/h+yjt7bU7PSrmeHU2kZZbiON1KIYV3KDKASSp4yB2rq7Twh4as7mS4tPD2jwXEkiyvLFZRKzOrh1YkLkkMAwPYjPWr8mk6bJLJLJp9m8kkyXLu0KkvKgASQnHLKFUBuo2jHSgDxzxP8U7jVNM13TbO3Nof7OkvbLU7Ke42yKk0aHazwRDPzjmNnHUZ9ev8AipNqkureDtI0wsLfUtRkS6Eeoy2LuqW8sgTzYlLgZXccEZKKvRiR0cHg3wxbzXEtv4c0WKW5DLO6WMSmUMQWDELyCQCc9SBWvPaW1xPbTz28Ms1sxeCR0DNExUqSpP3SVZhkdiR3oA87sPiLq+o2miyWfh2yWbWElltEuNUMa7IgTIXYQttP3doAbIJJ2bTVWD4sT3dsNQs9AR9Jij0+S4le+2yoLtwg2IIyH2n/AG1BHIrv73w1oV/pkOm32i6Zc6dCd0drNaxvEh55VCMDqeg71M2i6U0ckbaZYlJREHUwJhxGcxgjHO08r6dsUAeY6Z8Q/EFlpN/Lqdlpt5dnWr2ysoUubhpZEhmlDKI4LR2OwKgBwdwyzFSMHV+F/iqXxd4k1XUlNxFZXOjaXdRWckpdYGkN1vwOmTtUEgDO0eldVeeDPC97PcT3nhvRbia4kE00ktjE7SuM4ZiV5IyeTzya0dM0fTdKBGl6dZ2Q8tIf9HgWP5EzsX5QPlXc2B0G4460Aeban8XhY6lqkI0mK7tLa01C6trq3nn2Tm0UsyFnt1TJwQTG8m0gg+63fjnxJp3iW/uNR0uxTQrTQf7Wkto74vMEDOdwHkDMhChSm/aOu413I8H+Ghd3V0PDujfarpXS4m+wxb5lcEOHbblgwJBz1yc1bu9B0i9u7S7vNKsLi6tFK280tujvCDwQjEZUfSgDz/TPihqd5DB5nhO5hmubu3tbYyvPDDL5ySMCHmt4ySpj+YKpGGBBbpWzpfjm5uvE8Xhy50hIdaW4kF1FHdGSOK2WJXFwrGNSys0iIBtHzE8/Ka39N8J+HdLJOmaBpNmTKs5NvZxx5kUEK/Cj5gGbB6jcfWpLTQbW28SahrgaWS+vIYrcmQgiKKPcQiYAIBZ2Y5JyT6AAAGtRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFed3/w8uNU8Xa9qV9qky6beTWdxDYRFfLmkgQbTPlN5AdVIVXAOOa9EooA8E0v4Q+IkTUlu5NDt0vUsVlisWWGN3hvI53cLFbRbcorhc72BwC5HI1tT+F2ryeP7XVdKTQdM061vElgksYYreZIBHsMZC2+9myWOfOCEYGwYzXstFAHiM3wq1aXwhaaTFp/hyyu7aeCS5u7aUM2shFkU/afNtXAJLh/mEw3Z9jSv8Hbi40Ge2uI9Pku49ElsbBrmfzzaXTTyyI6OsEYVVDqFKopUDaBgZPttFAHkS/C+4Gp6gf7O0FYLrW4dUe9R2W4liBQyQuBF0yGI+cgluQMk1V1D4X61J4/ttXsE0Cy0+1uf3JtY44JPsv2doliZUt95IyBzMU2gYQYGPZ6KAOAvfCWrH4QaV4WtjpUuoW1lZ2k4ukElvIIggfbvjcAnadrNGwBwStc34O+FF1aT6QniaLSb7TbNtSZrIkSxhbh4GjQIIY4yFMT5GxVB2lV9PY6KAPn6f4L6sdK0uyhs/D8UNks8UkUEyILsuRtuGMlnKFlAG3hSQDw45B6e7+G8cOj+LbvVoxd300UEthcxqbu7geC0hQMvyAmQyw7vkA34XIHQetVheJNXuNJ1Pw8qrGbK+vjZ3DEHcm6KRoyDnoXRV/4EKAKnw40q703w4txrCqut6nK2oahtGAJpMfIPZFCRj2QV1FFFABRRRQAUUUUAFFNkkSJC8jqiDqWOAKzpdf0iJSW1K0OOoSUMfyHNJtLcqMJS+FXNOisJvFWmf8svtk3/AFzs5SD+O3H61XbxdESRDpWqSntiNAD+bCpdSC3ZqsNVf2WdLRXKv4suAeNEul/66Sxj+RNPs/E1zc3UEJ0mRFkdVLmYYAJ69Oan29O9rlfVKtr2/FDfhSzP8LvB7OxZm0azJJOST5CV1NeY/D3xHcaf8OvCkCaTNcxRaNYjzI5VGc28Z6HnviulXxgqx7rjSNRi7f8ALL+rg/pQ69NOzkhLC1Wk0t/Q6miuaTxnpgOLiO/gb0a0d/1QMKvw+I9HmGV1G2T2lfyz+TYqlUhLZkSoVI7xZrUVXtL21vATaXME4HUxSBsflVirM2mtGFFFFAgooooAKKKKACiisuTxDosdld3kmr6clnZzG2uZ2uUEcEoIUxu2cKwJA2nnJFAGpRVZL+0kjuZIrmKRbVmScxuH8tlGSrY6EAg468iqD+JdJTw5Z6813jSbxbdoJ/Lf5xOyLF8uNw3GRByOM84waANiiqWjarZazY/bNNm86282WHftZfnjkaNxggHhkYe+OOKmnu7a3ntoJ7iGKa5YpBG7hWlYKWIUH7xCqxwOwJ7UAT0VDeXdtYwefe3ENvDuVPMlcIu5mCqMnuWIAHckCpqACiiigAorKg8Q6XP4fl1tLxBpUSSySXDqyKqxlg5IIBwCrdu1WdI1G31bTob6zFwLeYEp9ot5IHwCRkpIqsOnGQMjBHBBoAuUUVAt3bNevZrcQm7SNZmgDjzFRiQrFeoUlWAPQlT6UAT0VSvtVs7G+06zupvLudQlaG2Tax8x1jaRhkDA+VGPOOnrirtABRUNzd29qYRc3EUJmkEUQkcL5jkEhVz1OAeB6GpqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuW+J8MkngfU7i2Qvc6eqalAq9TJbusygfUx4/GuppsiLJG0cihkYFWUjIIPagBttPHc28U8DB4pUDow6FSMg1JXEeANVt9L8B2dvqlwsT6VJLpTbzlmNvI0S4HViyorccndVt/Ed5qCuNLthbRD/lvcjLEeqoufzJ+orOpWhT+J2NqeHnUV0tO51MsiRRl5XVEHVmOAPxrDuvFemREi2eW+b/p1Tev/ffC/rWCNF+2utxqks111YS3rfIo7kJ90fgKgh1C3e6C6FaS6qU4LRgLFkZ6ynC4z2Uk+1ccsZOWlOPzf+R1xw1KHxu/4f1+BpR+JdWvZylnYQ26dFMpMpJ+gwB+ZqtdRazfTmG51C5T1jgkWIL+Kjd/49UU8dyt00t/rVlpzEZ8m0UPIg9nfgjg/wDLPtWc0nh+5CeTHfau7J58onM7oI+pLR427sHhNuTxxUctefxyt6FqpTg/civuv+Y+az8MWcuNRvLWS4jBOXm8yQn2BOT9cVPY6jYH5rPTL25C/cWHTmRT7l2Cg/gas6VNf20sEMWj2NjZkGSVomCiJcHCBQPmbpk/KADxnFZGqarpwE0F74zs7ffN5hC3casR/dxnKgDAAHcZOdxFWsMnuxSxM2rNm0lxqzx/uPD7RSsT897dxLj6BC+KdENbFsd40W0i5LyLPJOce5KoK4hNU8JQ/PeeLpLti4aRvNLeYo6IcA/KR17t644oHjvwLZeYP7Qur9SI1SA2jmOMIPlCKUVRg5OevvgAC44eC6GbnJncNHcxLG0uraOIi21c2RwWJxjJm5Oc1btRdXE9tO2uW0tusyjbHAoViGwVB3EZyMeoNeQ3fj3wDIzrJYatuebzmdeDnkYz5mQpDEbRgc9K2tH+Ivg7V/EeiW0Ol3j3AuY4bVnhj2QszABgN/HXqBnrVxpRWyJlKTNvwHcSReAPBwh1XS7d5NKsYUjmiLSb/s0Z2j94MnkHGOhH1rpDb6issh/tHSHmUZbfaMSo/wC/nFeWeGfFfhTTPCej6drF9qdvdyaJp6yNH5hEQNnFzGU5UkEZI5q8viX4aTG3iF1NFFCpVE+yzBCxOfMYbPmbOeWz1NEqUW72FGT5T0SS211pPMkTRLor90OrxD9M/wBaq3EeomQyaj4fgnXHA028Un8RIsf6Gubk13whcaJJYWXiiKOSSVZTPe3EuWYEE7ssuRgYxnb6g9K3NGRZLmE6L4mtbi0WNvMiUrcNNMf+WjPvJwOMKMdMZxjEujF7oqNSUdmVZovDjyFtRtLywK/de5tWAB/32Xb+RrT0uCRot+ia3O6Hp5cgmXHoFYsB+Ao0+TxNb2NuLiO2u7lkbf5swiCt1BJVDnk4wAMAfxGs1rk6jd3B8R+HIzHbsIo5YreSSWWQkjcp2jauBncCR833hjnP2HL8Lsa/WJNWev4/mb8mreINPwtzbW13j0zGzD1yMj/x2rln4usHAW/SWxk6HzRlM/74yB+OKwY54rC9Wz03VLy1kf7kF9bmeJsjONzAPnGTjfxjkVdnv9RMUby6bFe2pXIm06RWJHrsfGR/ukn0BqlKrDrf+u//AACH7KfxRt6afhsdfbXEN1CsttNHNE3R42DKfxFS153bafpl9PJcaBqB0vUoyPNWPMLA/wDTSIjp7EVdHiLWtJdo9TtYdRhQ/wCvtTsbHup4J/FRWqxMV8ehm8I5fwnfy2f+R29FZmi63YazEzWM251+/E42un1U8/j0PY1p10Jpq6OWUXB8slZhXztrvwl8S32neLDCsYg1HUb2/GnGVd1xN58htpA2doUxyliGIOYo+OtepLeXHjLxAI9NuJYPDWlXAM9zC5U39yjZ8pGHPlIwG5h95vl6Bs9vTJPIfEWi+L7jULsTW+s3+jy3t6VtbHVRbSbWjhFu5fzUPlAibMYYcsDtasA+DPFx0PRdMvdN1S4a1t9EW3EGqJHa2n2cwm5WWLzVEj5RyG2uPu4IIGffaKAPAtQ8I+P4LC0t9ObUba1Dag/l6fMpkimkvppUlIF3bqwMboQGMgByCnJr0vxpY+IbqTw+dHluD5LXH21oZhCGzZzKhK7uf3zRkDnBwe2a7KigDw7WfAviifw+9kx1m/R7DS7maGbWGZ3vYrkPcKjNL8h8scYKpu2kEEAiU6D47PjAXEMmuW2lb4WtkNyJ/KgEQDQzFr4KX3bsv5UrZIYOeg9sooA8gg8F+JJdN8Kx3l/4hM66LP8A2qy65KjG/wDKtxECUlGcMsvK/KSCWJLEtn32lfEebWvDUyWt9G1sNN+2XEeokxzABPtQkT7UsYIPmDiB9w5DA4r2+igDy6+8J6vcfAfV/Dn2Rxq88F2sUCTqhZnmkdBvDAYIK5BOMEg9xSat4T8RIvij+yL7WRsEC6OkmrytuTy1E4yzk72+cAyZ2thhjrXqVFAHkemeGfEt9qtpFeHxFp/hw380n2abW2a6ih+zAASTRysxBmBIUSMR6gcDGtvDHjGyuItVutK1XU9al8ORWLOutGFUuUacMJts6Fso6bSucPlsqSXr3WigDxXwT4a8Zp4k0i41+C8awstYkuojd3IkeKB9PkiPDXE7481sY8xupPA4Gj8VNO8b3/iSB/C1reJBCkBjuba/ZFYiXdIskZuY0Hy8ZMU27dj5cCvWaKAPGtc8Fa3fWUV/qEevaje2/iS4ultbfWnhb7CZpfLEQEyIpCshGSGAyuQBtqovh74h/wDCQavM11q6xOt99lKXAMLRvE4t4yWvPkdSY/mWDO5eXIJavcKKAPH/ABFpeu6XP4b03S9Z1P8AtDxBA1hfrPfySvAQEklu4ssVRkVZF+TA3SJivXo0Ecaou4hQANzEn8SeTTqKACiiigAooooAKKKKACiiigAooooAKKK8y+L18lrqeiC41600+28udns7rV59JS5b5NrC6iBIKfN8h+9uzjjIAPTaK8Rt/ilPo+izw3BWCUabYXOlR6sxa6vDLJIsu4gjzAoVSCoHBy3WrUvxP1iPxHe2dt/Y+qSQahfWn9jWcb/bkigikdJmbzCACyKmCgyXGD2oA9korw7wz8VPEutG1iij0F5Lq7tbYSq8TeQZUlLK8UV1KwK7FILFN3zAqpGRbu/HuraRdXVpc3+i6aP7QvIpdV1FJ3ti8MUBWJUM2UaQyOQofACHCsc0AezUVwHgbxTr3ibVttxb2Wn2sNjZXc8Dwu0+6eJmMYO4BdrAclTwCMZORm654p1q08ZXWlaObGKW51i108TXizToiPYyTFhGJVAOYwMLtByc5PNAHqNFeDWnxA8Qf2z/AGpc32nBzoly8WkCKQC/uLe4nQrADNxI3lqfuuQpAwetXfDXxP8AEmsxQpGmgySXGoWtokyPE4jEscxYPFDdTEFTGpBZl3ZI2qRmgD2yivKP+E58R2Op79SbSZtMj1p9GlS3spVmYrbGUzKfNYdVxs2k4P3s1xkXxGvfGM1tp929jcW8OqaJeQXFrEkRIe/VSrolxOAflBwWVhyCo4yAfRVFFFABRRRQAUUVz2teJI7WdrHTYxeaiMAoD8kX++39OvTpnNTKSirs0p0pVXyxRsajfW2nWr3N7MkMKdWb+QHc+wrlX8SahrDCPQrYwQMdv2qdcsfdV6fnn3FV7LSVu79b3X7j7XcBS+6TmGId9qngDpzz/WmrqtxfPIPDcSTpzGL2Y4t4+xK95COwXj1IrjniJVLez2O6NKlS395/h/wfn9xkWP2bTPEXiKPUXtyNlvqUU9xgDMieRJjtndbBj7ye9bMM13fWRTSrNkQ4Jvb/AHRK/ukf3yMeu0H1rDvI303xXoU0UsmqTuZ9Pmlugqo0zoJ4wCBhdptmA4ODJ1JNXvE72GlSWmo+J9fe2RJHm+yB9wlYhQFVQMsqhcY287iT1oeHUnzS1djNVWvdXczP7QsP7cS1vRea5crcC1eSeMJaQN3WOP7pYccHcf8Aarf1dL6904x308Wk2Ecv7+VJtp8lewbgLk454IHuePNtY+K3LWngrRI4S7sRPOigljyzCMcZJ53E/UVa0LwHrHiuVLzxbqNze87xCZD5aE+gHA/4CBWqiloFm9XoW7v4h+FtEe4tNDsptWlk4Zo1AibC7Qu89RjjIByO5JOeX1bxj4+1kSNZWp062b+GGMKxHu7859xivZtL8F6PpMQW3tIVYDBKoMn6nvWlNY2piZRCijHQCqs0C5PU+Y9P0LXvEmqSWmq6jMpCebIbmZpztHUgZPT6iup/4VhpsI066fUZp7OWRUd1wAd2QPoM4zXVwwLY/E/TBAoHmq8bKO4IrV12wl8Pm+gFpNcaBeIWXyV3G1lwew525A56duMcwm2mdUYQUku5etvhd4YtbVEbT4JXx95l3N+Z5qjZ+CNA07xPHu062Mc8REe5AcMOwz0yAT+FdF4N1savots024XSRqsocYJOPvfQ9ai8b23n+H7ttoMkKGRMnByB2q27q6MoKUajpzfl/wAEy9R06x1K4/s7Q4IoI4vmnnVcBfRRjuevHYZ4yM7Wn+E9Ht2s3itk82GVJFfYM7gQc/pT/DVvBDoNiLZdqPEshPdiwBJPqSa2rYBHXJA+YDn600tSatRpckXoj5xg8O2dzpvgy6ubZXFxpulI5JI3D7PCvr6V7TH8O/DAVg2lWYA6AQrx+OK8/ktZR8KPBV5AuWi0iwf34gjI/lXrmmajDqWn211bOGimQMGH0qV8TuEm/ZQcTkb/AOF3hi4J22IRvWNmX+RrjfEvwj0myjjuUmuxab8TchzGpH3hx0Bxn2PtivZJ3zypGB1piussbK+GQ8EGqYo1JbvU8M1H4ba5pkMdzouvXATAKFZWQgfVT/Squi33xKiu57ewvpLs2+N6TNHICCTg5cbsZB6EdK9E1WwufDziWxD3OlM2Htf+eWehT0HTI6Y6YPW/8L4d9td6nKFMt1IAeO6ls/hz+YPrURbbsdE6UVSdQ5CXxvq1mjDxx4KSVTGUe5tkDKU/ukHcME+rD6Vq6R4n8KeI72zew1p9MKEM9hOTAJSAdq5ztOCScKTk4J6V6fcpDOpWSNGz6ivN/Hfg/Q7gQvLp8Ae4uEiklUbHG7IB3Dk84q2rHJBKei0Nm+i1AWizeILDTtSYlgq2lq7uibS3ykknJCkfw8svPY1ZLiO3uzaaTrkkb+b5IsdRV5oy+ASqSfe/iGfmYDpgYNeb3WgeI/B1yv8AwjWt3KQp8y2kz5jPrwfl/wDHR9av6X8YbW9gay8WaZ5UxRo/tNqiyBSRgko+cfm30xUOKkVyyhqdrq4sUKy6rYSaNKPu31tJvts+vmLgx+uW21naxr+rm1uvD9xqfnRQlRqGp2K/vooGGRChBwZ3GTkY2J8x5K5db6o3kWdl4H1FLqfUo2li322Bax5Ikups4J+Y4VMAMwCjgMRa0q006KODTNGvJrbUliaaS3vl843QZstLcJ2dmOd3yt2xgBRKpuneUd+wOt7S0J6pff8Aed74Wn0iXRLaPw8bcafAgijihGBEAOFK9j7GtavJ47AWGpq1oX0LWXHyqCTb3PchHPDdztYA98DrXWaF4sEky2Otxi0vc7BIP9VIe3P8JPYHg9ia0hXTfLLRirYTTnou6/Ff5+qOsrE8X+IoPC+kLf3NrdXYe4htY4LUJ5jySyBEA3sqj5mHJIrbJwMnpXF6/Z6b8S/DZtdN1KRbODUYXa6hSRRIYJVdhFICpIO0r5iMcHOCSK3OEs6f4/8AD89uW1K+g0W5W6eye01S4ihlWZMZQYcqxwynKlhhhV+/8VaNaXcdoNQspr17hLc2yXcKyqzOiElXdehkTIGW+YAAkgHiPEnwesL25WTRbw2MUltJa3UFzJeTLcq7l2aRo7mJ3YljkuzgjHHArZHw+jWzuII75UM2u22sl/IyQIXiYRElsnPlY3E8buhxyAbkvjPwvC96s3iTRY2suLoNfRA2/wAwX9583y/MQOccnFc/4l+JVlpeJNLittXs30ufUo7m3u1Mb+VNDEUBUMDkzE5zxtxjnivD4C1208LDw9p3imK10+CQNbPFYyxz7PMLlJZUuFLggkEp5bd89c5Fl8HHt9NuLWTXzI81vewF/srnBubmKctl5WY7fK2/MxJ3ZJz1APR/+Ek0P+07jTf7Z0z+0bdDJNa/ao/NiUDJZkzkADnJFUv+E68IixF7/wAJToP2Iy+SLj+0IfLMmM7N27G7BBx1xXMXHwylnu5kk1Wzl0r7XfX0NpPp5ZzLdJIjrLIJQZIx5z/KApI2gtwDVaf4Z69NpCWB8aXKw+a7NAq3Qh8to1UID9q87gqWG6Vl+YjbjAoA7fRvEMeq+INW02CNDFYxW0yXKS71mWZWYEADgDb1yc5oj8X+G5Jr6GPxDo7S2Cs92i3sRa3VThjIN3yAHg5xisr4eeCj4PiZDqH23NhZWWfJ8v8A494ym77x+9nOO2OprkNV+D2o6tdahNqfi2a5a5sr2yRpYJnZFuCuCQ05QbAoGI0jDd+RmgDtLb4ieFrnxXc+HodZsGv4IBMxF1EUJzIGjHzZ3oIyzLj5QQa0IPF/hqew+3QeIdHlsvMMX2hL2Jo94UuV3BsZCqzY9AT0FYHivwA2ualqDwajHZafqOkLo91bLaksI0MrI0Th1CEGU5BVgQMcdazdE+FrWV1p91fanDdXNrqMN+0nl3LmbyoJokQme5mII87cCuMbcY6EAHd2eu6Rex2slnqthcR3UjQ27RXCOJnUEsqEH5mAViQORtPpWlXB6B4Tmt/iVrmtzxyRacDusIXdWUzSoguJlAJK58tFAODnzD0bnvKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5jRdZ8I2Uup22k61pHmrLPfXsaX6O0bbj5sjgsSoBBz0Ax2rp68h0D4c6/Np6tf6wmjzWs+qvYLaWwM8LXM0mJXl8xlk+RgwUKmNwB5XNAHoUHi/w1PYfboPEOjy2XmGL7Ql7E0e8KXK7g2MhVZsegJ6Cof+Ez8PxWX2u+1fTbG1a4e2ilub6AJMy/3WDkHI5wcMO4FcfoPwqmsNUhv9Q1wX0yarBqjBoZnDGK3lhVd008r5/eK2SxxswABjDdc+ErahfPe22ttDcPcXsjKyXCxtFcurNGRBcRMcbQM7sEdV6YAOot/iH4Xk1XXNPm1mwtZtHdVuWubqJFKsqHeuW+6DIqEnGGyKmi8YWN34h0PT9KkttRs9Utru4S9trlZI18holKjbkNnzeuRjb3zxzp+HWp2sOrW+i+I1021v1tWKxWsvmRvBFDFtEonD+WyQ4IBDjdkSccyeCfhvJ4b1SwvptYN7LbvfyOPJcb2umhY/NJK7/KYTyzMTu5PHIB183iPQ4Naj0efWdNj1eTGyxe6QTtkZGIydx456Vi6h8SfCVhrGm6bLr2mNPfEhGS8hKx4XcC/z5AbovBySBWT4j+Huo6340tdYm8SzDT7a+tr6GwaOYiMw7couJliwxDHc0TMN3XHFT2Xw/n0zSvC1vpWqW8NzockrebLZF0nEqsr5RZFKt82Q248jkGgDpYPFXh6eS7jg17SZJLMhblUvI2MBLbQHAPyktxz34p1r4m0G7tZbm11vTJ7aKRYpJY7uNkR2IVVJBwCSQADySa820z4Kx2enTWEmsLcW4tltLd5o7mSSOITxylGD3LREHygCEjTnB7YPR6z4Qk1H4n6ZqixNFpNvbrNd4ddlzcRMwtl253Zj8yR84xnyxzjgA39b8SRaHq9nBqlvJBpt0AiajnMSTFsCOT+5u42seCTjg43b1Q3trb31pNa3sEVxazIY5YpUDI6nggg8EGuHWW7+HrLHdPPe+DuiXDkyTaWP7sh6vAOznLJ3yvIAO+oqpcajZ22nfb5rqFbLaHE24FCp6EHvnIxjrmuQury98RkCRJrDSHO1YmGJLkZ6t6D/AGf++vSs6tWNJXZvRoSq67LuT6vr8+pzfZNEd0tg22W8Ucuf7kf/AMV+XqKkj2eiyW1lb273epMhlNrEcyOc9WJOFX1Zjzz1NLPdqt6un+GjCZ4SYpbxhuhtjjkDsz/7A/HHeGzgWe1lsdBdxLchJ7rUZly0gYkEkjGWwvA4CgjgCuPklWlep9x2OcYR5aasv63KWvebHai81yI6rcysuzSbXJhQD5juwMyEL6jBOAF5BqTxB9lsJk1XxLqR0zT7eZJbS3WX5jhF+UqAcnIb5Vzx3wSKwdc8a2ejXDaL4Ht/7U1hlWJ52cvFFtG3kk/MR7EAEnJ6isy28B3WsXMeq+NdQkuLmRgmXbZGuTwq9Mc9hjrXQoqJEYuWr0I9W+IDa/Fc/wBjaVJDpelbNUFw6/vGaCRZmAAOAGRJFxyTu7VJ4Y8C2tx4mvX8Q37X90JTiWRjJuUHg5PX69B+Fek6b4Z0qxsDaR2yiF1KOB3UjB/Qmuc8J2Bm8L6ZK7EalZobC4k6F5bdjC5PuTFn8apt2CHKp2XVFTx1oNpp1mZ4gFgSN1A+qFQB+JA/Gu+8MXMcuiW01s6tHIg+ZTXBancza/qdlo13EyBCTMxGFfHOB+QP+eYvCMtxoXimXS3Ym0uN2xCeFk68fUAms1KzudNWi3Dllvv8j1NmLZxVSeVYUdnOABmnK+Aax9fS4uLUwWpCySkLuIztB6n8quTOWELux57ZavDJ8Q4L+4yLaJjGjdg2K9D1NdVlkN3oeoQyK33rS6XKHj+FhyPxyPpT38L6a+iw6aYv3SfMW3HcX7tn1rCl8M6vp7M2k6hvhHIjk+Vh7BuR+lTFNG/NCo007W7lLUP+EnhvoL46VDG8P3jDKGDrnlSOv5D0POK6b+07fVNMm8ossoVd0UgwVz0+o9xnoR1GKxLTxRPp12LbXcxI3GZVAP1Vhw4/75I9COlbxzHZm2kl0+48u7MLzYikxuVQCSQPYA/8B9hQ9NUdCh7SUYyVuzRt+Brln8G2LqQxjiZFx3CkqP0AqTTdTm1Hw5ot0zD7RPPbrLtGBuEq7/8A0FqZ4HjSDwnpQhOV8kHI9Tyf1zWBIl/oniTStMgVDpdzqSTwucgxgklo/fqcVXkZKEZTlbdO/wB1zS8FWceofCbwpbydG0SyH/kulYVjd6r4Jla3lge70dmLAL96PPp6j2rV8D6nBYfDfwj577R/YtkSSOP+PePvUmo6+15D5Vhpt1eMwONsRC/ixGKmdrmVBPkSaumaOl+KNL1Zc2l0u/ujAqw+oNa0SbuVYY9q4Cx+H82o3IvNXlWzPUQ2x+YfVvX6V09t4euNOjYafql8QB8qzssg/MjPr3oV3uipRpp2izbmiLoVYZB6iuR0MP4f8UyWYbFhfsQq/wBycDcPwZM/ita9vrVzYyCLWrZkDcJNGpZT7HHQ/l/jzXjvVLOUxXFhMJLi2eO42oQSGjcDkdfuyP8AlQ7bmtGnNt02tH9x6XvXbgj5jzWT4mtPtmj3MYHzlfl7c/0+tJY69ps8KSQXkJEihhhweDT9R1G0Ns/+kR9Ofmq200ccYyhJaHmeo6sk6mDVpBHPCo85mHPl/wB8evQ5x3Bp9no+jw+CLa51bQ4NR1zWbmV9OsGAEshclgu/qiKvzM/8I/AGhr11Z3d2lxLD5mmwXCtePGm55OgSJR1LOcKqjlj9MjotLfXBqVxqT6RJJrdxEIUyB9n0+HORBGxIB7F3UHew/uqtRDT3mdeJ1Spw0b1fkUPEPw21mDTLaXRtaMWrKRNcPHmJJpAMKEK8oiKdqLyAM92Ynnrbx3rGkTJpHxG0yW4tXYFbhAEkGO+VIVwPYgjvnpXrXh7T7uCSS51S5a7v5OGYfcQeiitLUtJsdUtnt762inib7ySKGB/A1abepxyhGHu3uc19ut9c0tJNNFtruguixtCCDMj9d8jyONu0Dpjfkg1UmbT1sbi4F9Yan4eTPmXTXCeZYjHUyZw6fX5v9/PHKeJPBg8F6nBq/hvV5tKM0qw/Z1UztcEniOOPrIx5whyO+VAJFrQJrDxJ4pulvrzT7XXIZvOg0vyfMt0kUH945BUTzjHXJVOdozlypU4z+IlVJU37rNSL7Xq2lwLq51KDwWj4MJBFxdp6zfxRwdMR/fYH5to+Q+sWH2b7FALARC02ARCEAIFxxtxxjFeeIk08811a2/8AZuqyuwksLmZAuoBQQXCgnaTg4fHOORjBqfRNTk0Znlggn/srzMXVpImJbNzglsDqOckDIIOV5PzSqrhLlktCnRVaN0/e/M9DoqOCaO4gjmgkWSKRQyupyGB6EGpK6ThatuFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVdUvLXT9Pnur+RY7aNCXLdMemO5PTHepbmeK1t5J7iRY4Y1Lu7HAUDqa4WaOTxRcDVb0GLSbR820EhxkjrK49cdM9B75rKrVVON+p0UKPtHeTtFf1Y5hLKexhF9aaVdt4dSVrk6QpMktjkn99bp0K85aHnbklD1U9P9s/t+3gTSLkrpboHl1WNv8AXA9Egb+bfw9B833ZIVfxAVlMzwaK7LswSj3mMkAHqIvpy3+797m9X05rd59d0yKA6bJeR3E2mNdCOO7kDDEkRJCJPvHTlJMqD83zDnhD2nvVFqazny6R2/I0dDNvqln57QQ2vhW3G+2aQiHygIirnOemWfk988151418c3euC50XwRayw6PuYS3USkNOe4U/wp7dSMDgcHo57HUvibqTebcLa+EbeUhLe3JV5pAcsswIDI6k4ZCAVPTPDV31t4a0mws4re2tkRUXAwMAfQVvaw48rd3seafC5NO8NJGmp26Ru+PMuN26Pd2DHHyY6DOB1r2G/W21PT5IpVSW3lTaV6gg1y2q+GYyDNZbEmUHAZdysCMFSO4I4rmdF1q58N37WNxaztp8jExpGpcwHOCgHde4rPma0Z2ewVZc1PddDo7F7nQr+OxuJmm0yU7IJZGy0TdkJ7gjp6Ee4Am8ORi18ReJtOPRp4tTiHok8e1v/IsEx/4FWdrHiLRdU0m5tBcFLx1/dRMCrh85X9QKi0nVBP4k0DUHAWW9tLjTLhCcHzF/fxEjt8sVycH1q4tPQxr05qKqNW1JfFiHTvEOkahGvytMInP+98pJ/wDHfyrM8dRT6dq9pq1uhIicP9cZ4z7gkfjWn8QJ0kS0tF5ma6hAwe5Yv/KP9R611mpadDqNibe4UEEdu1Ry3Ru6nKoOXp8h2nX1vqWnw3towaGVQRjsfSnoNzgkdOleW3UOq+CL2SW0cyWEjHdG2Sp/wPuP1rvvCmsW2u6ct3bMOu2RM8o3cH/Pemnd2e5jOlyrmi7o6EAlCao6gt5LbstjcR28v954t4/LIq6WAUVD50UeS7r+daHPHTU4vUPD+u6oVjvLuyaNSCzeWSW/DAx+dUr3wX9h02Qxatcxz/eBUKqZ91A5rsL7X7G0DEyqSOwrhdU1q/8AEt4bHRoS4Bw8n8Ce5P8ASok0jtp1ar02Ri+FvF0vh5riyntgbVpTtILFFOBkL1x64x+NdQniKy8Q3+lQKPLuor6CSM+Yp6SLuGAc8jPBArpdP8J6bB4dTS7mFLlSfMleRQd79z+tY83w10XzEmtGu7W5jYPFJDLjYw5BAx2IFFpFPE0ZtuSs+434f31pF8O/CUU0kYddGscgkZ/49466VNQhZcJOuPY8V5V4h8H6lo1mEEBu7SCNI457UmKWONFCqrKOGCqABx0HNY2jP5ksatfXKWrAszhgzov94jncPUg8Y6UpSaZVPBKdNOEr2PdEnh7SAemakjuIcEs+DjgDmuKg8I6m8Ectnr0UkUi7lcg4IPQjBpf+ES11AD/bFv8AgrH+tO77HK4U39o7YyxyDb8rKeoNVpvDlhcyee9qiyY4dflI/KuZj8PeI4ELW+pWUzD+FwyZ+nWon8Qa7o3/ACFNNlaIdZYvnXHrxyB9QKOZfaQKMl/CkR+IvANkZmvbKBWYZZ4idquc5zx90+449V6msU6Z4XMMsc9ndWl5CpeX7RNsjhRRlnMnKlAOcgmu10nxjp2oxgxzIHPYmuG8VXUUniTSbFgJ7KS8ZniJG1yDuQOMfMisQdmdpKrkHFJqO5vSdWacXulfexoeFPCLapax6grXGm2y5OmROn7yPcMNdSK3IkccKDzGhI+8zY3APEXh4iO4iGrWXaa2U+YB7p3/AArrtOB+zpvJZsZJznJ9aurjt1rTlT2OH2ji3fU5nTvEum3Py+ekcv3THJ8jA+4NJr/iJNOmhsrC2bUdauVLW9jGwUlehkkbpHED1Y/RQzYFU/Ed8dX1SbRPDVra3mqREC6vbiPfb6eD/fxjfLjkRAjsWIGM62geGbXQLeUQPNcXVw3mXV5cENNcv/ecgDgdAoAVRwAKaTW5Epxl8Ohl6T4deKSbVNauRqGvTRGNpwpWK3Q9YoEP3E9T958ZY9APEPGfhu4fxOs2kmRdQlnIjSN9rb0AIZTxgnIA5/hr6URcHHavKviAF0jX7O9U8x3Uc2PYnaR+o/Ks5trU68LCMm6fci+HHjMavqP9leJ41sfE0OI47wwIkswHOxtyna2CeO4Jxg11P257y9e3MluPE9qhD2u0BLqH7wjk5IBIbj5sgkkfKSDQ+JnhK08R6Yup2QEOqIgkhnQ4OeoUnrjP5Hkd84XgrxN/blhfmdXtvGumWjqWWIs10iFWwyKcucoFK9fmOMbqbSkrHM04+8jq/DevxaUweJZRo80pWaKRcPZS/wAQI7AH7w/4EO+fSUZXVWRgysMgg5BFeW/bA1q2vB7K4t58W2sRWrlkiZTgTc4KsnAYEZC9fu10vhO6fTL1tDuXzEMtZt224yUB7jHK+2R/DWdGTpv2cvl/kaV4KvH2sd1v5+Z11FFFdZ54UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcv401KUqmi6dI0d9eLl5FOPIhz8zZ7E8gfiR0qZSUVdmlKm6slFFK9ml8U6sYLVwujWMvzyZ4uJl9/7qnP1Iz2Gc8mHWPPV5hH4cs5T57YOL2ReNn/XJTgHH3myvQHdLcr58Nt4Y03MNvDEr308fy+XGc4QEdHcAj/ZGT125WCWO/eWyeytodB08oxkLgJlPnVcA8ADy3yeK5ElUkqjOycrLkjsv6v6sJ72G5t4Nf1t0tdJskjvIct0co6tuxnd98bcdTjGa8pS5vPiv4tWS6VrfQrIgx2v19T/eOOfQYA9S3xnrd78R9cGm6Ej/ANi2bYBPyrI/Tef6D054ya63wx4JvdE0wifUf7PgQGWZ0+TJxyxPbp+GK322Lp00lzTdjpdd0tNLuYdV8OXkFprPlrFNbzPth1FFHEbgdHAGFlAJXoQy8VNZeKLC+tZJpHNlNBJ5N1bXJCyW0uM7H7cjlWBKsOVJFc1D4Yi1l4praO6tLQcm5lY+fODnoTyBg9+efXpr3/hCCe3tzpbLZajaR+VbzsnmIyZz5MyH/WRk84Jyp+ZSD1L30Y50oUrOLu+qG3Xi1r7dZ+GoDe3R+XziMQx+5Pc+1O03wJZyo82uO2o30pzJLISAPZR2FXvC2ow3bz6fPZLp2tWigz2BbIC5wJI2wBJEezAcdGAPFbehX9vqkDSQllZHMckb8MjDqCKOXUr6xaL9jovxOefwDojcGO5ZR0Q3UhUfhuxWVrHgNYrZX0GYwTwv5qQykyROwVhyrZA4ZhkdmNekMoxx1NQyoFzihxIjiqjerv6nh2g3ay+JNGj1COWAwXBhkjkJJjkIAXOeewA9vpXuLgRAd2x09K8z+KWi70XVbWPLINt0qfeeMdGHqy9R+NVbb4jtDpsNrcwPNqCqFV05WcdmH17/AOQM01DRnbiIvFRjVh6NHomtw291pssdzt2le9eP6DfzeH9dvmtFeSFosMY1LD7xxnHf/Guks9H8R+Jv3moXK6dZN/CPmcj0x2ruPD2i2Og2Jt7SLJfmR3O5pD6k0NOTT2OdSjSTi9TiYNZ8Ra0cadp0ioTjzJfkFXh4N1++Ja+1aG2Un7qAkgV3SdcR8AenFKCoPzNyKaj3M3Wa+FWOStvh/pkIzd3E16/fzCcE/TpXV2scVrbpBbRRwxKMBUXFZF94it45GisY5LyZeGEOCqf7zdBXGan4xnmvPsdrcPPcng22kxee49jIfl/FRRzRjsWqNWrrN/eemSTxQoXmkVEXksxwBWXceKtJhfatyJn9IVMmfxAx+tcD/wAIr4r1vDC0i06M8h7+4Msp/LPP1Aq9ZfCW6bD6j4im3f3beLGP+BE/0ovN7Ir2WFgv3lS78jqp/EMzwl4dKuSvZp3jiX9Wz+lebeJpbOXUUvPs9np19uEnmxXocE9clVGD9frXaw/CTw+Obm41O6JwT51zwfyArUtPht4St9oXRonOeTLI75/Mmm4TY6WLw9CV4pv8P1/Q5Hw54gs7BpbfT7uzktpG3rDLMIhGx67WPAB64xW2PEOoSE+Rp0E4/wCmF/E+fw610CeCPCxj2/2BppBPU26k/njNUbr4aeErlcjSlgJOQ1vK8RH/AHyQKPZS7kzxtCcnJw/r70Z8fjCK3k8vVLK9sG6ZmiJX8xmuhstQtNQh3280UyHglGDCuYl+GLRwk6L4l1e03dI7hxPH7cHBx+Nc3f8AhHxhpIadbez1TaSTJYyeROB64OAfoCTStOPS5S+q1fhlyvz/AK/U7XxB4U0rU43mniSKQDcZ1+RlAH94dseteQ3NleS63plvpyPPcwRvdYf7xBJIz74IrdtvF1zeF9H1S7ntMkLLFdQ7JQM/dzxwehyDkGtbwpNbWfinxHr+qTw2dpbxRxxyyOABEFA3fjtUcdTkdai6k7I6ownhaUpSd9NOxf8ADHjR5bpNPvbeSO6B2le/5env0rQbU73xg7W3h+5ksdDBKT6vHxJcY4KWp9OoM3T+5k/MIX0q48cTfa9WtW0/QmXEVm6bbm+HUNc90j6EQ9T/AB4+5WRPd6r4P1PGoubiykPyTKuFx2XA4XA4x09K2vybnl2WIfu6fqej6JZ2Oh6bDp+l20dtaQjCRoPXkknqSTyWOSSSSc1cecEVgabrlnqMCvFKuSOmauy3MEUZd5VCj3p81yPY2drE81wsSs7HCgV4h8RtXXVtQ8uOSJQzBFDuAcBwS3sOMe+TXVeJfESalKdOsTI0eQZ5E/hTPPP6CsjQvDl5fEa/pGnaekU+ZEabVpGbb2QxragKAOwZunU9azd5aI7aPLh/3k02bWseMLGLRra00hlmn2iJfNbagIA+Zm6EdTwa8f8AFX2nTPEkOraVNLLfQET3F0keFWXdwcD+HnaR0xgd+fUbNX164kiA8LQXEZ2P5umzyOCDzn97GT9M/jWz/wAI/f8A2SS1bWNJSCRSrx2uihFYHjBDzPkY9fz7U0n30M6tSm48sYO/nYq6d4yt9X0SHxJbx2sYDCzv7Nwiu7nOF81uNp3ZAOM5HI5FXLzT3tRPpKzPFNaL9q0+bdz5AOdvu0bYHuGXua4J7qPQPFkPhm5udStLC/kjV5raGwjjkDHCsV+ykn5uD84xgn69svh64XR9Qlju/EDXOnySRw27XbQb41IOE8raPmQcY+XJGRkUqtNVI76nLSqSpT0R6J4Y1Vda0aC7wFm5jmjH8EinDD8xkexBrVryfTNI0G98R29pcNqN3Z3cR8hrjVr2Ys4G8Kd8zAjbk9MV22meCfDWmX0V7ZaJYpexEmO4aMPIhPBIZskHBIz1wcVrTmpxumY16bpy1Vr6nKfEn4mx+EPFuj6WJtLSBlS41D7XMElELzLEvkjcNzDLueD8sZ45FaOo/Ei1tb28tI9H1ZzDdy6cl1sh8mS6SEyiMfvA3IHBKhc9SK0ryPwy3iTUtFuIJJ9U1y1BvYlimlVoAjovmMAUiUgOBkruO7GSTVmDwZoMMEMKWBMcN4L9A80jfv8Ay/L3kliT8nGDkd8Z5rQxOGg+NOn6d4U0C/8AFGn3NpqOo6cl+0KzWsatHsQmWPfOMqxY7UyZTg5T12r74k2klpezaXZ37W9nfWtnLfNbo8IaZrfaAplRjuW4HI+7gkg/KHtz+BvCek6VE8rXmnWenRMEuRrN1AbeHC5TzRKCsQ2KQmdgxkAc1sP4T0V7O9tXtGeC9u4r+4DTyEyTx+Vsctuzx5MXGcHbznJyAc3d/FXSbSxur+40zWE06OG5nt7sxRbLxYCRIIx5m4HgkbwmQMitzXvEcmneDtQ1qS0urD7OCVS5hSRyu4AN5ayDgg5ALKw7gHisjS/BngnX7G9u7Kze5srv7XZurXNwI03SslwsUbMBFl0YExhc444rr9Z0uz1rTLjTtSh86znXbJHuK7hnPUEEdOxoA5C4+JNqt9c2cOj6tuW5urGC5dIRDPcwRvI0a/vd3IjbDFQvYkGuet/jbpuneGtDu/FNhcWeo32mxahJEs1qimNlUmWMPPlkZi21BmXCnK9M93a+HvDl24ltYYZza6jPdkpOzhLp1dJdw3YziRwVPAz0HFZ6/D3wzYWcQiXUbOK0iKJLFrF3C0UIA/d7xKCIxtBCZ2ryQBk0AVrz4l2EEd1NBpGsXltBfR6d50CQ7ZJ5GjVFTdICd3mqc4wADnBwDDqvxU0rS9BbVL7T76ARXM1pPbT3FnDLFLF95f3k6q/GMeWz5zXRReHNBvLLdDAk9rc3sWrh0ndlknUo6Shg3IyiHA+U46HJqpqXw/8ADeozGa4sp1maWeVpIL2eBmM23zQSjglW2LlT8vHSgCDwP4jl8Q63r7xztJpiCzmslZApSOW2WTnAycls8k4rsaydA8O6XoCyLpNr9nEkcMTfvHfKxRiOMfMT0VQPfGTk1rUAFFFFABRRRQAUUUUAFZGueI9N0O80u11J7hJtTn+zWoitJZleTGdpZFITjJ+YjhWPRTjXrlPG2j6tqureFJtLjsWt9M1P7ddG5uHjbaIpIsIFjYMcSs3JX7gH8WVAN3XtVtdC0S/1XUGZLOyge4mZRkhEUk4Hc4HSnaReS6hp0N1cWF1p0kgJNtdGPzY+SBu2My8jnhj15wcgeNXPwYuR4YNhZR6LDeXGiXdheyfMBcXLyxPBI52ZYJsbBIyuRtHpoXnwouU+IkOsacLOLSIrq2ntooJIrZ7FIgoaONfssjFGIZiqyxBt7AjksQD1ua5SK4ghZZS85YKVidlGBk7mAwvtuIyeBzU1eRQ/Cq7g8PaNa2VxZWGqw215DeahBuMjPLBJHEyttDNsMnAJGBnGKg034W3xuYGubDQNM08XdlJNpmnSyNBIsKTLJIcxrl5PNUEYwVT5mbuAeu3NzHbvbrIsxM8nlJ5cLuAdpbLFQQowp+ZsDOBnJAMOs6rZaNY/bNSm8m282KHftZvnkkWNBgAnlnUe2eeK5/xj4Xl1WDw3b6Stpa2+lXvnmIgoqxC1nhCoFBAwZV44GAfYHzyX4LyR+G7Ows7TQRMmlWEF0jgiO6vLedJHdz5ZyGVZE3kFsORjHFAHuFFeNWPwv1WHx9a64yWEFok9vPHFaXMcZskSNVNvHmzLtEMEbRJEpDcqDkmxo3wgtIdK8IWmq6fot3/ZtjLDqO9DILmZo0VG+ZfnC7TjdjaMYHAwAeu1meG9at/EGjxalZJMkEryIFlADZR2Q5wSOqnv0rxw/CrxXJqHhaee50N5NIXTQ14pVbgiDZ5ylzbGVw2H2/vUGDgr1r0fw7pmteF/BdrY2lpZajfxTzM8ZumhQo8rvlW8s5YBl4IA68+oB19Fcj/wmF1aMF1nwr4gsx3lggW9j/DyGd/zQH2qxZePPC13OIF1yyguT0t7p/s8p/7ZybW/SgDb1W/g0vT57y7YrDEuTjqT0AHqScAD1NcZazTQ2N3qM1skmt6k4SKNnx8x+7GD2VVBJIHQE4NXdbkm1fxDbWgik/sy22ys5UhJpCMgg91UHqO7eoqh9oQre69mNooo2h00OwCkAfNLzgZYg8/3FyPvHPJVk5z5FstzvhFUqfnL8ui/UpXqRxqvhy2u5jqV44kuriMYaQNnzW/2QFAAHYFAOlcz45nYi18DeH5BEoQNqU8QCYQ/wcdC3Uj0wOQTWk97ZeD/AApe+IJoZF1J2ktrZbrmQysxZlOMAgPuywHKoOTxVf4T+HbqS3fUdU3Nc3MhuJZJB8zMemf5/ia0Ssggl8Utkdl4H8N2OhacojgRCOVUD9fr71s3vl3KGOdFkjJBKkZBwcjj6gVgWl9PYeJ7nS7mQtbTgS22f4c5yv0yD+mOtb3llyOCfSi/QqUWpczGPNEmPNdR7E4qSG5glAjhZRj7xBBNZN/4S0nUZA11ZKWPJKMyZ+u0jNQf8ILpcaj7I17aOvRobp+PwJI/Smrjfsnu393/AAS94j0G11qOFjNJaX9oxks7+DHnWznqVyMFT0ZTkMOCK4vTtWv9L8WFNVjiivZF3TJb5MN2i8NPBnr1y0f3kI/iU7j0a+D5Qu2XxDrcijoGkiP/ALTrI8ReCdQmtD9j1ea7McizxRXkMb7ZFOQyttBVh0B9yM8mm20gpRgpaS33vsehs25BtOVNVLmYRoS5wAOtcd4X8WpEq6VrhFnqMPyFJDjcOxX1B/MdxgAmv8RPEBg0+OGxYPLcHYm05yTxSc1a41hpKfKZXifWb7XL3+yvD8TTTH7zD7qjuSaqz/D2/sbCMQyQXci5LQOxVVJJJMbjlT9OD3ru/BGhW+h6Mq7Q15N888x6sfT6Ct3aXPA4rPlvqzVYl03ansvxPIbLXdS8PlYby6mtQvyhdRiLRgDssicH6kZrpYPGNx5Hn3Fgk9qOs9jOJR+K8EfTOa6DxDNbwwsjqrccqRkV5KZLax11JdJik8+Ztq21vlhMT2CD6ZP0z05qH7uiOulyYjWUbeZ6ND4m+3wiTT9zxkEk/d2gdS2cYA9TisdNWvdceWDQ7abVZFJR2RjHaRn0eQ4Ln/ZGOvernhzwFd34Nx4tcxQs24aVbuFT6yMp5Pspx7mvSLaC2sLWOCzhigt4xhIolCqo9ABwK1jBtXkcVWvSpStRV/M4HSfh5Pd7H8W6kbuNTldPtMw2yH3AwW/Su70zTrDSrfydOs7e1h67IYwgP1xUGp6vY6ZCZtRu4LWL/npPIEX8zXLv49srgEaVb6jqbAkEWlm5/wDHmCqfzq1yw2OSc6lZ+8zuS4pgnQ5Brzu48TeKShktPB94y54867ijb8QN1cvrHxI8Q6SwOoeF5bJCcb55H2sfQNsA/LNKVWxKo3PaRMNyntjBpfNx3HGa8Gb4x34OToceB6XZ5/8AHKki+MkuR52iMqkYO25z/wCy1Ht49y/YS7HuEM3yEnNWI2DAjjpivJNN+L+hSYju7a/tjn75RXX8wc/pXX6F4y0PWGCabqcEkx4ET5jcn2VwCfwq41E+pEqbR1shKj5O/FKr7hjGAOv1qms4LYU85wBVlTlR3A6e5rS5m4mV4m8NaV4jtfJ1ezSZ8YjkHyyRe6uORXkmt6PL4P1Kyh117i90lHK6deAjZbORne6AczjLYcnAUZQK2a9x6ZJb5j19qp63pdprek3GnajFvs51wwBwc9QQexBAIPtUuN9tzajW9m0pax7HLeF9bleT+ztSmSW7VBJDcL925j7MD6jof846ea1hvIGjuI1kjcYKsMgivHvD9teafeXnhy8YHV9NczadMf8AloOu3js6np2OR1r1LwrrEOq6dFcIcBuCp6ow4Kn3B4rOm7+6ztxlFR/eU9n/AF/Xmmjg/H3gQ2Wny6j4bmltniBZ7dG+Uj29Ko+BfDU/ifT0ubrV7hoeMxg4/D1r1vWAktjKpAIKkV558GiYYdYhDfJBcMo/E0OCUkjOFabot31Rs+IdP0nwj4Sunt4FXI+Zj96QgE4z6nGPxFXvANgdO8F6RauMOlupb6nk/wA65b4gzHV/E+haW7sLVrsB1HRtmHP6lfxWvR1K+UAoAGMDHQCmrOWnQKqlCjFSd3LX9DzDVdAt774ieWHkh3wF3eIlTkFQORXTReGLWyZXjlupGX/npOzfpmtCLR2XX5b9iPmQIPpW1KgMTKccjrQobkSrNWSZ4t8bdFW40JNTgG26sHB3L1KEgHn2OG/A+tdZ4cvE1658LeKNtwgls3huJY5ysXm5CBHjzhvnMm0464z2pPHqK+iX0LgFZIXQgnrlSK4T4U6ndyfCvxBZ2s9mktpOJAbwusIikABUshDL91zuB4JzTRFVbM63VkmstO1CK3QLJomohrRsc7GCyouepUFiv0BHrXq9jcx3tlb3UJJinjWVMjnDDI/nXn00S6pqIuIWKQappkMyo45ZkZh+eJV/75Fb3wxujc+DbONyfMtS9s2e2xiFH/fO2s6F1OUSsQlOhGfVO33/APBTOU8V+ENcuPFPizWNGbUYLm6tdNisprfUWiBKTSeeNm8LwhUjcuPmbbyzZZrHh3xRbeJmTSDrk1sJ7RrC7OsMbe2iDg3C3Eby7pS3z4yj8FQCgWvRPEWvaf4dsUvNWlljhkmS3QRW8k7vI5wqqkasxJPHAqfSNSg1ayF1ax3ccRYrturSW2fj/YlVWx74rqPPPF9f8B+L9R8KTWgn1We61DT9TivYrnVmeMyGRWtAFMhVeAR8oAwSH4OKm8RaT44n1PTH8N6Vrun2ts1syG51lp5ConzMs2b0oflzjMcxZSBlcAD2+qVxqllb6vZ6XNNtvryKWaCLax3pGUDnOMDHmJ1POeM4NAHH+H9K1vR/hhqVlFYCTWTNqUsFsbryt/m3Uzx/vUbKZV1OQQRnqpHHHeGvDnjySWG31WTWbbTW1mGZwdRKyra/ZJllXd9qncKZTHwJSckMoXHy+3UUAeFXPgzxXpdlq1n4ct9bhZ9ae6kmbVnmW7s23kLGDdxusgYoWJaJmx99uh29B8M+LHhjGr3+uOsGkuIQ979nY3YnlaMOI55NxCFBkyMGGN5J4Ho+na1b3+satpsKSrPprxpMzAbWLoHG3nJ4POQOa06APE7Tw/8AENfFWkT3t5qn2OIWBLQSiVEVIoxcRzA3kasWcSZbypThgVOcAdN8KNN8Rabd6muvw6q0DJGYrrU7wyTStltw8pbmeNcDB3J5ec42YANejVS1LVbLTZtPivZvKkv7j7LbDazeZLsd9vA4+WNzk4HH0oAu0UUUAFFFFABRRRQAUUUUAFFFFAHD+OfGt94d1Ga2sNItr5LbS5tVuJLi+NsFijYAquI3yxzxkgepFY03xZRfEdjZQ6Ws+n3cv2dbqOSfdFL5Bm2SZgEQYYwVWVmGQcdcdfrPgvQtc8Q22sazYW+oT21ubeKK6hjljTLht4DKSHyMZB6E1Zk8K+HpdWbVZdB0l9TZtxvGs4zMTjGd+N2ccdelAHnt58Uruz0zRNd1LSJbaxv9FuNVitbe7WYuFW2KiQGEEHMxAKt93JZSSFWM/EHxVqWt+G7ax0BdPafUZbeaO9e4t4btPskkq7HltVkGGU5IQfMijJDEj1D+xdL8m3i/s2y8q2t2tIU8hNsULBQ0ajHyoQqgqOCFHoKzo/BPhWOwaxj8M6Gtk0ona3WwiEZkAwHK7cbgOM9aAPLfHfxTuLnRvE2mWNubYtpd/PYarY3FwAxgIUkM8Ea5+brE8gUjBPQn03x14mbw1Y2j28FvdXt1P5MNrI84aXCszbFhhmdiAucBMYySRjmdfBnhdZ7mZfDeiia6V1nkFjFulD/fDnb8wbvnr3q/rWi6Xrtqttrem2Wo2ytvEV3AkyBvXDAjPvQB5jJ8UdV1vw3eT+HNFhhuF8PjWDNdXmwQbmnQqF8pt7KYMjIAboduOVufijrWlpptjceGZNT1VtNh1G4XT3uLjdG7FV2eXbEbzsYkP5ajgBzzj0uz0PSbFCtlpdjbqYRbEQ26IDECxEfA+7l3O3plj6ms6TwN4Tktbe2k8L6E1tblmhibT4SkRJySo24GT1xQBgv4/vY47y/k0SJNDsdUbTbm7a9PmRgSiMzeX5eNgyC2WBHPUDJ6fwhrT+ItAt9WNobWG6LPbqX3F4dx8uQ8DG9cNjnAYcmjXPDdhq3h/UtHZDaWmo7xcm0VY2k3n95k4IywyCcZwTyDzWtDGkMKRQoqRIoVVUYCgcAAUAPrK8UyWUOhXcupWsN3AiZEEyB1kY8KuDxkkgfjWrXJeL3W91jS9NyWVCbuRB3I+VAfbJY/8ArOrPki5G1Cn7Sok9jmIPCOlWlvYJZ2a2WoXEiBpNMmk09e7SNtgZAcKrcEHJxnIpDo+o3l/caPpviDUHtI1aMm/giu4VOxflyixyDhyOZO3Fb1/dx2uo3upyqz2ul2wgATG55H2swGSBnATB77yK5LxHqT6B8MNT1CK6Bu9bmPkOpYDY4ABUNyv7pc4ycEgZPFY0XK3vO5tKKlL3VY5zVdR/4TjxBb21xLp2rTaYzBEtJ5bNJAGALBHjlRgTt6yjI9s119zr2u6eqQLo2o6Vaoo3tNp5vcn1DWrycfVRjvXj/w1ebTNWi1WaF1s5MxeZt4JyD/AENfTem30F9bxyRSBlI6g5rW6bsaSpzpxTWx5Nfa819rFpcQanpV3dwEZto7tYpyu4NjyZAr9R0xz616HpesmVYzdQy2zvwFlQoc9cYPQ+34jI5rV1q3026sjHq8NpcW3927RXT8m4rzDxNY6Ho0XneGhDalWxJDpd7LagDPZYnCfgyke1JqKNISqV0ocqf4HrcVzHsyevt3pjXUatl2VfYnFeQafq+u3d82n6Fqd/dusYaRb6KCSJM9vNRY3H1+c/lWw/hrxgYvMGraYJOphFopX/vog5/EUc/bUI4RJtVWovz/AOAelG4VuBg59KFweteTDxNrnhy6VPEGnFIAQpmhBMRHQfQ/iPpXc6Z4n0/ULdZYLhCp7Zp8/cKuDnTXMtV3Rb8QeHdL1u3KalaxTADhiPmX6HrXj15pt5pvi6PTfDd/NtcE+XcHzlU8YHPI616f4j8VWen6dK6zIz7TgA1yfw0sJr/UrjX72Nl8w4hDf3fWs52bSRpQlOnBuT0HweMdS0aSKx8TWBt5c7ROrZjl57Hs3Tgkg+orrV8SWh00zW0oZW6ccj/Pr0rN8d3GjppMy6xskRuiHG4t7e9eRaZaap4p1K10fR4xBCPmKknZDH3eQ9/Ydz+NJuSdkbKnRnT9pUXL+p299qE+u6iunaGi3+oudzJuzBbp/elccH/dGQfVulegeEPB1h4dzcH/AEvVZFxLeyD5m9lH8C+w/HNXPB/hqx8LaUtlYKWZjvmnYDfM/dj/AEHQDir+rXsNhZzXM77YY13Nxn8h3PbHetYwUdWefWxLq+5DSJHq+pW+n25nuZRHGCFyQSSTwAAOSSeABye1cy02v6xOotYxpFiTzJOgkuXHYhPux/8AAtx9VFT6ZYTXl7FrGrpi7AP2a3Jytqp9uhkI6t+A462tc8QaboVsZNRuVjcjKxL80j/Rfw69PelKXVmajbRFS28G6RFdLeXkUuoXw6T3khmYfTdwB7AACugULHtAwFHQCvJ774k6zfSFNE0yKCHkB7gGRz6HggD6c1z2oan40uwWl1S7QdvJAhx/3wBXO8TTRusPUlue+gqcEEUjqWQqwVlYYYHkEfSvmY694p02feut6nvHTzZ2lH5MSP0rq/D3xdvbeVIvEdqlzB0ae3XZKPcj7rfQBaqOIhIUsPOJ1vi34a6XqCSz6PFHp+oHkIgxBIfRlA+XPqv1wa8zl8LSxzvBcwNFcR/6yNgMr1x9QexHB7V79our2OtWS3mk3cV3bnrjhl9mHUH2NRa1pcV8BMsebqFSYz0J9UJ9D+h57VNagqivHRjo13DR7Hz/ADeFWC/cIP0rE1HQp4AQFJB68V9Cw6ZbXlrHPBhopUDofUEZFYWsaAmw/LXC4VIanYqkJaM8y8I+OtV8OTpDdSPd6fwGikYlkH+wT0+nT6da9+0LW7bVNOjvdOnE0Djhh29QR2PtXgfiTRFiBZB0rU+CupTWfiWfTGYm2uombb2DoMg/lkflXTh67k7Mwr0ElzI+gI2PylhnPOKnaTPTlqpRM7GMfwY/OrKgIfvLg+hrvTOBo8w+L1u+m634f8QQfI/m/ZJHA57unPtiT86pTanY+FZZH+2agJ75vNFnaxI5ZiPvfMOM8dK6b4xxibwvZxIQ00moQpEMfxHcP5Zrm7GJdW+LNyfv2+mwCMH0ZRs/nurCorSuexhanNhrS2V/0svxZFN4/uYEAubXVIoW6m7tflx9QAf0qt4Y8U6LoX217e6W5Nw5kKhnBz9DGOK6P4j6oljpTRRANNJ8iqOpJrQ8F+GbPTvD1r9qt45bnG4l1BIJ5NCvzWTE6tLkvKG/Y89/thtV1+y1FNP1INbSNIk8drLMuWJPMaKXYdR8uTXe2HjQJhJ9M1eSXt5emTx599sqrj6Zz7V0ixxk4CLg+1YXibwhpmtwEvH5dynzR3EXyvG3Yg1cVy6mNeqq7Sfur7ywPFV1Koe28K+IZ1bkEC0jBHr+8nX/AB9qbN4j1goSPCl5EPW5v7VMD32SPz+f1rzC08W6to0l5p1/JLLLay+Uwih3mT0cAY2k9SenfGSakbxfPcuNsOqzsRkItoUwfckkYo9qhf2fO/xaG/qt7fa1dGxbS7ISSKf3bauw2r0yxS1kA/UfrWH8N/M0a/1rSPDaaXNd+UJLmCe8nuMrHkYXNvEGJ3gduoqxp/ifR9P0l47Wdhezc3DXCGN2boRk8YHAA9MVh/Ce6LfFrWbmMo6tp8zjEgIbDQ4y3QfWiE7meJoOCvd2O8vZfED22nTXB0iy3RSpBCNNuGeJBtYjb9oj6hF44/xt+A7PW7zTbwaTrtnY26XbpIqaQVYybVJI33EmOoHJPQ9KGS8g0zw4t3DJ9rD3KlJZhOcGN8HcOoxtxySBgEk81tfCaPZoN++Dtlv5WUk5yAFX/wBlpQl+9a8iJQ/2Zyu9119ehP448L3fiTQdH09rsNJbX9pc3M4ke3aRInBcoY+Uc4OMEYPcdazNS+HMV3rM86TE2y6SbOzmu7iW7uLe582R1nDSliSu8FWLErjAwK9CorpPPPF7H4UXzrFFd2Ph+xsBLp/2iwspJHhuxA7GWaTMagyOGAxg5A+ZzUj/AAouodR06e2tNCkis7nUlgWQlTZw3EyPA8P7tsPDtYqg2gFjhh1r2SigDwLV/hzrGmeDr6KPRdHDvHpdo1jpbyut+8d7Ez3E58oFSVBydrkDcSzYrUPwt1NYEb+y/DN1bfarycaBPNILC286OJUaNhFyyGJ2/wBWv+ufBU8n2migDxa9+F/iI6Q1kLnRtTV2svON+iM0vkWghLAywTIjFxnJjYlSRlSc1sfDv4b3Wh6hpt14iNhfyWOkW9jC2WkMc0U9w+9QygDCSoA3BHzAYHX1GigDyT4k/D7X/E3jC21PT20aOG2e0eC4cJHcxeXKHdS/2d5GBGdu2WMDJBBBNQXnwkVtG0p30jw7qes2ms3N/P8AbgdlzbySXDLCZDE7AATI23aV3Kf96vYqKAPCm+EOuG88SSNdWkkuo22owxXf2lEaT7RG6okyraeYyqWXrMwG0FV/hra8SeAkGuaDp2i2a21nqVubXXmhtz5c9vGyS5eTHMjsGj+Y7mWVz2zXrdFAABgYHSiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuU0iRrrXtU1EgFBMbZM84SP5T/AOPbj+NdNdzpa2s1xJ9yJGkb6AZNcLp97Jp3ga6uAAJTaPMcjBMp6DPPUn9a58RKySOvDx9yT9EZt9cXEPhZXZYmstUuJluHd9jpFIzCN0G0hiEC8Hr79Dw3xwVIp/C/h6xCxW6Q5VAMAb2Crx/wH9a9XvUGl2WkaTaNOrqEhiaJMjCAL82QQQMhiMg4UkHivIvi63mfGPR4wCVWO1Jz0yZW/pinFWVi6b989X0bwvpg8Kw2d1ah4GTbgNggdiCOhHXPrXGyCbwVqrW0F+bm0Yeapk+8oJ+63GOxw3c8YPUegS/a5dJhjspY4WIAMjLuKj2Hr9aq2WkWsETRtGJmfJkklG9nJ6kk0pK+x00anLfnd0+hR0vxNomsSx/a0tRc9FMyjP4E1b8Rz6VfaXNaSTQhZEKYBAwDxx6VieI/AttJA8+iCOzmwS8LjdBJ+B+6fcceoNcX4X0TRdRmaO/lWC4RiNjyKyE5/hPQ+1TzNaM3jQhNe0pt2XTsWvCGrppHilYbrYpliWBpF4ErLna/1K9fcZ717Rbss8IdCCCOCK4W5+GegXdovkPJa3C/Ms0Q6H6VnafqGq+CdQi0/XSJ7Fzthu04VvY+h9qqN477GNZxxDvB6o9GurVJ43imjSSJhhlYZBHuK84134etZSy3vhqZYN3zPZyZMTfTuPw5969KsrqG8hjlhYOrDIIqPVp0t7N5XIACmrkk0YUa9SlK0T57jiubjVp1n0e6uZLbDPBDJ5i59+M446En8a7qDXfFNzbrDZeH2tlA2h7iQIqj6cH8jV34ZkXOpeIdUH3JHS3X6rlj/wChCuo1q4W2s3kJxxxWMVpe521K65uVxTaPINd0+7+3QrdTNqesXDCGCJRhAx/hUdh1JPYAk17N4H8MQeFNGFvCVnvJj5l3PjBlf+ijoB6fU1zHwtsjqOr6hr86qUjJtLUnrngyt+e1f+At616Uy9wcH9K2px+0cGLxEqkuV7IjMg6Dg/3TXOzyHVtc8sE/Y9PcFx/z1mIyB9FBB92I6ba09bu47OwuLq4RisEbSZTqcDOKoeHIJLXSIDdvumYNPO3+2xLN/OnJ3djGKsrmZ468SJ4d09Ut2R9TuTsgRiMJ6ufp2Hc/jXn2laGbq6a91uS7kuJTveSWCQj6lsY/Wt6z1l9ZCX0I8mS6zI7gAMY+iJnqABjI9Sa0o7dCAfmLHnJPFYTpe1d29DohP2aslqR2H9hW5VRe2WPUzL/jXU/2Xaz2yvFsdGGVZcEEeoNc0kMu7BmYIOgqZRMpaSOYCT+90P0z1x+NJYdRQpTbZzPjfw9GquyKK80udIdImZxwPWvXNbuLmbAumUQk4Mh42n/a7YPY8Dt1xnnfEVrHFY7AQSecg151WLpydjupS5oq55xourah4c1MXulztHMvBX+F19GHcf54r3Xwn8S9K161RJc2epZw1uQWUn1Vscj26j9T4jLagpIx5Ap/gWLb4gikJwqEkk8ACt6ddwWhnUoKbPffD+oodHgbgL82B6DccD8qravqcRU8jJrh9NlvpdRuNO0uNrtVmYxvEQU2E5BLdBgHB56g10cPgnVb3AvL2CD+8sStLn8Tt/rQ/aVNIoi1ODu2cd4ivo5AwGAOuSelb3ws8J3NpqB1u9iaNZIysERHzENj5z6cDAHvXV6V4Z8PaJcrLcSxTXicq95MhKH1VeAD74z71uvquk265bU7SNfVrlFH860oYbkfNJ6kVsRzLljsaKKSAoXGB3qzGnI4XNcTqXxL8PWDGG2vpNTuh0isU83P/A+E/wDHqwNa8XX+qWLrqlxFoOmsP3kUUnmXci+mRjZn6fRvXsc4x3MaeGq1fhWhB8S/Ea3OtwG1kRrLRmZ94wVku8YAH+4M59yR2qD4dONL0O81S8OJ71y4LcHaOn5nNc5Z3+ia+w0qON7IKVWyZjtSXB5UHoGPQHoa6a10e71m/wDs0qG1sLYhGiIwzYH3cdhXO23K5604wpUVRj82WfDumy+K9eTU7pCLKBsQK3Rz/e+lei3TqgEcf3FGBVZZbXTLAKXjhiUAFzwB7Vy1z410iSfyI5pZQx2iSJd+Pqo+YfiK0VorzOBqVV3S0Rrpqg/tFrdyBgZXJ61qrMAhyMmsBvDVpdoJEeeKcncJlYgj8Dx+Yrn9R1nU9MvY9JKi5uZV/dsgI3c46dj0796fNbcfIp6RKOvTxaZ8Ro9QjBZLiHbKi/wsuCD9SoYfWvVrO4Se0jmhYGN1DKR3GOtcno3hCAabdPrY8+9v49r4biNewB65759a3ra2j0rSYbZZHaOJQoZj8xx64ogmtxVpxnFJbrQyPFCWswZp4YZXAxuZATXmvw+iih+K3ieTZuij0tiY1APUQkgA8duh9a6PxLqgEjgH5ck4rk/heLa4v/HerahD9osUs3gkiDAGaNtxKgkgZKx+o6jkULWRNZONNI9BsWu00nwg91DLHPbwzlo5YjEwCJgZUkkHb7mur+GsPkeELTIALySuce8jY/TFc1IQbTS2mSOBo9MuZ/LjlaUAyPHtIZgDgjd1HHI7V2fg6JYvCmkKve1jcn1LKCT+ZNFJfvJP0M6rthku7/K/+Zs0UUV0nAFFQWN3bX9pDd2NxDc2syh4poXDo6noVYcEe4qegAooqlpOradrFs1xpF/aX9urmNpbWZZVDjqpKkjIyOKALtFFFABRUN1d29oIjdXEUAlkWKMyOF3uxwqjPUk9B1NTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGF44kaPwnqQU4Msfk5/3yE/8AZqw9YWN9D0ezXhp7+CNwe4Vw5Hv8iY+hrS+IMm3RIYR/y2uolwOp2nzP/ZKo6ygbW/CagZX7TJK4HTcIJR+hauSs71Ev63O6mrUE+7f5FLxbbQNrtne6o72+n2gEy3MbbCJVcYUnuCCflI55xzXA/Fm0Mnxg8OsoH7y2hP1KyyH+WK67xC6ar47i028ubyCyVEQ20sJNvdSbvM69D8qHryDjGcHHOeOZ0l+OPh2InKx2QDezfviP/Za0XUIfEj1KNTFYxA/3R3qhfJe3EYhsJktt33pyu5lH+yOmfc9PQ1rTlWhTbjp2qpI4toWlkDMiDc20ZIHrjvSZcH1MePwbYTAm/lvr9icsbi4bn8sVJe+ENDltzEdPgjwMK0a7SPoa3kuVe0E1viaMruQxkfOPY9K5qSw8Q6lmS51CPToyflt7ZBIQv+05/i+nFJqKWxtCrVk/enZL1/Iwl1C+8J6lFaT3K3Wnyn5DI2Hj/wB4njHv1+vbotTitPEekPA+yW3lXg/3T2I9CKjl8J6fPbtHf+dfu3/LS6kLsPcdh+ArnZND1LwtcfatGaS80/OZLRm+YD1Un+VTqt9jpfsq2ztP7kyn4T1a78N60dF1ViVH+qkPR17EVt/EvWDDo3lwHdJNhEGepPAqt4gtbfxj4dS80kj7fA2Ysja24H5o27g+30PSuD1zWHvrKwW5VkubS4UTRN1Uj1/Gk3ZWIUOad2rNbnsfhbRhoHh6ysMkyBfMlb+87ck1kfEK88qxKjIUCt3Tb9b7T4J8gb1AHOecVxnxRk2aXK2eiMf0qpaLQ56abneW53/gawXTvB2jwcCT7MjufV3G5z+LMa3GY7feo412W0McQXaqAAewFAYjhlIH6V0baHn76nP+LQZbO3tGzi5uoYz9A28/ouPxq3rKNJoV+kYJZ7aQDHXJU4qr4muIoJtKlnOIjfxxg+7BlH6kVsHC7RnjpUPc1T0R5r4OjH9iWDbQS8IJP+0ev65rp0hVQQoBrJ0qz/sy81CwTAghvJBEB/CrhZAMdgPMI/Cujij3KrfnRHYuW9yqtsu35gM0fZiD8oH0q8sZL4xxU3lhcdKGJMxZbVZOJEBA9RWRrvh+21C1KRxxwTgfJMifowHUV1zopGMVXkticms5RUtGXGbWqPDvFuk3Oi26LOilZfuyRnKk+mSBzjsR64ziuy+C3h60fSn1aeJJbiSYxJvXIiVQDkA/xEk8+2PXPV6vpMOpWctrdxebbOMOuSO+QQRyCMVleDLY+FrfxDapOZrS1Vb2NZPvLlG3A4GP+WY6VjCgoTutjWpWc4W6i/EPx5F4cmOm6agudXZAS0h/dwA9C3ct0OOOOSegPlV5qGqaozXGsavcSjnPmTbI1z6KMKPwFZVylxqV3OxBnvpN1xNO3RQcksf14pkWnSsY3tfsd+4GVK3kMzDPTgMcZ9KmU5Tex2UMLCCvNpeb/RFy1tdOZ9llayahKx4W3jyuf944H5Zp2uaONOtFuNXeztpGOI7GL5mA5yXI78YwfyqdbLxkYsraanb22ME2ls7D6FgMU/RfDOo3V0RDplyLjdgz3iHg+wPejl6GyqUqbunzfkZunaZf3iLKjR2NswyJJfvEey/41r2OlacJljjWfWLzjAYfID/ujgfjXoFr8P44UVtYkNzIeodsjP8Au9K6zR9NtLCL/RoIo0UdlAq407abGFbHSnq3f8jkNK+H9xqsYfXVSK3A4t4+AnuTjr9Kr32ga14d3vpmp3d3bRj5ECxSSoB2HmKcj2Ur6cV317qgY4jc4PX0rOafd1NapJbHPGrN3Utn0OMtbl/E1mJJddEi5CmGWxhDhvTbu5+gyTxweK3tP0zUI0A07XNP2DjH9kISvt8ki4+hFYGo6bp0Xi3y7q3iks9ShMjqyjBkXg/TIfdn1FZV3ocn2ppdKvZtLgj5V55SVJHYKTwPejmZpKhTezaX9eZ199qWt2kq28WuWs87dI4tFJI+v+kD+dWofDmtvfJqh1Tw+LwrgNJotySo9MfbiB+Fec/2m92kryeIJ7K9STBinxJCxHTnnj8+BnvWrYeN72FZIriaC4mRVKrbyblnBONybiMEHGVyOvFPm7ieC6Qlr8zv2bxTActq3h6XHT/iUzx4/wDJps/pXNa94r1S2uVtbq+0aaV/lCw6dOc9j/y8Dp6/h14rIvPHbGFgNP1XzcHgwKoz2+bef5VyUOr2y+bc3a3FteyMctNCSu3ttK54HTGKUqj2RMMJFaybOmvroTOBcHSi57AXFReEbBJdEebRbXTZ7a61BF5muUkM0SmQYGx8rtLAjHIJFcgL281W7ay0C1n1C+dcboo2xHnjccgY+pwPevStA8OCxsPCWk2M8U0bKZpLqC4wkzO6tKYXX5sqisoYEDacdSKcG92jmxEUmoqTNPXZdZabVLm9tdERoIUtZ/LvrjCADeAv7jk4lBP4elddpsvjG1htbU6D4dFvEqRb11uYsFAAyF+ydcds/jXPajIl5pyKeZL7U+Sf443lVU/8cVR+Fen0UJKTk13IxEHCnC77/oecfEGxt5vGej3PiXR7nWfDCWcyeRFYvexw3RZCHkgQMWygYK21gpz0zmsnwHZ+KYr3SNMSTVdH8PNDf3UcUlujyQxi7jNtA7yK+xvKZhtJJ25HBAZfXaK6DjPnTwgfF1t4GsNKhttZu7S30q1FxaalooQWtytzCBHEHhBlHl+YSTvxtDBhWvpB8RaCmoWaXnimC3k8RXj300OjrO8Fu8k7xy2+LciXzG8veQJNmeFTPHulFAHndmnjLVvAplv72K1eWwuElt200i9dv3gjcN5mxHK+WShibB3Dvxz+gWnjbS9HjsdNvNSaPT/C1rc2lvcWcCLJfYmH2Zn8oYUBYgV4cfKSwyS3slFAHjNjqfjW+mhtbHUfEZsJbuyjk1C90aO3uI96TG4VUaELsUrDhyhALEZYdaSt4oi8T6RrOrv4lea2s9UsFay01Ga6ZLxPJWQeSyxiWNAd+EX5VIKgnPudFAHgeh6h4y169jh1qz1mext9V0q6tpLuyZHQeZJ5wY/ZbcELtQn5CFz94g12Hxm1rxNpkVpF4Th1gXLQTyCaztxNEZAF2RuBbTtkk5H+qUjdlxxj0yigDxHxTB4w8SeF/Ez31xrNtFbyafJbWNrYR5lXybaSbG6JnfbIZCAvIZSp3fdE2ma544fx5bWwn1JtE+0wrE97p0qC5tig3vIEscJLuLfeliAKgFMcn2iigDxo63430TwR4Z12/u7y/wBU1CJbS50u4tYYPLupY8QkKIw4xKFDgk8OxwAAB65pcNxbabaQX1015dRxIk1wyKhlcABn2qABk5OAAOadc2drdSW8l1bQzSW8nmwtJGGMT4I3KT0OCRkdianoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlPiAQF0LPQagCfwhlqvq4xr/AIXIO4M8rk+/kvn+dWPiCpa10gqPmF+MfUxSj+tN1iHy/EPh8kcFpz9P3Z4rjqpurf0/M74texj8zOu9ZhuPGlrZQNbPGscqO/mBt0owdigZO9ACSDjAk75rxn4g3U1x8ZZFs8mWCa3C/RYwzD9T+de1Ca3Txhc2zTRpM6RzRwm22lyFZWYSY+ZsFQeeAuMdz5DLGJP2gLgEZ/fn/wBEf/WrVdRUnaR10Pjk2kKrqCzQSKPmWSNuPxxg/hW7ovjfT76Nikikr94ZGQPUjqB7niuru7O1UriKMjaOo61yus+GNE1wq7W0SyoSBLAdrDB9RUWaOqM6U1qrFfSNat9H1u5tEctpdz+/hA+byJD95MdlPUe+a6iPW7aUZiEkmOpWNjj9K5CL4d6btxNdX8idlac4/Kp5/h/4Yjt2Z4rlZAOHWcjmhcxpU9hN3u7+h0UmvWgcqx2kDJDcEfhWdfeKLC3H76aNE7liBXnMtvc6dcmy0q7ub2S7YLbwMd7IvPz+3seO56Cr3h/w2urSqNJmExjJF1rr4kiV/wCJLRCNsrDp5jZRT03EbQ03IdSlQoJOTbvsupfv72ysfE0NxpF2Y3nUSX8CghY4yD5csmQAjE4Cg8uCcAjNaOr6Joni62RvPjstYIwsqN1OfT+JeM8dK1rzwNosujrYRQyIiu0pk8wtJLI33pJGbPmOe7Nk/hXD3HhnxB4ckcaf5N9p5ySkygqB7gnK/UGpnp00KouFaFpStJbenbzNjT9L8X+H4/s8KWl7bA/KwbBNZPi/T/FOp2bG40xLeDB3P5gfjHoMGnvrS2GlQz6jcXFnPMN0NpbXUihl/vAZJAJyB61Vi8ZIF8rUf7Ujifo7Sb+P91xz+dTdG31Wb1TX5fqev+CtSGqeEtJu3IaR7dRJ7OBtYfgwIraJXHBP868c8I+ILXQDOE1AXWjTuHyqENaOfvF0PIVsjkZAI/2q9VguUeBJQUeNgGV0bIYHoRXRCfMjx6+HlSm0zL8d6b/bHhm7sY5PKuHAkgkHVZUIZD+aj8M1g+DfH9jrGgh9QLQ6jB+7uYgpOH7MPY4z+Yrrbm4C/vGJSJRkk+g61843kF7o2syXsEJVmY742PDqTyp/TFY1anI9CqVLnXoejaD4p+3eN9Vsb2M232h1ls0f+LYm1lP+1gK2Pr6c+hQ4Kjb0rxjU449c0231rS5Smo2zK6seqsnTI9R0I7ivRvA/iaDxJpu4KsGowfJdW2fuN/eX1U9Qfw6iilU5tHuOpDl1Wx1aDctJ5RLcdaQyx20DTTHai9T1rnLq+1LWHeOx32dmOrLxI49z2+g/Otm7GUYuRsX+o2Gnki+vYImHVC2W/wC+RzWZN4s0KNubtnHqkLn+lY48PWsZ+b5mzyT61DqOjwQwll8vj+EHmocmbxpw6s218X+HnAAvwhJx+8idcfUkYA96zNV2yJ4ujt2SXz9FWSORGBBytwvBH+6PzrkL+wifduXFYBa70W8e406d496eW6ZysiZOVIz05PvUe07mn1e691lLVV/sPwFZuoQXeqA3Mz4yQmQqLn0z1x12jNb3grV9OTR7n/hIs6ncugWL7Sqyqueo+YH+vSsXWIW1f4faTOWLPZq9jOO6EMWQn65P5VxFjcv80ZYpIpwwNZKTjqj0K9NSpxT21/P/ACsd/eSaTe3scOn6DoP2hmG6YaZAHVf94Jn9a7fT9G0VLQGW0eOXbtH2W8nt8f8Aftx/9btivMfD08dhlz99jk5PWukXxMI+jKR0JIyKuNR7tnHPDwe0TqriK3gUtDea9GOoP9tXUv8A6Nkf/Cq8EupXQm/srVdddYVzK7XFkY4wem5prdv6muPvtbutUvEt7KOSeeU7Y4ogSWPsP612l/a/2V4P/wCEYWAX+rahG730FvcxpKARnaoc5YFVZQR0wTWkZuTMKtKnTW2pT0671uXTJtQvJ7uztkj3q13ZW0m9920REIYyGJ4wcEHIJHSp4tR1FmCC/wBKckfx6TMh/wC+hdkH/vkUnjyWOwurDQNPRo7aENfTZJYvI7Pgknk/xkknqQaw0vLZgGR0kByBhsgnvjFY1a7jKyLo4fnhzNs3HivjMst2mj3jJ9wNfXNttz1xsic9O5z9Kv2t/cWxBj0DSg4/jg1Te313SwRk/jz/ADrAjvlLqCiY7Mz45/rU898sW7zbmNOM4J+Yf8BA3H8BUrEN9CnhZvqzpB4lux/rtC1Rl4/1N3YP+huFP5A1T1CTRtSH/Ez8L6ozdPMOnCRwD6NCzH8j9a40+I44JCJUWSPP3/MwCPp1H5VpR+I9KkjDfaYgvXiRXB/AHcPxUU/bf3QeCqR2f5foQ+INI0owvNpVxrVjMBuFtfaReiI+oDtDkfXLD6Dmq9ifD1mVFxqOleaELtJqd6LeMMChCBCVPzAyDLEjgHvitaDxXp0Z/datb5zjADKT+GM1Pq9//asUYGrXlhcBT5U1rePAxB9s4bn1GfpVKrDdomVLEJWv+Bj2fipbfWrKS0tI9UtrYgo9rqttAgc/ekEUDEMrcYDEj8672K0ns/F9vqcE95c6N9n8wrt3CBhldhKqWc4lJCk8YOSflx5bd6PqzP8AN4vguDz8t9GszH1PJYn345p1z/Zs9pZwR6L4d+1W8ZN3qR0yBdyAk71+TcOOPzyOza+2gle5isLVnsj0qOdEbw7YzwyRXkFxAkv7t9qkMuBuxtPQ9/SvU6+ebLTHg0Zbq406O1lmJZIoZpoPKjP3Vby5F5xyRwATjHFenaR4V0zUtMtr3TtW8SwJMgfA1y6m2t3B8x25ByCOnHSnQcVeMTPE87jFyWh3FUotVs5tZudKjmzf20MdxLFtYbY5C4Q5xg5Mb8A5456isjT/AAzc2N5DMnifX5oo23G3nkhkRx/dYmLdj6MD71nXmleIrLx/f63o9npN5Z3tha2jrdX8lvJG0UkzEgLDIGBEo7jpXQcZ0niLWLXw/oV9q1/5n2W0iaVxGu5mA7KO5J4Huah8P69b619rjSC4tL2ykWK7tLgL5kDsiyKrFCyHKOrfKzDnBwcgeMxfBbVmttZgvZrC7lureWIXUs8eLlmmSRWnjW0Vyw25DNNIVPTg8d/4N8CQeF/HOv6hp2iaDbabf7Gt5rVBFcW4EUaNCEEeNjMhckOOT909aAO+qlq2q2ekQwS6hN5Mc9xFaxnazbpZXCIvAPVmAz0GecV4/qXwv8SX/jTUtXaTQoI7lNQh8y3CxPLHPC6RCQLbhyQShYtLIDgkAcCp9R+EDfZpYdOsdBNrs0qb7FMCsM9zbSu07Sfu2x5iMEL4ZiM7hjqAezVA1zGt6lqVm8142lDCFzHgEAgvjaD8wwpOSMkAgHHjEnwn1h/FM+pZsI4pDvh8i6SM2im38sW6/wChmR4V5UKJUUrg7FIxWhefCq7GnWUOlvp1nKugtp926Fh9puDJasS5C5ZGW3ZCx+bawAHYAHr1FeSab8Mbh9QsJNRsdDtNITVZb2TRbN3e2iiazeDYmY1DbnYMy7VUgkYPOfWY40ijSOJFSNAFVVGAoHQAUAOooooAKKKKACiiigAooooAKKKKACiiigAoorHtPFPh+8vLi0s9d0q4urdWeaGK8jd41U4YsoOQAQQc9CKANiisJfGPhltJfVF8R6MdMSQRNdi+i8lXPRS+7bn2zVDTfiJ4V1HVNSsYNb08SWEaTPI13FskiaMP5iENygDDLcAUAZFx4s0/RfitrNnruu2tjbPpVi9rb3l4sSPIZbkOY1dgCxAQEj0XPavMtR+IviPxj4W1qxuItKsUlt4zNDuiM9tuuYomhkjS6aVgVcgsyRYxjb8wx7qvi7w22nx3y+IdHNjJu2XAvY/LbaQGw27BwWAPpketRp4w0JYLKS+1XT7B7x3S3iub2ANKVcoQu1yG5HQEkZwcHIoA4z4Ry3tj4k8V+H7/AFfR2WxvP9H0u1tGt2ii8i3w8UZmbZBlmG0LjeWO7nbXqVULbWdMu9QksbXUbKa+jDM9vHOrSKFbaxKg5GG4PoeKv0Ac149X/iVWcuMiG+gY/i23/wBmqpqkbx6/4eOf3bvMAM9Mxsf/AGX9a0fHS58MXRPGx4ZP++ZUb+lYOtzyW914Qm4aJr0xDPo9vJ39sVyVl+8T/rc7qetBer/IZC9zD41ZJ7C0t4rnzCJDJuaVkVdsie5QlWG0EbB8zDFeX3my2/aCuHc/LuDE46Ztgf616VPeNceNlgP2ac28qr5UqkNFmFmEkZ5+Ygup5GQDxwSfN9St1uPj7cxOSVYqDg4PNqorRdQpL3j2ySRZoEeN1dGAIZTkEe1c/f8Ah+1uLhruKaWzuTy0kOPmPqVIIJ9+vvWTJ/afg+4YOsl5ozNn5QC8We4H9Oh9qzta8YR3CiKwYySycJEvLsT0G0c/096zk7bnbCjJe9Td13/zGan4kvNBvGhn1OC5swudzofMB7DGck+w9Ky9R8UXGpWEs0ZaGzQZku7hTFAg7Ek/MTnjYAS3QVqWmk2Wgw20+v2zar4hvsm106JQ8jEdQoJ2qq5y0jYUdSemduHQr6WaPVNY8i51OL5rW1gJNtYHp+7BALydjKwz2UKOKai2ryCpiYKXLTim11/U5zw94XN6Hl1nz7fT5Rlreb5Lq+/6794ovSEHcR98gfJXpNq9uqJHG8UMSKFRFAVVUDgADgADtXlOs3Wu2k7PNZkqSSDHJkkfQgVz0/jOaFijrKjf3W60vaJaEewcnzSldvqe/vdWUajdcrkjJwc1w3xF8TRWel/Zrch3nzvB7oPvD8eB9Ca8rbxZfyk7VxnpuNZ+q6jczB5Lwjzl2KYgc7Ruzz9c1E6t1ZHVhMKlPnlqlqeveBNHt3X+1dWKTancYZnYDEQxgIo7ADiu3uNM0+7haKZoGRhjBGQa+fbLxpPAoTkAevFbNt4+dsAtkfWqjOKVjCpTlOXMmXvHng86MTfaK26LkSRK24Y9v8KyvCnjbWNGtxa2Rtrm0JwsN1nER9FbIwPYnHuKuXHjJZo9p5yO5rCupLaxt7Z7SCKS+vQZ5C5OxEJ+VQvTJ6k4PpxznOTs7wO2lapTdOvqu/Y7p/iHfhkXWdOe0QjeT5LCMgdw3II/EipLjxL4b1yHEzQKx43ROOfwrhrHxC9in7iG8sWzlhb3BMRPrsOf510Ok63p+tjZeSWFzcsDlL+zTDe28cj8VNS/e3Zi8G0r02n+f6lC4/4kl3Jc6NcJc20mPNgc4Dj29G9DS21wEv4dd8MTgXsP+st3+9jujr3U+31ByK6AaZ4ZD+VfaLa2suOkQ2qw9VZCAw9xTJ9C8I280TxWwnJOUxdTEKe3BanGnbVM55Jp2kjudI1GfxLpNnd3lp9iDZYw79wJyRuzgcHqPrWvd3MNvD9ntcFcfM1czd6tFEiJCQEACgA8AVmT6wFXhua6OYwVJs6IyqTgmoJ/LkO0muTn1oRgktz1q34fS61eVX3FIScbvWle5pycquzVu9BluIHlhKlV4PNcJ4ltxZQu0hyFr0rWPs+mWBjWfNxwNnt/n1rznxDepIfJwHmm+RUPQ+59AO59KmaSLouUjDttE1uaEXlnHaS2N0oL7Z22n0524B/OqNp4K1C/vD9mk01WwN3+k79q+pAHPt0rp9GtL6z0OEadZzTRSyq4uVcRkkMc/LycYLD0wfrXQ6rpOs2GqRX/AIc0kNp3lk/ZARsyQCThT1yBz14xWCTeqR3t1FD2bkl626fqc3B8NQeJ9XZdvysIyOvpjGf1rD1az8IaLceRPq81zLGwWba/mFOegVTy31IA5zzgHD1ibxNp2mPbSS3UV+v7t5I2ZHaLABUrxk/KOep96xtC8Jarf6SZ5raKy08yDN1dMIy3baoPJPPYfnXo0sJRtzyqpr8fuPCrYrGRl7P2LT+Vvv2/E9Z+HvifQE1I6bo1za6cJ3VUN1akTXKbvmBlzjJXIAGADjAqx4jsL3QtT06We4nv7m3MDQsWEgk2tgtLkh40B2DOWG58nPIPn48N2NrEv2jVbaVh0HmeQDx2aTH6AmvSLrxDpV/4Eitr7xNotnrghEJme/hDFVkXOGd1ViyoCRnknmsU2+hdSEYe9zJ38x3xJswdegvZt0MN7Y7GWRtpRkJLDPQHa4/75JrjtD8KeIr+Ay6fdXQtEPlowZICcAYPXdzkHkDg+9dbDe+HJfA9rp6eJdDutR064FwqHV7eXzirncR8/CupbCnpuAPTnodC1nTkmhYaxpD+cHjmjhvIjs2kmNyAxxwCCfdPSsJp+1S5dGtzeliHCFoyt8zhk8AeIbkhbm7YRnr5t0M/mEJP6Vo2vwtsio/tO7eeT+8ikN+JZmB/IV6VFf2E7lYL+zlYDOEuEY4/A1KsYnYrbssrAZ2oQxx+FaqFthvEOekpX+Z5wPhpocPKCVj/ANNArf0qleeAtIbr5igHoscQH6oT+tenT2VwFP8Ao83/AHwax72xuRkm3m9M7DUy5i4OLPPZPBWmL0kuPTgRj/2Wsi/8JWsG5raaWJiOCgCn81xXo09pMoy0MgHqVNZOoWzCMl0YA8ZINYSnNdTeMYtnmraSA5S4me6j/wCeczMw/LdXQ+F9C0+O6inZGkKkMI2PyAjodo4/PNQ6lCEkOBV/w8+2cBjznvWPtJN2bN3BWueliJL21KN1xUvgi+bRdTfTblsWdw2Yyf4JP8D/ADx6moNGkGBVrWLBbm3LKOfpXUrq01uefNJ3hLZnolcldeKb4+K7/SdN0y2nt9Mihmv7ie8aJ1WTcf3USxv5hCqepQE8Z6mrHg3WzfwGyu2P263GCWPMq9N317H8PWtLUPD+jajqVrqOoaRp11qFqQbe6ntkeWHB3DY5GVweRg9a7YyUldHlTg4S5Wea6b8YLy80STVD4TvVtnW1ktXJnRJRNcRwhTJLAibwJQ2EZ1IB+bvWl/wsnUk8YNoDeGJ5ntrm3tb6azNzOsLSqrB1YW+woqupYu8Z+9hTgE9fbeEPDVrLcSWvh7R4ZLhleZ47KJTKyuHUsQvJDgMCehAPWqBPgfXPFS5PhrUfEtkcr/qJruAoc8dXXafpiqIPPPDPxM1PQvB2nf23pn26STTJ762nGoNJLOIpkRvODR/u8+aNp3ODjHB4rota+Jl1oviGy0y+0e1fzLy3s7o2t1cStaNO4WPefswiB2sjYMgPJA3YBPRXmieDfDGn3d1LoejWFpdPFb3DQ6egExklVEVwq5YF3XrwM5OOtXNS0Lwxda9a3Wp6Xos2tv8ANbzXFvE1w3lkHKMw3HacHjpxQBz3g/xBJYfClta1O6WWSA3TmW9ncBttxIqhnCuwHCrwrHpgHpWTo/xVvtUvYtNh8NhNWfUW07yZbmWFFItGuFcmWBJAMLggxggcjdwD3mjroeteGYxpttaT6Hdo2Ifs4WKRWY7sxsB1Oc5HOap2+leFPD2paZZ2ekaVp93dTSPZrbWKpmRYiGYFVwp8vcMnHBI74oA8/wBO+JfiLTdIlk1vSba+vLnXbzTbNbWeaXb5Us2UYRWpfaixhVYIzP1YLzW/YeP9b1SdrXTfCbLfR6UmpyQX909qwLSTx+UFMJbJMOVJUZDZO3AB6u68I+G7s3puvD2jzG+dZLrzLKNvtDLna0mV+YjJwTnGTUuh2GhwRs2gW2mwrEpsi9jHGvliN2zF8o42uz/L2YtxnNAGZ4H8YReMBd3GnWxXTYUgC3LPy8rxiR49uONgZATk/MWGAVNdTWV4X0K08N6LDptgZHiRnkaSXG+V3Ys7tgAZLMScAVevru2sLSa7vriG2tYVLyzTOERFHUsx4A9zQBPRRRQAUUUUAFFFFABRRRQAUUUUAFeN6Z8LNR1jRHtPE19HZ2yS6t9mtrW3AmX7VNLiSSXzGWQbGDBQq9QGyVr2SuT+I3iO58N6dp0ttNY2iXd6lrNqF+pa3skKO3mSAMvBKqgyyjLjJ9QDBvfhzqF8t5dXusadJq9zNbyC4j0+eCOEQxyIpjWK5SRZMSNl/M6HGMYxBefC7UL3TdUsLzxO9xFqUVobiaS1YXBuLfZskEiSrhSYxlcbvRweayF+KGtHxzZ6LA+hXtm09rCLmN4YFv45Qpea3L3e4hSxAVElyUI3AnAj1P4meKLHwv4f1eePRootYMn70whYrXYDw7TXUKEucY+ddu1h8/GADqvC/wANxo+radqNzfQXNza3FzcuVjnbznmjij3Fp55nDARYzuwQQMDGTmXHwmnNhc2dpr0UcV9Yvp18ZdP81nhaeWYeUfMHlOPOYZO4cKcAiuUtPHep2Xii81JJtDj1LUbbSC+j7xcTXpk3KwtnjlxhQxbcBIMYzjrW3qfxJ1yz8N2+q3Fzo9q15qN3Y2sZstykQTTIS8kt3CikhFwC3UHGdwVQD0jwn4dj8OxamscqzNfX818zeXsI8w5Cnk7sDjP6Cq1x4J0q4uJZpLvxCHkYuwj8QX6KCTnhVmAA9gAB2rjfg5r83inxJquuXMMcM99oWkTSRx52qxa7zjPOM16xQBxWreCtNttKvZ7a68RGeKF3jD+ItRKlgpIzifpmuW1TTba28M2erwTa4ytJbicN4h1L5VeRUfH+ke+QfzzXrkiLJGyOMqwII9RXnFtbtffDjUtNbmZIJITjqJEXGR/wJciubEScbNM66EIyg7rVNfiUdR0rS7LxDp9jLqWsKl2MLG3iDU/MyA3OftGME7AMgdD1zxzWpTJZfE2Dw88urDT5UVxIfEGp+ZyhPX7Tjqp7V0/iKJru28L+IYnhWYNbq7SRZHlyvEW5wdp4wDjjd1GSa4P45ibSvG+karb4SRrZdpPQsjtn9HUVak2KMI3SZ1/jG20/RYU+wza9PPJwkb+I9S+Y9hxcdzgfjW1pXhSBrCJtSu9b+0lQZPJ8Q6kq59s3BNcb4Pln8X6xa6jJDLHa2p3fvR1bHyqMdcckn12jsa9J1K/W0Tk44qFOTbbOmdGmkoxWvUxj4L0NL+S9j/toXrxiJ5xr+oeYyAkhS3n5IBJIHuabc6Dp1vGXefxCFAzk+ItS/wDkiqV14rELEogJXuTmuN8WeNbmWF181kRhtYbsAjPTFJ1bdQjhU+g3xJr1nprMtrJq7kHA3+IdTP8AK5Fc1F4wvpCTtvQnb/ifarn/ANK6wHMl5OZpsheoB/rWnp9tuPmeSfKQF+RgOAM4Ge3v0xWLrS7nZSwUJuyibUvia5SGNANQN5LhlX+39V2onq3+ldT26VNbeIZzKUuTqI3IxQrruq/eGDj/AI+vTd+VZWmWvmRNczEGaU7mP8hSX42EFcfKrt+IRiP5U/aTtuafVqDqJKOhoR+I718jF9uBwca/qvX/AMCqc3iG+HQX2P8AsPar/wDJdZ8M4MKRzKnnoucgYLr1z9eo/LHenwxzTEMkZ2HkGl7SfcmeDpR2Wha/4SK/AyRfY/7Duq//ACXVi7165ilhijOoM/krJJ/xPtVO1m5AH+lelVJrT/R23jGeDj0qIRsWnuSuC7scegBwB+Qp+0n3EsNR5G+UmfxLfxt8yX7L3269quf/AEqp0PimWYqqHUA5OMHXtV6/+BVQ2xiuRgY64pW0uPzo3C87geOvWj2k+5Cw1K/wlzxDrSWV5NptwLi6MYHmvJql7coGxkqEmmkGQeNwGeuDgmq2nXGl6k2V1U2zqc+XMhfB44yOfzFYl3bTT3l3NuGWlbdlec55qi1gS25wu7txyKiTbd2dacaS9koqyPQrSAz3YtbLWRcEqWJjiPbOR8wzwB1qB7W4ukkfStQF/NHy0EiBHYYydm0kE8dOvoDXN6HL/Z2k615ZC3E8KQo/dVLAtj6gY+mazNLnfTb5HiJUkhSVOOvT8QaXQ2TjKycbX9P8kdFFdvcmHaPMeUhUQHHPoSemOea6671bU9BtIRnT3jdcrBHIRLjHXnr9cCvPbi/Ua1LJC7gyyF1XZkFmVs85469MV3fh7XLbQNMdrq1je/mUl5mI4J9WPp2HHSjna6nLVpWbVrlb+0NS1abbFbiMnrI0gcA+2O9db4c8OWdhZzS30iXF7Njc0i5Xg5AJ4446CuYPiq7liRgoVc537Nox67mwCPcZ+lYl/wCJJtTuls7cz6ndOfks7bJjP++/BI9lGMdSKIOUnqKVNqN9kWNV8Tvo9rfbrmOW2BMVuIhhTgc7c8kdt3cg156nj27ScyKJkB7pIQSPpXZ+LvDdtPfW39p3NubmVdyJZXiRkgAZHkTERjGRwtxj0rnPEPhx2leV54IhKoEEV2psdxAC5DyAROTg/ckbk+vFexg8DQnG9eVr7br8TxcfnmKpTUMJHRb6Jt+qOvHiB/FGji4uCkjxDIl2gMe2D+X6V594nu5rjxDbt5pHl20bRDdgowkIyvoflH5V3K+Hbjwp4MgW7Cm4vWynl/dwSSTkcY5AFecJL9t1yWVTlR+7Q+w4zn0JyfxrzafuVJSWqSf+SPfxk1VwlOD0cmtFtpq/lc9u8A6Pf3Hhz+0r3V9QQuuRHHMwOAe5rptBu7mb4c6ldXGpajF5c0ri4gctKqoQeMnkcHI6YzXJReKIbDwrFYxsCyxBTg9ff+ddcw/sL4YWVteTTW0zr5jSoDmNiTL82CD22kD1xWdCXM7+Rx4qnyQs1u9PREXglLrVr68/tC61O4W0D25mluxNDKwxGwC4wpBjDBgAfmbPfNfwuP7U8KrLeJBc3durO4miVi/lMm7qOM7XX8aufDjVnuda1m0MMcCyBL4wyIFmieUBmTK8SKCT82QQTgjpVfwnAyaZrMoiORcahCrggBgXfj1OCvb1FLFSkuRp9TlpxXvXR1M2gaJOAs+i6XKAcgPZxsB+a1RufCXhmZQJvDOgyAHID6bAwB/Fa3IJRLbxSA8OoYd+ozTJW5rtuxKnHscxJ4N8LIcxeGNBiOPvRadDGSPqqiqc3hrQojmHRrGI9MxR+WfplSDXUTNWbcEc1m5PubRpQe6RzsmkabEcx2RjP96K6njOPqsgOPaqksNtCS0S36EDGY9Yv4z+azgmtm5zg1i3rdaxlUkupssPSf2TMvL8xdJNU/HXNQf9HnYfpVeDVi8gBm1RR6jU5m/Ryw/Sq+psOfUViGYo341zuvUvubrCUWvhPRbB/PI8vVdbiOOouo3/AEeNh/WujtdJuZVBj8Ua/ESPSzcY+j2xH6V5tomoEOASa9F0W/DKoJOa6KVdvc5a+EhH4UFzo+o2EoubbxHq7ypnDva6fkcY422qn9fwrW0Wz17UrNbi28Y3m/JWSKextm2H/gKKf/rHpV2ORJk2nBFUoxNpOofbLUExNgSxjoy/4+lbqbTv0OOVFSVludFpmnapBaXcWpa017JKu2KVbZITDwRkY69QefSvMLHw/r0PhvwnosvhwabJ4cbzZ9XW4hMcnlxOrNDtbzN0pOW3KmNxyW7+wWV1Fe2yTwNlG/MH0PvU9dCdziaadmfPGhaB4q8UeA9PeOPXTZ3unaTLMdR1UTPdXC3UEslxCTK3lKIlc/wMcj5cjnov+EO1yDxZp15d2uvajpthqd2lt5etN50dtJHAY2LPOrMgkWXIZi2MDBGBXstFAjw/S/CPjDw94esY9Kt9QuJZNJuI7yzk1d1jW4M8RiEeJV8siMzYMbIDgBmBOag0nwv49azLX8V+bi3uNQeyee8UyxJLYhIsM1xMw/fFgMysR1yBjHu9FAHjTeCvFNsb2Wz1DxC80NtpklmJdcldWuRKfte5Wlww2BflYbOTtFTvo3iwar5ms2viHU9JN3qLR22l6wLaVN90Wgdm8+MtH5OAqb/l6FR29eooA8/+Ltl4j1CxsLfwzaXUuWkM01reSQSQnaNh2rc2+8E5zlzjAO1q5C+8E+L/ABF4F1yz8QS6k+pS6FaQ20H9qFI5LwQMJt4jfa2WxndlGJzz1Ht9FAHiWp6D43m8Q2M2ljxDYaQqQGCJ70XU1qVlYyictfqsm71YT/IQBtIxV3U7bxD4X8FprtxfahJ4hg1h2jsrjUHeO7ikupY4bcKGKfNHMpHGQQgJAUBfYKKAMrwtp91pXh2wstQvJr69iiH2i5lcu0kh5c5PbcTgdhgdq1aKKACiiigAooooAKKKKACiiigBk8scEMk08iRxRqXd3YBVUDJJJ6AVjWni/wANXlk95aeIdHntEfymnivYmRX2ltpYNgHaCcegJrQ1q1nvtIvbSzvJLG5ngeKK6jUM0LFSA4B6kE5/CvN9B+E89lqRvtU17+0ZmvrO9fzIJn3G3SVQMzTytk+aDnOBt4HPAB0ui/Enwlq8WqS22vaYkOmzGKeWS8hC7flxICGP7slgAxxkgitWTxZ4citILqXX9IS2nQSRSteRhJFLbQyndgjdxkd+K5DXfhtd6n/acaa6sFtPqq6zbBLeVJIZwoUhpI50ZkIBwF2MCQdxxV7wb8PovD2p2t9JcwTyxWtxbuqRS4d5ZhK0m6aaVwTyCCxySTx0oA7G31KxuZo4ra9tppZIVuUSOVWZom4EgAPKns3SrVcJ8KfCc3huy1Ca+jeO4nnaC2hkdXa2sYmYW8O5cggKS3U/fx2ru6ACuS0kLp/iTXbV2AjdluUUjtIOf/Ht9dbXL+Jwtnr+kX5JVJibOQjvn5lz7cP+dZVVeN10OnCu7cO6/LU5iG1N74S+xxGczabPLahYJTG5VCyYBAJz5ZDAdzt6dRy3xvsv7R8C6Lq0Mkly1m4V5ZIzGzJIoBYqQCpLKnGB1rtp7aOLxbqlgSwtNUthdKqM0ZDptjk5UgjIaLoawbLSRrfgrxDoUeo2d84LJHHDLM7QyIcoj+a7MPmQcZA64rOm9C5b3G/DfUof+EU00LgN5Sgn1IGD+oNdBq4s721k+0smFUnkjP4c9a8R8J3l6uhLDDdmBbd2jZDH8wOSevXv+hqafV7i3TE7yXk0gJUPI6qoHGTz6549qmUrOx6FPD865lKxe8Q29pEz+TczBQSeWzXLfYJ5pfM8md1z8pkXA/M4FWpNQmaMMEiSZpOCiZIAxnliT3pszM9vvmkmmvJXCb3diUTvj6nA/GudndClHq7ifLGNsAWSb+KRlDKnP8IPU+549PWr+mSKt8st3M0jOrI7yHcdpUg/zqKC0fy8KrU2axeL55ZB5hYCKI9Xbjt6DOSaevQIyvKy0RHDcuifZ4UZ2XKgLzx25plzBeSKDKqopyBk5JypH9a1tLj8uIqy5feVJ+gFWtRTb9lbH3plGfSna+otqolro9vGu+Us8vZyeV+lWLeGS3JRWV4ieQQQR9Kn2nZ0qle3DWsJduudoB6Z/wA809FqZQlJ+4uo/UpFjs3Dkb5BsXHcn0pmniOOKeOaRWWKV13k8MM5B/IiqkdhPeMJPIKqRzLIxLuPbsv4Uun2gJntrpMsh3cjqcAZP5D86Svc2lCKpuKd2tzO1JYTOZdKMvm552j5G/P+dT2l7dq8ST28i5YfMBkdR1rV+zmMbYY8D6VTupZo1YspCgcnHQdzQ0YQ+JWM62v4VeZbj5JDKxO4Y6mpGuLQ8h0P41IpDBrqZVErkyOvVSOSR9R1+gx6VNLHaYJ8mPJHXFLUuorSutitZxwXRuY92FMTZI7e/wBcZx71zqqzTKuCr7wpB6g55H4c1u30yWenSTQkI7t5SAdTkEk/Tt+NJoMQ1XUYrgg4QAzf7wGM/lUtnTTpc/Lr/wAMdZZ+CbXTkh1LVdTFtNNFut4IR8/IyDnjBP1Fc7rt3qtrrMNpbQ21q7yCH7TLgbWJ7yn5gOvIPQGrLSTeLfHWm2RJMZm3SHPSGMZI9sgBfxrV8SaXp974svIbRDsgmhtzEDLKTI6yFnKfeO3AOAwG1T+OsI3s+hz4qtGlKUJfE9b2WnkR2/hS0nm87WdSvdauvOeA22nodpkVVYq0rdRhgc8d+Tirt1qmieHE1DTWli0+QylIYdEcvcMi7sF5W4DcpkHJGDxzxm/EDWJrfXJPDHhgNbRyupuTHndLK6rnnrgKFzj6VleIdBs/Cqx2W/zdUKgzEYwg6gE+vPQYArSU/Zr3UceHw8sbK1SWhzN/b6jq2orcXF9cBEXyYjNJvlSMkkqWAAPU84HU8V6B4b1PSPCGnzvFLJqGoSgBot7eTjGPnP8AEB/dAxxXAQ3Mt7dLaadE91dOdojjGef6/hW/pHg+81Ilb+4HmliqWkHO8jqPMwUXvjcTyNvXOD2+IqxSk9F/Wx0vD5dhLunG8nu9/lf/ACJ/DuoT6nqbRaZZWlnEXBubu0lbT4o1JxlhGRG+Tx86Nn3rpdY8J6NbXUqQahpV00SeYwmtDA6goz8zWwEYOxCxzCTjBzyMuEHhvQrdrTWdTjtpPn8yys9zlBvDIrEA5cDGWOCeDwFFVNU8eQFfI8K6Gv3mP2vUP3j5bG4hST6LySeABim5qMbSf3nnTj7SpzQVvTQn0nRLC0mtbq70zV2EM0cu+ErqFt5YfBysSiY/dYAmIAlfrXXR6zp2qXM8tzrFnq1uJJPMsrW3eWaJMjy98a5dSo35JUZD85wDXlWr3HiLWSItW1GeRHIZYkARcg5zhRgYPOa7LwT4autYsxe+IW/tPRYm2Ri9QTlQDyyFwWXnOCpBrOFam9IoqtSqr3pyub/hSLQYtSa+0C/ikhheWa7S5BWeFSgBZQwDBcooxwMZ64AGh4AUT+H7GXyiJHSSaUuMHe/zke/Dda5y9sNMvNbay0i71GG38sq32qVb2ONWG0jbMGcKQSMJInBI6cV0cDa/pYkLWWmatbxI0YksLg2roMDnypiU6Ef8tgP6c1aUK7hGElo79vuIvKmnzp6m3ozf8SSwz1+zx/8AoIp7v19awbXxNpVhZW9vqsl1pDRosYOq27WyHAA4lOYj+DmtZnEkCTwsskEgyskZDI30YcGvStZFwlGT0Y2aTjGeKzp3znFWJXrPnk61lI6YxK1y3ymsO9brWnPICtY16/J965ps3ijE1A5ya5q/l2EnJFdBfyAZzXEa3ctJMIrcb5G4Ciua12b3sjc0i9xIDnvXoOl3TBFIPavOvDnh3UXPnSocHoMV6Ro2mzKFEq7QPWtIJ30M6jVtTrNKumbGSa6CKRZU2vzmues7bygMGtWBtoHNdkXbc82ok3oTRST6Rdefb5a3Y/vIuxHqPeuqsbuG9tlntnDRt+YPofeue3rJCQ2OR3rN8MXZtPFDWKN+5uEZtvbcOc/kCP8A9VaRlytLozmqU+eLl1R3dFFFdBxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWT4p01tV0O5t4uLhQJYG9JF5X9Rj6E1rUUNXKhNwkpR3R57NeQ3CeHdWLeWVlNrcBiQU81cAH0zIsY/Gqdwp0LxdPqWoXWoy29ygAEcLmC2VVP8ArGBxjIOPlyCeTitTXtNgsNRuobtC2jaxkSYOPKlOc/TP3gfUN7VmajcbrddK8Q3OoWFxAwaDV4iY45cZCsXGUDY4KPwT0ByK44rlbgzuqpO047P+vw2OB+IGiTaJqNz4l0WJb7w7qaia5WD5jEx5MqkcFTnOenJ9jXJLeaPfj7T/AGlBF0XZJlAgHQZPB65z717T/afiTStPKrYvqKxTLsuyySvcQluTsQJtYDpgNnH41l6tpHgzWLdLjXbO10fU5gSRHP8AZpupwSBt3k9fmU1UoqRVOvKnG3Q8ygi0vJkOr6cy4AyLpDx6DmnS3WjWpZ5Lvz2DqAkCFjtDZPPTPJPJ9K6rUvhD5lt5/hvV0ueM+XeAAsDyP3iDA4P9zn2rz3V9C1LRbjydXsp7NycK0gyjf7rjKn6A5rnnzQ15TrpYjm0TLUviq6yw0+0t7Zc8GVTI+PwIA/WsyHWdRjuWn3wSSEYBlizgZ6DBFMS3yTkdqtQaezkYXINc7ryNYprRD4tc1RHeSOaBGfGcQDB/A5qS513VLuAxSyQBDg5SEAgj0Par1voxbGVNaEOhA4yKz+sS7lcutznxretBgy30mR6xRkfltpLzVdXv1RLmdPlGMxwhT/hn8K6xPD6Y5FP/ALEiSl9YmJJJ3RxNv9vtZjPBfXizMfmYzM276g8H8q0E1/VYrlJ5Y7WeRU2hmQru/wB4KcHHtiukfSYwKpT6ag6YoWImuo0ktjGk8U6wc/NaR5/55wdPpkmkTxDdSxyQ6jFFNFIpXzI12umRjOOhFX/7FkuX2QQySN/dRST+lR3vh25sl3ah5OnrjOb6dLUY+sjLWsK1SWyuQ+WDu3YuW8tjfwk2Mys8fWOQYcDvlT2xmmWlm8lhEeSwG1s9iODWdD4XW9IlgvRcbRkPY2txd4Hs8MbKB9WAq+mmzWyAS6nqwCc/vLq1tR/6NeU+mTH29uOqMW9WrGbxULcqd2ZPiCKRZLG3RcsA5A9SxH+FdVJpy+FvC0ay8X10u4qRggGtTSPDssdo2uSTaYsUR+We9kuL4k+iqFtgfzx2z3rjPFWp33inxAltaDzLq7lEUaqMYHTOOcAD+VTKnZ27no4euuVzaaUd76a9kdV8E7GKN9X8U6jIsFsB9khkkO1doILNk+rbQD9a6rwGt39rvdV1ONY7dw8zXJnJwRgbWO4q21QV4yFKMQfmNReI7MaF4c0bwtZWUV5BcoYWTzWiZnUqQ4Kg4G9gW9s1m/FLWY/D3gmx8NW0rfbriFUm+bJWIfeJ/wB45H03V0q0dF0PBqTdSTm92cn8L5f7W+JV1rN0o2RrPe4bkKxJIH4CsnWUuNf19YhJ/pGoXi24b03tyfy/nUnw2nFteag5KAm3KEFgONrH8etRWLF/EVhsd4mDTSrJH95SsZYFffjj3xWDfNNI9ihT9lg51OrX6tHfarpWnQa5pfhzw19ltjZhpHvIObiGbDZZ8dfugYJHUemK5LVfiBrJW40y3jsbW4MrJc31oGbzDk8xj+AZJOR3YkYzWt4w8TQ+H47vTdLSF9du5JRd3igZRWc45A+9t2/T0zXCaRpTPG0jAiMcZOcE+mcY/OtZztotzhw+FlWkom3oukWTBWSeK5nfnYrBsH356+1d34Z0jToXeXUHLLk/JCQNp/z/AIV5hs+zzebCxSZTwwJVv0/xrS067vVhmmSfgnaBI3U8ZAx/X8686VCcpXTuelPDyXuL8DtfEM9vHdq9ioWNgscUR+9kn1+p/Sugv7iTw/pceg2N+J5lAHkwguWJ65HRfXHP9a80t7qa4u4pL2eVIk5xbqGJOMfeyPU9q6Cw8S6LpSPJaW9+92eMvD179c8dPfrWclKnHl5W2+2xlUw87pOL08jpLgXPhLwzcvcQKs11G0skjj5mJJAX27ACtTQ1eD4fRC6fde36pCPmJYvLjPPqFJPttNeceItfvfFFykl/lYQrMkQPTGAOB/vf55r0nSHju7/QlWIpHBZPcA44d28tVb8FLD8a0pYfknGTW7b9Oy09bkVqMqcU6m/X5HSu5QHaSARggdx6VzFx4d0dZ5J7SyGnXLnLT6ZI9m7H1byiof8A4GGro5zms64b5j6V63McSpxl8SMSSDVbcn7Pq8V4naPVLUbvoJoNmPq0bmqst3dAEXmkXkZ/v2Drfx/gq7Zv/INadw4AOKybuTrk1nKa6o2jQa+CTX4lWC5ttRleDTby3u7hfvW8b4nX/ehbEi/iorL1FmiZhIpRh2YYIq3qdwLyAQajDb38K/dju4VnVf8AdDg4PuMGs2a9ihj8uOW+to1GBGs/2mFfbyrgSbR7IU+ornnyS62NE60N0n6afmc3rF1iN8Hmqfga1hu9SluLjB2naM/mf6flWpqH9lXuUlmshIehikeyc/8AAJfMiP8A3+Qe3YUbPRW0ZJLhL7ybZzkSX0Xkpn/rupe3/wDItZqjK11r6FPEwvaXu+p6xBPa21uNu2srU/EMdsC3mKi+pNcu39qpDHLLbyNat92eM74m+jrlT+Brk/Gul6jeyQtH5jQAcqv86HN3s9BqEbcy1O8PxCsI5AhvIyc9A1alp40hlUFJ0b6GvK/D/hVTbs935irjkkYrSjsxcXiWWk2stxcscIkalmJqXUd7RZXs42vI9Uj8XIIyTIuPrWh8OLo6140mulyYba3Y7h03MQAPy3flWN4b+EGpXkay+Ib77Ep/5d4MSSD6t90H6bq9b8L+HNP8M6d9j0yNwpO55JG3PIfUn+gwPauqjSqOSlPY83EV6Ki409WzYoooruPLCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCpq2n2+qafNZ3a7oZRg46qexHoQcEfSuT0e+kt7qXRdRZBeWi4JIwJ4sHbIB7jgj1BGeK7esDxdoH9tWsclq0cOp2x320zA4H95GxztYcH04PasasHJXjujqw9WK/d1Phf4Pv8A5mQNHgR/M0O5bTXLbika77dyT/FESACT3UqT3Nc94o0mG7v4LzxLpbrcWoxb6nYg3ESdSC8eNy4PzchlHdq2dFvWuQ8Bga21O2Gy4tJOuQOoPfIIOe+QRWtdara6XAJdVvbaxixkSXcyxDHoSxH51FGaqq0lZoqrB0mcVaeH77RrCO88Iamt09zIHlBji8iZWwDIuzaAQBxyw9skmpYPEU1ml3b+M0tRavJIWM7xAiHaMZhVmLAsCAOTgjNJea54dluZb7wnqjNqUjFpV0uylv7e6b/posKsM/7YIPqSBil1rUzrMcNlJ4d1mO5uFyha8isC2ACduZVlYDjjyyPUVo4NbGftE9zCuPAmj63atqXgu8EKEn/Rp0cQlvQZG5OvuB0wKxNNsNl7JY30D2uoQjLwSdcf3lPRlPqK3NT/ALSso4o9U/s0Xaqsm6fUZrydgh4Zoo1gVQM5JBxxliTWjZx33iGS0OraveQv5jGIW2lWsYTCg5DubjbnIxhg36GuarhoVNXozpp4mUNN0UUsVTCohd/RRk1Deq2nrvvvJsY8ZDXkqW649cuRWf4rFxo+oNY6nFfXMcmTBNc6lcvFMv8A1zV1jDDuNmfwPNfQ0RZQ+n2Wn2Lk5L2lnFC2fXcqhifcnNcU6dKm7Sb+46oyqzXMkvvL9vf2tyP9Fu/tn/YPtp70c/7UKOuPcnHvTsSMMrp+on3uZLa1X8mlMg/791sR6deXp3XlxPOSc5lct/Or8OggAFhQlDpD72J8/Wf3I5WTzE+8mlQg/wB6W4vSPqoW3H4Bj9abGXkOFvLgZ5/0Oyt4B+cqzsPwbPvXWS6REvXFOtrG3jJ5GafPNfCkvkLki1q2/mc2dPWZNtyl5dr/AHbvULiVP+/e8R/+OVWFsNM3NplrZae3XfZWkUDZ9dyKCT7k5ruvIiK/LisPV4AQ2B+NKpOpbWTHThTvpE8/1mW4vHIu7iaZs9ZXLfjzV3wX4TGp3Bv73MWm253MzDG7HP8A+oVJHbRXN6pY5j3cKONx/wAKj8a+KjBa/wBn2rGO3hB3AdM96KUbe9I9WnQklfb9PMZ8S/GS3xW1tV8qxtxsjjBz/k1t/Cfw4dE0648Va5EwneImGMLlo4upP1P8vY1kfDDwK+sXEev+IIymnp81vbvx5n+23+z/AD+nXq/E3if7bex2lm4jibCxMCJ1uQ6F1JiDKxU7dozjkn8O+MXH3pbs83F4hTtRp/Ci/wCELXTdb1S91X7LG6wTOq+bJ5u1/M3iRSeMMuxgw9x2FeEeLtXfXvFep6hvLRSTER57IOEHt8o/nX0Dpt7OvgbWNTuJUfFpJLheACsPOPbjPBPfmvmW3GxlDDA65FEtInHTV5am3ojmBbh+Rucj8lA/xqS31htJ1T7VEu6aO3kEQ7B3G3J9sdu/TvUNpG8dhCXUjzBvGfRiT/Wspz9q1GVwPlVtij6cf0zWENJt9j3sTLkwkKfV2/zNDSrNrqbLuGlkfJaRgNxPJyx/rXRmIpuWJWR1G04+RiPcd/wqLRdPV4f3csYm6fZ5gRvH+ye/0yD6A0y7zFvjYMuDgxP1U/WqT05mdmEhGjT13IYIXvrxIRkliclUyQO5x69h7kVvmJVi+WIGGMbdqktsA9V4dfrkiq3h2IrbT3BdG835WQjcAg7so55PcegrUiQzyIse92H+rXfhx/1zfv8A7p/+vWkI6XNaOt6r6mZ5CufMkjIhY4EoG8fmuD+hq1Y2wz+5+0TL62tyC34qRn8xW7o+nS6ncKIMLKx2STx/Ky46iVM89Oo611+qeF9G1CJY5LRVkUY82M4b8fWm1bUxxOPhRkoS6/gecX5KtbszXzKhZP8ASui5G7H/AI5+ld94YkENlo0xzw8+ntgcZ5YNn/tgR/wIVzfizw2NH0fzoL64khjlTbDIcgEnb/X0rQ0Ocx+EAY90kUWoQN5noxuF3Z9yGes607KEn3/RnHi5wr01KD0udxNJyazbl+uKsXLHmsu5k4OecVs2efCJWuZTzzzWPd3HB61aupODWNdPmsJyOuESrcTZzmsHVJ8KwBq/eSYBOa5vU5jnbmuWTNrWMa7hN3cLGg+8e1d/4W0KWxjSSznntpyB88DlD+lYPhSzE18jNg817FpFogUEj9K0px5jnqyUVqZNh4biLmd4ES5brc2ha0nP1khKM3/AiRWk2gXyrut9SiuFH/LLVLRZD9BLD5bD6ssh+tdJCgA7VMzxqpyQB9a7FdKz1PLkk3eKt6aHmniCzunhME2myQSHjfp8y3qH/gB8ub/vmNvr69d8G38N6XYtZLqFh/wkUzt50Ts0U7LuwoEcoWQDGOCo5zXO+N7ZbsjyiXz0wpIP496s/CiOz1OK+8OeKLWDUrZz51tFfRiVRgYdVDA44AOB6GopyiqlnGzLxFOp7C/NdHqPi/xFB4X0hb+5tbq7D3ENrHBahPMeSWQIgG9lUfMw5JFZ+neP/D9xbltRvoNFulunsmtNTuIoZRMmMoMOVY4ZT8pYEMKTxT4Ks9a8LWmg2kradZW93b3C+TuyFilWQqrBlZScEBgcrnI6Vhax8LYGN0nhy+i0yG/sZdPvhdW7XzypI5dpA7yBhKSzfM+8H5cj5RXceSb3ij4heGPDlnqst7rFjJc6bC009jBdRG5wMcCMsDkkgAHHJFXo/GHhqR7BI/EWjO9//wAeirexE3PzFf3fzfP8wI4zyCK43UPhbcXi65aprv2TStTtZ7c2ttDNgtIoUSSB52jZxjJKJGWPU9qTV/hheavrp1XUdatpprlYFvoFgu4oJjC5KFI47tQOMff8z5hkYzigDs18V6LLqdpY2eo2V3PO7IVgvISY8JI2WUuGIPlOPlDH5SSAFYh9n4r8O3ttJcWevaTcW8cqwPLFeRuqSMcKhIOAxJAA6k1yzfDOCTQ9G0yTUWEVjPfSyvFBsaYXMU8ZAO75Sonzu5zs6DPFVfhfPdGJ9Y1m1uZITp0aLBpwhjaC0m80I6mRtzPypbIAHRexAPRrC8tdQs4buwuYbq0mXfHNBIHR19VYcEfSp6KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5j8DeN7rTH07UbnW5LvNjf/bIotXuNVlV0BeOW4tGIEKrsKgIw3FxlgK6K1+MOtT6NqNx9o8Oxm0vooftUj26rJE8LP8AIn23y3cMuCBcdMnGRtr3qigDwy/8Tvqeu6FeXBZ4bfWLK4DrFMpcPpNxISIHdtnJPyLz6ljyYNC+MWt6nPNb2y6ReM02mrbziIRKVubnyWDrHcz7WAwRlgwP3k6Z96ooA4vx/wCJbzwh4Pt7y7vbMag80dubj7GPILtk8o9xGI1OMZeYAHHJziuP8K+PvE/jLTrWGw/smyup9OvLiSY27zDfDcmEbFSbHzAZ4dsE8Fh19kooA+drL4qa/pHgvwrHDqOi6lPNpgeW+uWjRROkcY+yzPNeRjzwWJd9xb5gfKHNd1D4z8T3Om+JtVgtdL+yaJdJG1osbyzSxiG3mlxIr7dypJLggEMdvAx83p9VNW0+21bTLrT79He0uo2hlRJGjLIwwRuUgjI9CKAMLwxq+q+IvC02qW4s7ZruSSTTDLE5X7PuxE8i7gSWA38EcMB2OYhoPie6H/Ex8YPBnORpWnRQDHoDN5x/WuqhjSGFIoUVIkUKqqMBQOAAKfQBxOoeALe5s5y+p6ve3xUbGvdSn8osP70cbKhB/wB3jPHpXO6Dp2k6VqD2snh3TLHVYjmTZaRbpFJ4dZMbmB6ZJ7diCB6xWN4k8P2uuWwEmYbuMHyLlB80Z/qvAyp6/XBGNanKa912Z1YerTj7tVaPr1RCJPOiVxIT/dLH9DVDVbCy1W0MOo24mj3ZUn5XjYdCrDlW46isCzurnSNTj07XttvPIcRy7t0dygPXPrzjnkcZ9a6O3nDbkJJA4BcYyPQ1FHEcz5J6SNa2HdPVarucjcs+nKum+J7iWTTZWEdpqscrwv1GI5nQgq3+3kBgOec1V8VaXfWtvdnT7eK3juG8vZYWqySzA5z5hbAGeckk5OBznB7yWziuYJIpY45YJBteKRQysO4IPWsJ9I1TQ3LaEyX+lkf8g65m2NB6CKQg/L/stwPUVrOnfVGMZWZgOYrmH+w9YhudQtWcx+YQvmrJnIcEEbFVep2KM9M5wc3SNHm026MenXdlq9tvKxkTqk5xyQVI2sQO4I+grUvtZjsLqRNS8NX1tcToUZ/Oi27TyQsm/gZ5IGOTk1QsZLKFIk07QLyFYY2ZFS4hDhWB5WQkyA+wYdcEc4rCVNT3VzqhGrFXitGbp1a4s2CXWg6uh9Y4VmH5xs361Be+LbO2AW6jurORuFW7geHd9Cwwfwqn5VpC9vdjTNUs5ZGJSe3u4pi2QVJLOxOcE5wM5PPOKbfiXzglhrzzCWHyzZazAGScbhymdiseCDyTUyoq3Yd5LWUdDKvvEzzy7YicHpipLa5uZAGL4HuaXUfCunw3U9xZPqWjQbgD9ptg9vGT/ECSCq+uTge3SuI8e61qehW9rGstnNFdB/s97ZSh4pQpw2PQgkAg5weOa43hKrlvc2WIp8t9j0SHUY4CPMn6e9SalfWjaVcXszZtIBlwvVz2QfU4z7Zr5pn1O7mk3y3EjP6lya9S8M6pv8G6bBcO0kR1GN5iWyMAjg+2D+Ga2+rOmrydysLUVepaKOj10t4b0VZbjC6zfr5h2cC2jPRF9D71g/Cvwza+MdUuNS1KdZLSxddtkDy7HkO/+zwQB3wenez8VbsavqBliJMW0KnfaMDHFZ/gax0b7B5dxqsNjfSYEsdyxhUkejH5W5yRz36CjnUJNpXsduMVVUop6X1f+XyPb7vS59Vga2ujFFYyRRK9suWwQSXXIxwcqOcjjp6x3Phu1+1wyzSxeXG+UDqFMaeXs2Ky4I9cnJ5NcMPC/h2QHdremCU9hcIc/rTbj4c2X2Y3dr5F0oGfkwQ3ryKr28kuZ03+H+Z4/ItuY2viJr2j6P4G1HToNQhubm5DxJDG6syh2OQQvRVBOM9gOpr5xaF59sMJzLI6ooUdyccV1HjTTJNMvEXynSNsOAR7np+RrD0Qp/bVk24FROremO4/Wrp1VUSkjWNL7F9X+p3PjSy/smZImX5reNRjpjao7fhXE6JbsWiTGXwMn1NekfF2WGbVpnt3DJJbhgQc9Ywa4rw5hZIZA8kbbQdycke+PxrJ6OVu57dSPtJUW+3+Rv3DrFamPDOpAzFIPXup7fh+Vdd4E0mBbCXWdZQyNuxD9pKnjAwRuPGTjqOBjBxmubeN9Y1WysQsbvI4HmRgqGUdcr2OB2A+neu88XTRR2MOl2Zy1rhngI4K+3A/T1/LphHW/YMU3Vqxox+Z5/rFkyXH23THCPnLRr8oB9AO3ToaXTbiK+cIgWK6z88LnCSH2z90/p9OlX4z8ykyL8x2xySDgn+45/k3+RHJo3228GzMNwrhSWHKNnAVvX2P+SnHW6PR5fZL3WemeE7Ly7L7TNHIs7ZQeao3queQT1PPr2ArXKfvD6dqtW9oYLSGBiC6RhSRnBIHNL5ZwSwolufJVqvtJuRxXxLUnw447NIn6HP9Ko+BIVuvDOrWU0iRMxyqHnLAbVI9w6E/nW34/iV/C92ZG2qrxHd6fvVz+hNcn8Pr2W312DpKs6NGUboZAS35YZz/AMCrnxK/cuXbU9LDxc8HK3R/5HWx3gu7KC4AKCVA5U9VyOQfp0rOupOSKnZTb3ep2hwPJumICnIAkAl49h5mB9KoXB5PetHIyhbcp3Mmc1lXLHBq7c5wc1mXLcGsZM6YmTfvgGubvG3P7Zrd1FuDWBcL1JGcdKwe5o9jp/BrL9p9hXq1jPHHEu5gD9a+f9K15NOucyNgDnrVvUPHl1P+5sGbc3HA5GfSt6bcehz1Iqb3PYPEPjWx0rdGriS4H8IPT61weo+PpriVWjZkIzk56/QdBXHWGh6pq0haRvLB+Zmc5P4//XxXTWPgiw4F1duzAfwsOOn+NXeUjopUYU9o39SJvFM8hJkmf8Se9XNJ8QyW99bzQSFJkcFWHUGo9T8FWcUBewvH3BQQG49fX6etbXwp+H17rGqR3epxeXpdvId7Fh+9I/hUdcdMn696SjJuyNamIp06bdRaHs3jjxNdaH4StdUtRawPcTW8UlxeKzQWaSMAZZApBKrn+8vJGSBXFXvxM1G21BYINZ8MagqLbGAW8D7tZ82Zkf7LiZguzG0/6z5lYnaOnq+p6jp+jae95qt7a2FlFgNPcyrFGmSAMsxAGSQKz5fGHhqKxivZfEWjJZyxmWOdr6IRugYIWDbsEBmVc+pA6mvTPjH5HA2vi/xlqOuQWtlP4egt7zVtS06DzbCaRoVtXcB2InAcsIyCAFwTnPasmL4neK9R0RtV06LQ4I4NL0u9lgnt5ZDJJdyPGwVxINqjZkZVj25616BofxK8I6t4esNZGvaZZ215hUS8vIY3STAYxMN5AcBlyuSRkVtyeI9Divfscms6al35nleQ10gfflBt25znMsfH+2v94ZBHnUPxJ1HStdax8Uz6NDZ299eWE9+sTwRu8dvbzQhQ0jbWbzXG3LE7OMdKzrT4l+KLzR/7Vij0VLe10jStSuYWtpS0zXTOHRG83CABMgkN757eyW13bXRnFrcQzGCQwyiNw3luACVbHQ4IODzyKnoA8at/H99BqT2E2p6HoFq1/qgGoax500UphvGjWJN86ANt+YjfgDAVABgYnin4paxqN14n0PRbm3K/2fqnkSxW/k3VtJAjFRhblpNxwwDNHFyAyhhxX0BRQB4kPHmrxXNuul6lourXFxaaTEl9GJmti1xfTQN+7E7LuUAZIO4sDk4AVZNU+Jmu6eZbO+vPDumzW0t/G+o3dtJ9nuXtymyKKPzgVkcSZwZG+6cA9vaayfEPh+w8Q26Qamb0wqGBjt76e2VwwwQ4idd4x2bI6+poAf4X1CXVvDOkajcqiz3dnDcSLGCFDOgYgZJOMn1rTqO3hitreKC3jWOGJQiIowFUDAAHpipKACiiigAooooAKKKKACiiuY+Ivir/AIQ7w3/av2e3n/0mC2xc3P2eJPNkVN7ybW2qu7JODwKAOnorg9A+IcGoWdhcXsdjaR3N7cWnnJdvNBKsMLymWCQRASJhDy3lj5WwSQA1PXvippUWnQ3GiSTSut1Yectzp1zGTa3FwI/NjDIpkyA+0ruBI6HpQB6RRXCr8TNJn8SaLpdjBf3Meoi5VplsbgNbywvGhR4zFuXmQ7i20IACeGBrX8Q+LtN8PX8kWr3EVvbRWf2uSTEjyAeasY+RUII3OBndnP8ADjJAB0dFcHcfE/Rxq2kWdnBqNyL25mtZsafcrLayRxiTDw+VvBIZeoHB3dAav/8ACxvC4W6d9RkSK3iedpXtJ1jkjRwjtE5TbKAzKCULYyKAOtorkJ/iP4Zt7w2093eRSqI2ffptyqxrI7RozsY8IrMpAZiAeDnBBNfxf4/sdI0vX47Pz01qw0+8u7eG9sLiKKdoIyx2uyqsig7c7GPByD3oA7eisXUPEVjpGjWV/q8rR/aTHHGkMLzPJKy5CJGgZ2OATgAnAJ7VUm8baLb3FhDdnUrY3zxxwPcaVdRRl5DtRGdowqMTxtYg8jjmgDpaK5I/EXw15SSR3d3MskphiEGnXMrSuN+5UVYyXK+W27bnaME4BGcWf4saT9q1tLWJ5LWw02HUYr5obj7PKrrKxDukLeUAIxyckklQNykUAej0Vw2t+PbaHxRoui6QTczXGq/2feu1pMYogIJZCqzYEfmAony7icFuO47mgChrWkWOt2LWmp26zwkhhngqw6MpHIPuK8/kj1HwvqSQa1PLc6TIwSC7QYPJ4R/Rv0Pbn5a9PqG7toby1ltrqJJYJVKOjjIYHqDWNahGqtd0dNDEul7r1i+n+Xmc1pl3HdxBo5AzDjOetaakMuV4buK4qbRNS8N67EIBd3ujTsFR4Y2llg/2XxyRjOG/A89ettRcmV1aGYbThWZCNwrKhUmn7Oqte/c2r0oq06bumR6nZwX1o8dzEssRxuVh09P/AKxrz/XPDk+nN5+mtJ9lB3Kwb5oT6+47Z7d8jOfUBExXd5bZ6EbetUPssw3I8EjwNkY25/Aj0rad4u6HhsVKg7p6djy+w1Vgk0OopiBuZ1XkRnnEyj0z1A6D16KySS5s5Xt5gkjKfMiDjekwxypB4IYcfUdu+j4h8K39jfLJplncSpgmPbGz4GOY29iOmfpVZdG1WSwSD+ztQAhXdbkwOGVc/cJxnIO0g9cH1XFXF3R78Z0Zx5otWl0/r+v153xHqd3pXh1/7Cu5Dah94hmRJojERkDbIpwykOpCkDgHHNeTeJ/EGreK76GbU5jcTIohiRIwoUZ6Kqjrk/X8hXtkvhvVHZ4/7LvjDIvmqot3AVsjcvIwOQGH0A71B8L/AAvdaBrDu+hX8bO23zpbVztT0BI44IzzzjvUSkodDzcdhYaSpteep89lCjlWBGDg+1bOh63NYQS2kgL2cxyydwem4fh+dfSPij4UWWu35uniIZ+S+CkmfcgfN9TzVC4+GmhaLAY7bQrvULtl++8csiKOTk449eByePak3zqzR59BSp1FKlLU8kttUkuo5JY382OJd7sOwyBkg89SK07LUtLddt7abjznYxU10ln4LvzfpDDol3a6VbMJpFa0cmdx90YIO7GfXjueorumsbmSMf2hoU1wp/hezMsh+pIwPoO2ME4rn+qp6pn0ax9RRtKz9HY81gHg+4YCdLyD3Ta/8wKkuNHbR4JNX8KaoJIEI814D5MiZ6Bl/iGfqK9Qi8JaddxMLzwzbxJtA+W2w/1DKAR+ea898Y+A9T0a8ibQ7PUryyuAf3awNI0RGOG2joexPp+cypygrmVPF0a0+SenrZowPEniOTW9FMN+I5LpAPLmRNm/n5gyjgMOuRgEfiBwMGIbqNshQGQ/rz/Wu7svBPiO+u/JOi6lDD/rJGktnQBR1xkcsegA5yfQGsjU/BniN5Lgw+HdXABYKBZS9M5GPlpU1K+q3OOuqdObVN7FzWLo3zwBjnEYj5rN8JXMtvcWdxA7xzBAQyYyMD0PB+lXdR0+/wBNmiGpWN1Zu3zKtxC0ZI9sis/w1am6mit0kRG3iP5mA43YJ59OtZ07nsYqUeeEltr+h6P4U0vEVxr17ldgY2wi/dEseAcDAA7YPB9MZrJe8knuVFzdMS3MFw4wfdWx3HGfwPSuh1/U7QRQWFqUa3gVQ2zkjjhlPcgDn6/ly1/EpyrbVDHduXoj9mX/AGT6fUdhXZL3VZBhKcleq93+RqWyK6yM0f7scXUPeLnhx7ZI/wAkV2XgeLzdWjju0ZprdN0FwvHmRDja3qBlT7YHbrweiXcwmUphLuHKBHHDjoY2z+XP0r1nwBBEbOW4gdjCTtWJh80LdWT6dKqLurk5lPkot99v6/rTTodBLuEgNRSdCPWrsgO7OOKqtEWfJFQ0fLpnD/Eq4MXh8R4yJZ0BB7hcv/7JXG6Ups72yn2nd9oWMA/w4Kxt+hUfjXY/FKP/AIp4yA8pOhB9zlf/AGauR8P+bLqlpBIrFXuPNXd1KgrJnH/bNP8Avqpnb2U+bazPocBb6s/nc6/UVWPXLllGxJ7eJ8f7S7kP6KlZs5zmtfxY7f8ACQWMgYskkU8RJAGSPLYfpmsa46nNcdCV6aOSGyZn3NZVyOta85yKz5k6Z5qpG0Wc7foTWVcwExNx1FdPc24cZxVT7JuB4rFo1ucBY6Dc6nqflxkLzyT2r0nQfhqYkBDlXPJbrmk0Cw+z34l245r1jTXBgBFb0256M5akvZO8dzzq68E6larm1kWUD8DWLqEGo6d8s8Uids4r1rUr42y5IrjNb16KSNlcKw6YIBpzajszooY2q/iV0cNc6rPsCsWBr3P4FyTzeGbqSTPkmfCZ9doz/MV5N4S0KLxf4rhsFLxRENJK8YzsRep/MgD3NfSujaZa6PpkFhp8XlW0K7VXOT6kk9yTzW2Fi5PnZyZtjYzh7JLUz/GmjX2vaIbLTNWl0qcyo5njD/MoOSh2OjgMOMq6n0Nct4D+Gn/CLavaahcaoL+W3jvlAaBgd1zPHKWDPI7ZXYVySS24knrn0aiu4+ePHn+Dl42m6XaN4ihcafYvpaD7NcxJLaHbhZBDdRlm4OTu2sD9wYzW5eeAl0/wb4ws7OM391qrC5t44AsTpJHBEkKq8jnO14Q4Zjxnv1PotFAGH4L0RvD/AIctbKeUT3p3T3c+MedcSMXlf8WY49Bgdq3KKKACiiigAooooAKKKKACiiigAooooAKKKKACsnxLoNr4isbe1vZJ0jhu4LxTCQCXhkWRQcg8EqM+3cVrUUAcTefDjR7iVm33f2QTz3KaeJFW3V5oJIZQvyllVxKzEA8NyMZIPPeF/hrqTajNeeLNQkk8saetpHFdrcMi2kzTIGk+zxAqWYAjYWxk7iTx6vRQByC+A7KLXINWs9R1K1vYru4ui0bREOJzGZYmDRn5D5SdMMOcNVnxN4M07xFfNdXs13HI1stqRCygbVmSYHlTzujUfQn6101FAHH3fgKyl1uTV7bUtTstQe/OoebA0Rwxt0gZAHjYbCiDqM5yQRWJZfBnw1ZR6hDatNFb3cTw7EtbRXiVnDHbMIBKemPnduDznjHpdFAHMaz4K07VrjW5rma7VtXgtbecRuoCrA7uhXKnBJkOc54xjFczJ8GPD8mo6leyXupNLfQ3kEhxbhwtyrLJ+88rzHwG+XzGbbgAccV6bRQBg6/4Zt9YsdNg+13llcabMs9pd2xTzYnVGTI3qynKswIKkHPTpXL6n8JtK1XxBba1qeq6pd38EtvP5kqWpLPCylSG8ncgO0bljKKeeM816NXjGp+JPG6/EOW20601saSJbqF45rPfEAsDtFLGy2qjaXVMZnkJ3YKjPAB27eArKPTNKtbDUtTsbjTJppra9gaIzL5pcyKQ8bIVO89V4wOcjNZ0vwq0k2F5ZQanq9vaXumrpl5EkkTfaUXzNrszxswcGZ2ypAJPII4rkbu08WW3iHw3r09/r1xqU/h+ZBGmnRmFLxjbuttKFgJijdlO5nII28OgyKTw1rXxEvLdFuri9VpLuxjkMumyebAHdhOfns4EKYx03lccuQRQB3y/D+xTX4dSTU9UWGHUX1WOwDRfZ1uXR0d/9Xv5EjHG/GTxitTVvBnhfWL573V/Dei3944Aae6sYpZGAGBlmUk4HFcrp9/4mh+IS+FpdRmu7WDZqkmoSww73tDGYxA4RFUO06s24KPlU4r0igDlf+FceB/+hN8N/wDgrg/+Jo/4Vx4H/wChN8N/+CuD/wCJrqqKAOV/4Vx4H/6E3w3/AOCuD/4muA13whoWg+IVgu/DHhuTTLti1vMdHtQU9Y2Ij/h6g919Spz7TWJ4x0f+29AuLZMfaExNAT08xeQD7HofYmsq0HODUXZnRhZwhUXtFdP+rnK2vgrwXcW6keEfDQkABJ/sq35/8cp0ngXwfhgvhDw2D/2Cbc4P/fHSofDup/al0sqjK5QhiRgsuDt3e9daVDYdetY4Ss68HfdaGlej7KdjlI/AvhGSN428JeHEkPAZdJtsqfUfJg/lXnWtaBp+k6nLZ3Hh/wAMjP8Aq5P7EtAD6H/V9D3/ABHWvcBGrRnjBHoOnv8ASue8b6GNY0YvAAbuAFkxxnvjP5Gt1eOjZvgalKFS1WKcX3W3meSXNlo+3914d8OqJV3RE6JaZUg8qf3frlfyPQ1z2oSWkVxE1v4f8NvGX2NENCs8nP3cfus+v5itq+nM0LMvRsPjnAbGD+Yx755qLQ18zX7HcI2VXMuHk2Z8tSBn1G6VOOpIFTUu9Ln0NfBUFSvyJP0RUnSzfUbS0/4R/wAMQFkMsoTQ7Qsqg7cHdHwSwORxgLnvmrcw0efWIbPTvDfhuRIvnuZBotoV4yQn+r78A45449Ti6hvv9duVLMkYIkkdTgkN86rkdBznjn5vxroNKs44LQRxJsiJxtVeX9jjkn/ZXPueKinzNbkU8BRtrFW9C3HpukM758O+HX+bpHolmFX2LGMgD25b6VpQ6HooulNz4b8MR5/5ZHRbbH/fPl7j9cgVn3uoxWCh5bhINgwpBAYD2/hT/gOT65rCbxY3nldGs2uE5y2GVWPbdgbm+nHtWznGGsmZ1qeGhvFfcjuF0fwykhB8LeHDg8iTR7bOPXasecdeScVesNO+H87EHQPCxJ9dKth+XyfzrxXxBca1dR51R3W3UbvKUBI1HA+4On1PP1rp/E2j2uj6HoaQxD7RcRNJMzKOecDnGex9vSsJYhWvE4YYeniJ8qikemeIvDnhDT7IrB4R8PSXsynyIotFgdj0+YgRnCjPJPFeMalKtrJcRNoPh+GdEJCSaBZA525BH7rkV6b8H1VdI1KSZnZy/lIGYtsiToq56DLMcdMk1zvxEWKfR7q8VcvaTptY9QrNtIB9PnB/CsJV7zik9zlVGMG4tJ2ONVxPaxTLZ6fbZUZFnZQ2ysfcRqoJ+tZ0IZLmbacYlJU+hPzD+ddd4a0tr7wLqE8Yz9kKuc9xkqefauTfC6jKOhKo36Y/pUK6bue3X5HShyK1rfirnQWmpPclpZMC4U4l45b/AGsdM56+/Pc1fkcOgwOAOB2IPJH07j0NYBRlvYZFwiOQhIHDA8H1/wA+nStlhd22nTtNBOscIVpFdGi3jJBZQwAbGSeDwM++OhO61OqhXVNctR2IrWTy7/GSyOAVb6f/AFq+g/BkYh0yGCQBZGXe57lj1z/ntXz3KcBLiErlDu5PGe/4H/GvYLS4ntmRwXUEBlz6dhU87gcma3lFU+m56S0aADkGoLiDMZ2iuYtNeaNsuCwxlsce1btjrEUsDNxu7ZrSNWMtD56VGcTjviHZy3Phe6SNDI8ZWRkUcsFILY98ZNc38LrUanez3yMJDCAiluikYLY+uF/WvUtREch3K688Eg964rwDBCItUYF4f9Od1EYzndg4HpjpXHjpuNPlXX8jvw9eSoSh/Wpa8b/PBpd0AokTUPJYL0AaKQfzC1z045rs/HVoF8PrKIiiQXlu5Xj++Fz/AOPVyF0vzHHrU0ouMEpblUWpQTRlzjrVZkzWhInWoWi6+tUdCZntECeRzT0tgT0qy0WDmrECZxxS5RuQ2ztwGGRXS2E2xADWXDGB2watR5GK0irGE/eLeqRC4gIry3xRYS27swBK5r1NH+TmsvWLCO5iIZc1NSPNqFKXLoX/ANnrSBBo2o6rKv765mECZ7Igzx9Sxz/uivW683+Ed39kjutGkPAYzw59DgMv8j+Jr0iu/DtezVjx8Wn7aVwooorY5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCCKztobue6it4UubgKJplQB5AudoZupxk4z0zU9FFABRRRQAUUUUAedaZHBb+Kta02Vfl81pI29Cw83/wBnA/Cug06ZpIsNksPlPvXOeLo/sPj23u0fy0ngiDnHHDurE/gV/wC+a1tBkEkl0ySCSEzMI3xgEV5VKXssW4dH+up6tePPSjU8l/kbW3PzD/8AXTYsMXOAPXPepoR8pDHA7ex9Ki8vbxg4z1r0qm6OCJ4x490VtI8QSFFxaXRMiEcAZPzD2+Yg/wDAq5F3SyNtexkrJ5r27bc7mDxhlx6DMZU/XHI4r2f4naV9t0ATJ/rbZi+e5Q8EfyP4V5UulSTW5mMJaMjIbsrjPHrnGD7Z9cVnOLktD6zBV1Ww653qnb7v+Ac/pV4kjXV6fLijmmdgHOAi54Gc9MAD1PT6pca689yLXREkuLiTCB9nGegAHf8AEAe1ZF9pbILu3JzLbuJEPTdG4BBx7jH0r0jwJZ6daaDbSWiouoTrmW5IyU5+6M/r69K5qlf2VO5jicRVjFQhou5X8MeA7a6kFz4hna4uGGdhfaq/rz+n4V2Fx4Xt1iWO2YfKBtQnbkj9KLu0gijXE+0MAPXcT1x65z+grS8MpckNuke4UHCgjAHH/wCquaylZT1Z5Tk9zhdS8O3Atbu0uIQPMjIDHp0wDn1ziuf8SzteadpzMTvt4/LYE9GB5H55r2uS8SNN8yCMjjB5NY2o6R4d1GYXN5p2ZMDdskaIN7naQCffrVrkasnY6MJifYT5pK6OH+G8s9rpWpzSfLErmONiuN+/B4Ptgg+9YnjLUYk0aeycjz7ps7fQKQcn8cfka7HxLq9hbWErIiW2m2o3CONQBnsAO5PArxTVrufU7qW+kQqZDuC5zsXsorOjD2tX2i2X4sznJa6b6nqPw2kC/DXXjjh4ZCD6fvWI/nXnN2caqo/vWwzz/ttXSaLfiLwELdThpHJbjrl2b/CuRu5CNbBA3kWq5UdfvvXS3zTsvP8AM9KpH2eGUpdeX8kjop2EmmLHu+YqR9MdPqOvP8hwfQLkTeIfCOjSKAxQFXB7qwAP1715hFqUJjRGVh2zwRXfvL9m+GWhvGWSS4fHB/hCg/zNVPY6VOE5R5Hf/hjn5NI1jSoWivdPnZF+UyRDcPyHP5iuq0f4g2PlQWOpwmGWNAm8nGcDHI6j+X0rzGxe8mKyx3MqyNk5VuT3q/Pf6w0Kx3F5JPHjIWT5h19Px9KrXY43NVYK92l5f8E9waWznsI7qCYNBJwPoAW/kDU37yNNyf6tTlMH73PNeQaBq1wulz20jEDz0AxwBzkgfgDXoelalcJq9haDLIYFY57bic5+m0mm6cZbaBLC+7zRNz7RIW5J5yTz3qTwHItlf6zAf9W0scie3HI/WqFnqUF5ZXc6BeS7xjIGVA/wArc8M2KWGmXbXLK9/Mxd2A4BI7H06AfSuDFt0knf+rHJWhyJwkjofEFo+o+FdTtUYmR4HCHvvAyv6gV5rHKtzaQzocrIiuD7EZ/rXqemTeYi4I2tjr615jdabLo2oXemSg+XE5ktm67oWJK8+oOVP0HrW0J+0pqSOfCy5W4P+u5UdPaoilWT1pNvtQdyZB5WealijxUyoMc1IEB7VSQXEVMY5qwgzTo4+Bx+lTqgq0jNkRJWmyuCtSzLxVOZsZFJiSK8F4+malBfQffibdj1HcfiM17JYXUV9ZQXUBzFMgdT7GvCdUlxG3tXpPwkv/tvhTyj1tZ3i59Dhv8A2arw0/ecTkx1O8FPsdrRRRXceUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAed+PZ7X/hLdNt74kW5tyZCOuCWx29jW3psSLpy+Vwudyj0zzzXJ+M7iCTx8/nB3SKCK2ZVOMH5nI/EOo/EV2umIxslV12sMrj0HavKTUsZJeR61dcmHp+hbtiCm4nj+LPpT7ggfN1H8qbbjqB07j+dK5xG47LxXpy1ied1MDVYZNXAijuQlkH/AHm3BMuG+ZenA4I45J9AOee1zS44LcQWUKxRq2UCjOfxJz+fpxjmtrQJ7eS1mt7eZJY7WZofMHfvk+/P44yMZxWFrN4y3zpKrLIg+dAfvp13r7jrgdv1uKsj08FGXPoeRavbLYaoLmQ4iEn2Z1z/AMs3BMZA64+VgR14HStLwtI1rd3WnyOAFXzoDxgr3579RVzxlpg1GZRGwDz/ACjnAeTBMbD2JOD6Z9CK5rT7hmtbK9QK0sQJ2nIyOjqcc9OfxHpXn1aSneDPdqUvawcVvujrdWn1HUriHRtDiMmpSLkyH7ttH/fJ7Hrgdf0zO3gW302UM2paolyqjdPFcsjFu7f5/Wuk8FWEOlW9jcR3Ru5b8ebPdOm0yt6Y/hC9AO2K2vHMKxwrJyvTBHfNc8m6cJOO6Pn95JM4DUrvxF4SjjvLu6fXdAY4kW4A8+L3DdSee/HHQda0by6hlgiv2u400ueMSwyswRNp6ZJ6Htg854re1MI3g5hOqkFwrK2CpyehzXisdgsetR2FvcTmyMhCQPIWSMtySq9vrjNOahNWlvuaUKblJJbXsJ8QdXg1K0WHTS5tY28yZyhUMchVAz16k9MdMVnWdh/xK5bp/lRAoX6kjjj2z/nFXvH+nLpV9q1iMlYHCgt1I3rg/wAquMqp4EuWJG4h2UA9wpA/mK2o6NRStqdNWgoStF3uk/zMiJmj06ON8glQ5B9Tz/WsuONj4hmZTyIUHH44/ma1ZlLM3OeT071StQF8Q328EgJESMZ48sH+tZQd5SZ6OKVoU4+aX4M0ZrCOZC5UiYkkOvBz3BHfn0wfrXRC4M3gbQoQWPlA5HbOAP6H9KpCRJ3aO3lSZkXJTOSB1z+vvjnpW54IiWXwpfM8NtKtjOQ4uLp4FRGJ53JDKSckDG3vnPGDvON0rGjVOg1USv6a67fqcToMTtOlu5EEu8p+84wc9fpmus1m1SOzO1AsTETDnIQEYYfX7uf92r82uWFwoizooWL5So1CXt6k6Xk/nWdcQ6T88G7T4TMjbhHrFwo2/wAXH9mYA7VpHTX9Tz6OIjTXKoydvJmf4XtjdXlohIUSytO5P8KgHk+2CT+Brq45/NS6uoQY5tRLLb9tkGMM59AVH5k1n20GnxrNHGunr5kHzZ1q5G2IYyP+QbwCMj3yce2rsjk+0L9m0r57VZGH9t3A8qDI/wCod8u735O7jrVKJ0/XIpJcsv8AwFkUcptrCK7jlKyTfuba2IyJYunzDtuPTnufSu+8Oa5FGstvfxA3QTlQQeD6HuP5Zrg7q8gmuYtTkj0lB5RWD/ic3AWNR8oZQdOzx2Jzk56mrErC1NtLNbaUskqr9nB1y53rnoQo0/OSPUdK5MVhPbWlF2ktjCvVhXVnCV/8LPYrPdDDCG2gMAy7TUHijQzrNivkv5WowZa3dvunOMo3+ycD6YB7Vxem+IdVSd7eKx0GaeD5SsmuXOV5/wCvECuifVPFxuAp0Tw55mMgDXZ+n/gFWeHj7NOMmtLK11/XoeLU5oTuk0/Q4jLCaWGaNobqFts0L/eRv6g9iOCORTww710euaZ4l1yWGabw/wCH4rmEbRPDr8wcp1KHNkQV+o47Yrnb2PULO9azutN0iG4Ubtja3cDI9QfsGCPcZrd0rapqx108XGa2d/QVSamjPI5ql5l0Dj7Fo+f+w5cf/K+pElvAflsdG/8AB5cf/K+hQ8195ft1/K/uZrpjFP3AVlC6vwP+PHRcf9hy4/8AkCkN3fZ5stF/8Hlx/wDIFXy+a+8n2v8Adf3M0Z5AB1rMuZQAeeKjlu7vHz2ejAf9hu4/+V9Uri5bB8y30gD21u4/+V9RKPmvvGqq/lf3My9ZuRg813/wHlL6dq6/wiZCPxU/4CvOr6SxckTjTV+mtXP/AMrq9J+EFvfWtpvsLDTW0a6lZpLpdVmmlBVSAFja0iBGQByR1J5xijD02ql7r7zLF1k6XLZr1R6dRXivj7SFuPivd3d/pVpcWjaXaRwzXvhS51lN6yzllRoiBEQGUnOc5X0pPGcvjDWF8YaKg1h9FnsL+PT5V01Fe6m8nHkOdvyxAlgj7VL9NxwC/oHkHtdFeEXut+Ora60q30S41htNFpEYri/0uVGlm8xhIk8cdg7KFAVR/qePm3PyR0bP42uokk/tXVrVrjxHcWOyLT4f3Fgss2yUb4ieVVMSHK4KnBOSwB6pUNtd290ZhbXEUxhkMUojcN5bgAlWx0OCOD6ivCfFPif4i2OhpHp8HiCXVbf7XsnTTw0d2I7mRIg6JaSfO0ao3DQqwbINei+DIdTtLLxjMlk6Xk2qXFxaxzqUWUmGPaQTjKlhjPsaAO3orxaXxD4kj8JWskN14zutYmkhF35mji2Syby3LKoFjKzxlhtyqSkEJllBJMuhan8RdS0t7if7bb31v4dS6jtnsUiW61ASXK+W7OnGVSEsg2nlSCoJyAeyU2WRIYnkldUjQFmdjgKB1JPYV4Pq0nifWLCNpbzxXPpljqGmXQu5dEWG8V9z+eEh8jLon7tgRGecjLgczajdeJ1sry0K67Z6XdSamRPp+hq1xdSbkECyoIDsV1ZyZCgJI5ZaAPcLeaK5t4p7eVJYJVDxyRsGV1IyCCOCCO9SV53qF1q2ifCHRBp9pqo1JLSzgZbOLM0B2oGLKYZjgYIYCJ2AzgZ5GD4HvvHuv3On2es3mraVb+Rfma7XT41kdo7mJYDmWBVDNGz9Y13KGOwHlQD2KivnLR7vxzoPgXwtpukNr0KQWrw3jT6Y4e1uEWMJCoSylZ4fvEOFO45HmjAB7j7R45ubHxPfPqc1nNpyW81lbi0SO3ucWkMky7pYt5QyeaoPyspLA9AFAPVaK5n4eajqOteH/wC2dSMiR6lM1zZ20iKrW9qcCJTgZJKgOc5ILkZwBXTUAFFFFABRRRQAUUUUAFFFFABRVE6tZDWv7JM4GofZ/tYiKkZi3bSwOMHBwCM5GRnqKXRdVstb0u31LS5vPsrhd0Uu1lDjOMgEA444PfqOKALtFUrnVLO21Oy0+ebbeXiyNBHtJ3iMAvyBgY3DqR1qHxJrVv4f0eXUr1JngieNCsQBbLuqDGSB1Yd+lAGnRRWZ4l1q38PaFeatepM9vapvdYQC5GQOASB39aANOiiqmraha6RpV7qWoS+TZWcL3E8m0tsjRSzHABJwAeACaALdB5pkMiTRJLGd0bqGU9Mg8in0AFFFFABRRWL4xv307w3fTQttuGTyYT/00chVP4Eg/hSbsrsqEXOSiupwVpNa6pqerXxIbzrktAwJGdhVQwPoVRfzrutOJW2h3d1rE8PWdpDp2mW8cEe+JShYeg6A+vGK6VE5U4xivKwUXUqyrX3/AOHPSxlRO0Fsv00Fj77fU1na9qY0yxEghe4mmYRxQp1kf09h1z/U4FaCEDf6gkCqMyJNdpKVBeMEKfQHGf5CvTWpxJanmfizS9T8LhdY0yNTBNhru2UFghPX3K9sduoxzlltqcWv2cckMu2ZOY2Y/Mrf3Tj/ACc+uM+mXgSSJ45l8yNlIdSedv8AeHrj8/0z41rulLoU01xZufspy0eEyysTzG+O2MkHn8iaptx16HtYGamrP4l1JNaCtpzFlw8TqyAH7j7h8v06kfjXHWADw6m9ucxR3kjAegLHDD6Hg+x9q3L3U4NS0echh58YJkGfvKqlufyx+P5ZPhmIp4cExQs8jySFc/6xTgMB6/8A11x1Nc7d6mnY9qL5ZK39bHW+ANSE1jPpzj57Y/aYMddp4dfwIFd54iYal4bWVQQyABh7qc145od+NE1+0ut+63R8s2PvRMMMf++ST9Vr2WyG57yxJV43Usv1xn+VclWD5mujPHzGmqdbmXXX/M5LxvJJbfD8XsW7G9DIR/CPMAJ/I153o+xfFXnyFdkTCQng88f/AF69p0m1hvNK1DS9QQSW8gaNgR1BGK8pHhDV7PWb+0t7S8uYchIJ2TAdeuS33RjpkkUlFuKl1sZYScVWUZuyv+hzniVpde1W8NuB5l9d4QN7vuGfyqLTbNbzwfq1xdTzie3QhIkOEUj+8OrZGR14rp/Dnhu/TX/MmRPKsJW3ssqnMgxt24PI61X8O28Ml/4qsg6eSZXPy8gDceh9ATitaeiXe5pipRqVrQelrGBCm+28xSCuMg1kxzmLxRcMTt3xxEZHYDb0PXpXXeBdMOp79MfIuEDxKAR99QdoP1wPzrmfEli9vMs/lsJrfKuMclM8/kefzrKC5ZNP0PUxf7ygpQ3jZ2/r5mte2b2tgmr2GZJLN/LuY15PlMAY5B7dVOehUVY0G8nh0HVlwypeSAHkjgEH8elReCrlpNYtEjIeK4HlOvUMp559e9d18SNEj05rW006ALGqZfaOjE9DVzb5dCcO4ymrvR6peh5XaXKWl3M0ieZtkOE/vc9P/r1NFcvNNJPNh5n2jaOA2MAKPYY5/XvWZdBxqF1uQg+YwAIwSM9afFLtBJJxjbkfyHt71TkY0JW37s6OK+CLJJMiSbiGKf8APZhwqj/YX9cVp/a5JrKdbiQ+SziW/nzhp5MfLEp9h27cn0xycc3z5/jx16iMf4//AFq0PtAWGDz13Rxj9xa5PzZOSzegJ5PQn2FNSO1yT1/r+v63N+2dSq6rqSL5fAsrJR/rmHC/L/cH6nPqaJbyZb1p7iVZNWl+Z3LZW2Xvn/a//V7VgNqlzLcNcu6+djZ52OIx02xj6ce3tVdbpIjhQCAckHkZ9W9T7dB3z0o5hKajqztrO6TzYUt1ZSmXjbgSyMR99z2XAyB0AHp19R8Fa1Fe2GfL869f5CR9eMZ7EYNfPcd/L5bjecyn5gzYaT13HrjPPv8Ahiu8+F+oXF54kkSDBURglgu0ZyMYHYDnryeT61x4yKcfaL4l/X/DHPjIwq0/Q95hZ4JRFOwEjDIGc0ur6Raa7ZC2v0O9PmSVDh429VP9Oh71nNbXCXUT3jKzkkgKenpWvZyGVyuCMUYSs1Jwa67M+bqK1pxep43q1rPpOp3On3jBp4CCJAMCRG+64Hvgg+4I7VXS45611HxfCQ6hpMwAErwyo7d8Kybf/Qmrzt70A8H61dR8srI9WhJ1Kakzfe696rPdYzg8+lYj35xwapz3x6VHObKBs3V+ACN1YeoaiTkbvwqjcXLMTyciqRSSZjjJ5qLtlWSJVEl7dJDErSSSMFRVGSxJ4Ar6s8H6QNB8NafpwILQx/OR3cksx/MmvNPg/wCA5Ipode1RCgX5raFhyx/vn29Pz9M+yV6WEpOK5n1PFx9dTlyR6BRRRXYecFFFFABRRRQAUUUUAFFFFABRRRQAVFd20F7azWt5BFcW0yGOSKVA6OpGCrA8EEdjUtFADY0WNFSNQqKAFVRgADsKdRRQAUUUUAFFFFABRRRQAUUUUAcP8TvCmqeIoLGfw7eW9lqkAmtmmnzj7NPGUlAwCdwIjde25BmuWh+Fd7Z/ESDV7WWBtLguLeS2K3EcU1tDFGqeQAbV3aPCn5VmRSGOQDkn2GigDxzSfhINLs/A8o0bw5f6lpEBg1B7gEGYlVCyLIYnZihXKhgMZwCtYunfBrXbTS9Vt5bixurq5tVgNw92qJeEXEcu6dEtFfcQjfO0krDcRyCSPfaKAPJNF+F8w1S3n1Sx0SDSTqE91JotozSWsMb2qwhEBjUNuZd7Aqq/MeD35+H4SeKH1DWrmeXQIG1DT5rWT7JtiSaRp45FdkjtkI4Rs72lbJ4bBNe90UAcN8VvC2peK9O0+z0+LSpoI5zJcR30cRJGwhTG0kE6qwJ5/d5IJAIrjtM+D11N4Y1TT/Eh0q+vZvD9tpdpM+6Zbe5iS4XzQGUYx5qbWHzDDdO/tVFAHhepfCTV72/024ittHsIILaKAWdhdRxLZOkjMZYHeycgvkMdoiORgswwRra34Hm0Twzqeq2NlBc+LI9bn1TT57eFpnPmXTMkTHbuVCkhVwPlXczZ6k+vUUAcrpfhvUNF8J6bpOiapBa3MA3XFzPa+f58jZaR9oZcFnZmz79KT7J45jH/ACGfDU/HfSZ4sf8Aky2f0rq6KAOUMnjlM4tvDU+en+kTxY/8cbP6Vz3iXUvEV3d2mm6ho2jrcqwuY4rXWpHL8MoB3WqgDJOPcdsV6ZXlula5C/iLU9akBlFy+22b+HyVGFx9cbv+BGubF1o0YXl1OvB0ZVJOUei/EsabLremkGTwvfTunC+Vf2zAe2Gdeen5dq1z4nv1B87wd4ji4z/y5yZ/74uGrU0+QT2/nckSSbh9K0GzsYe39aWFUI004xsmTVcnL3ndnJ/8JZFGGM2jeIkHXH9lSyZ/79hvyquni7SopC8/9qQngkT6NfQ8evzwjj39q29QuUgVImJ8yRtqL3c+n+elI8r6YGlky9meXYdYz647itKbUnoCjLozn9Y8ZeGrlVV9cs7cjJV5n8kp7/PjI6g1yratpGoIVi17QZ5N2P3Wp27hs9uH7/54zXfale3COn2W4YMMtH8/Eg9M+voe/wCdc7eXEt1DJJPM8tuxKEzHe0Rx907uq9a6NT0sJGrFe6187nC6h4dW5kllsIhMl2phmFvIHILdGwpPIPPqckd81maJouvQaZJZ3uk6jC8buY5JLWQcjkN07jPPQjI9K6HXbSF4Jt2naS88SHIl0+CQOntuQ+vQ+tcZoN7Y/wBpXaXmjaKturHH2fTYYDGCTgjy1XkcHPXjrXNJRjU9T1o/WYpSSi/m/wDLyJpbK4VcT2cqMuZAjoQGH8afTuD0xu9q7bTdd1OOytLXRLMyXMUK251G8UrFxldyrxv4C85654Nc3JdtayokUMcZMioXhvbuFcnBV/3cqkAjnPX8q7GyhjuJURbrWoizdtau5dv/AH8kfP8AL2rCtOEGk3q/I4cfKtK3PBfJ/wDAKGp6L4u0qIahYeJpru6A3yW8kKiNu+APujj2H4VgyfEue/iFpf6a0RH33tpsZI4PyN05/wBquv8AFZfQ7WOZtX197dyN586CQIOmf3kD8ex49q4LXL62W8e3c3Ek7Fdry29kMqSDndFbxnuenfPJFS5Rs1f8Diw8XKpFSjo33Rg67rt3JYiK0eSxt5JsSqkhLPnONzDBIwMYHH17dH8PrSGwM6rtdXiwxK8c559+lUviBpdq1yy6aFSO9tUuEjAGIpOu0YP95SO3WjwXqqukdqdyz43KG6MM5JBqG3b0O3EUY05JxWjX/Dkl8z+G/FUGo2xCxNIN5U4GM8P+B/Q+wrrPH+hjVLaPxHpSr5M2POjUcxvjr75qn4l05Lm0eZ49gIwxB3I/sf7pOcA8g9+uRc+EmvNaJJpV+S8KsYyJOdw7E++OD75racVJX7/mdlOrLlVWmrtbruuq/X19Tj/CGimw1GXUYY3SKEEsp5VWOOnp0/WrGp+Nr+K5mmzvzlcHndmvQviXdW2m6V9ksEEcTEyFV4BJHWvE44459Vt47gsI9rSEDv8A5waxcXz8lzeM4uh7SMLX2Owj8QaT4nEdlrulwWUjnZHdQgjafUgk+3fNcZ4k0afQtSe3mGUBxHJ2Ye3vXpd5o8Oo6V9nUKiIA0OD/q/p/X161kaneyx+FLJ54re7Ble0nt51yBtGchuoPbjHStalJqx51HFRqqV9Lfl/XyPNVmx05rT0jT9S1qcxaZY3N9KT84iUkZ/226D8SKv29hb2969xa6f9rgXLtbzku0A65IUjco9cYxXoOiXmvavp8C6VfadbWWdoNuu1U6cYPTrWFpuVoxuTVxEqa3M/SfhXdToJfEerW2n46QQYldR6HB2r+Ga3YPCfw60tdt9ez3jJ18652/omKtJ4YtVUXGs6rNd4bDq8vloCMZzz6HNWtSstEhtLwQ2cUEUuxIJDb/Kc4z8xGCepzn/CtY0Kn2ml+JwTxTk73bMzUp/hxaWcpg0yykZFyq53MxxwBmrPwm8PXdlbXGsrbeWly4KxKMbVGSP5nj/GuMk00X/iq30nTlC+TsmuZCvO7jaPyxx7j0r3G1a40uMQFSsQwcEYJP1rzMbJU5ezk9OrXTsXCTcbrr3LLmea5h84lV6gn/CttCIpVCndgVhX1/bWKwyz+dJLIT5NvCpkllI6hV9BxycAZGSKzdbtfE/iGH7Nb2SaRZN/rDNcKZpB6HZkKPUc1tg6M1ee7ZjJKTSbsv6+84T4naquqeJJnt3DwQIIEKng4JJP5kj6AVw8ud2DkY7V6s3wuv5FG68tEPoNxwPyqxb/AAlXINzqoP8Aspb9PxLf0rolQqzk20dsMXQpxUVLY8e2MTgDIpy2MkhBIP6171p/w00S2x5z3Vz6h3Cj/wAdAP6102n6HpmnY+x2METf3tmW/wC+jzVRwU3u7Gc8ypr4Vc8G8P8Aw91fV9rLbmGE8+bNlFx7dz+ANeo+FvhtpWjSJPef6fcryPMUCNT6he5+v5V3VFdVPCwhruzhrY2rU02QUUUV0nGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcx8QdQltNCa1tCwu78m3Rl4KKQS757YUHB9SKo6b4bs7e3tLeTDEICyrwBxwB7VTlul13xVdzK4azsv8ARocNwzA5kOPdgF99nFdLZxurTTScErgV5NWX1jEeztdL+n/kemm8PRUU7N6v9PuJYkC2qhRgB+PpUyvxntinKoMSjOBUAdRbE9T1/CvR+FJI49ynOiSagrlQSoPb6f8A1qsfKd6tjGOc9Px9qpWjm5vrhkYFI0VeD0PJP6baq3t9LFdNHGFMqH5RnAkHdT6H/wCt+N0o6GsYOTsjz3xFenw9eEwmafSLiQD7OSWeBycfJk5xnIK9uMYqe3vzIUmhZZDIvOeVmX39/wDD1yKs62lvqguG2mUR/NJG3BKnjcO4ZeVP0/PiLN59Cne2mJmsuZISOrIOpHoygcj2z24py5fQ+iw9NcvvHUXSRvECjEWT/IpY5MLH+FvY8/z9q83tSsPiO6TYPLktkEi/3iFAJ/Nc/wCHWvSvOiFubxNjjyy7g/cuIxyT7MO49RxzkV5tpCi51y9lVTKsUCLgdT0zj3BPHr+NYVdZxOyn59/8/wCv+DcuWT/Zr+3STc6K6lQM5ddwIA9weR9SK9DsCI9QEZPAfqP8+1ebPF5sTIGDsPmjYdW//X+hGO9dvpVzIY7aWYNvdA/PUg9CffvxXBjI3lCXn/X5HJmUVo0dlrBi+yvDPCJEZdrBhkY9MV51ceF/D2oStbadO9jqKEPG0kjPE2DnYQScZ7Y6eh6V1tz4z8NTSC2k1aBplG1iUfZ6ffxt/WuZ17TbSe3kuItStY4QrGO5Eq7ehxyDz+FEuZSVloePBpa3szkr5Jzq8MSYd1B2DORxk4H45rJIOh6/o0b72ljsFWXykLFmLyZwOvcVtbtL+3xXN1q4iEIDsIbeQkEc4BKj88VhtqH9peLbnU4t21pCtvnj5V4HHbgZx61UVyxbZ3Y6q6s4pdF2t6nocVtqWrWLXl1fyaXp5yqQRwBpQOzTBgc55+UHgEdzXKQi50fxZD55Rt3yGSJvkkHVWH/jw/w5Feq2txEvhVc58xXYNJt3AAjPzL3HP1ryvxbDGL6GWIJDiSOTZG25QS3JQ/3T+h4PNdCd6bQ8A3dm548mkltoixJG0Yz6VxmkIZNfshzl02ghd3OfTv16V23iqEtodpIw6r19f85rhbd/J1TT3zjaWOfoVNc8X+8uerVV6St3/U9u8D2Uf2CQTHeYJGiB4IZcBlIOT/Cw5rh/HtuttfXGn26gRvfCVFLAAF0VjyeByW/Ou48MzGCK88wBd1yGyp4yYo2yPb5vr681y3ip4r3xLbRxBWlkvCeQD9xI06HggnPX0r0Jq6j6nzN+SpVa7P8AE9L0vwtpepaBp32ywglZbdFLqAHQhRkbl56+9WNJ8D6FpBl+y6em+Ugu8vzlvTr9aLbwL4SmRZJvDmkLPgZmhtEif/vpADUk/gvQrRAYLvWtPB6C31m7VR/wDzCv6Vdle55/PJLl6Glb6RZQOGgtII2znKxgH+VZfjvSft/hu4CKCyjOPUdx+VVZNJlt2/0Dxl4hT0VxbTqfr5kJb16MKmlsfFEdqTB4o024iYfdvtILE+2Y5o8fXH4dKZLdzyz4bRS2vie6eQI8qvHncc7vlbB/Vf0r2mcSXwRpI2Qg7sPxx7V5te6ff6Bq8N7LHoskknyqyXVzbo3PGR5U2COP5fTrF13X5Y4ZZfDLzKAMNY6hBJnj/pr5XY+39a8TEYSTqzu9HZ2uvTqdcaq5Vpqi54NC3XivxJdPh2tmhs4Sf4ECB2A+rNk/QeldpXmHhPxAuk3mty3WjeID9qvDI/lWS3HksFA2MYHkyRj9R7V0f/CwvDaf8fV3dWX/AF/WFxa4+vmxrj/649a9ahHkpqJz4iSlUbXl+R1lFYekeLvDeszrDpOv6TfTtwIre8jkfIGSNoOc1QsvGsV9q89nY6Nq9zawXrafNfxJE0McynDBl8zzQAerbNvfOOa1MTq6Kyn8R6IlrFcvrOmrbywtcRym6QI8SkBnBzgqCygnoCw9ar/8Jh4Z/sltU/4SLRv7MWXyTd/bovJEnXZv3bd3tnNAG7RWBqfi/QdPs5Z5NX052WD7QkQvYUaVSjuu0u6r8yxuQSQuFJyACRYXxLoh1NdNbV9OTVDGJfsTXUfnBdu7OwNnGOc9Mc9KANeisZvE+inR7/U7bVLK7s7GHz55Le4SQImzzASQcDKkMMkZBB6VzVj8VfDV3f6cv9p6bBp19YfbEvJ76JAsm9V8gjOPMG7kbsjGMd6AO+oqg2taWqlm1KyCif7KSZ0wJsZ8vr9/HO3rWfL408LRQpNL4l0RIXZUV2v4gpZlDqAd3UqQw9QQelAG/RWFc+K9Gsv7QfU9RstPt7OaOB7i6u4UjZnjWRRnflSQ3RwpOMgEEExeGfFVpq/gqz8S3jW+nWU0JndpZx5cS5IyZDgY468UAdFRWGni/wANvpy36eIdHaxYuq3IvYjGSgywDbscDk+lZehfErwlrGiTatHr2m21pDO1vK1zeQp5bB3Rd3zkAP5bMmT8y4NAHYUVjT+KvD1uFNxr2kxBo1mUveRrlGVmVhk9CqOQehCsexrSivLaa6mtobiGS4gCtLErgvGGztLDqM4OM9cGgCeiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArn/GutSaNo/+iANqN04t7RMZ+dv4seijLfhjvXQV5vNqNvr/AIrmuDI5t7L/AEay8vGHY/6yTPoSAox2UHvWGJq+ypuXU6cLS9pO8lotWX/CemRwadHbGALPA/7x85JI6c55/wD110swIix0yafbQJDEqRqF4HT1ouxzEgrmwlF04ty3Zdeq6s7jgCIlX9awRe3Mj3dvY2xdoCE3yEKhY+/J4+n0zWzPMyI2ODuC/TJApoJC7cfL9Mc11uHMzKOhyRtr7w7m9kkEq3DeZclRwrnjueg4A9gAexqHVrz7bKsse1xjdsQ4LgZ+ZT1DL+vp2HWajsNrIk65jIww7YryXXxNo95sAYWmcg9TF7+4/wA8YNdC0R6uBiqrV9zVvN8spu7UqbpQXyB8s68ZOPwAZfxHOBXP6nbW1zArKzx2cr7opB9+0nAzj9PxH0zVm3v1aRGMnkNuyJBz5b4+9/tKe47j3AqG4dYpZXlTEEmI7uBTkxnPyuvqueVP4egqHY9qNNwdn/X9dPu6mBaG6N5b6LdyvZ28jYkCjcsp4/1bY4BGOM9PXgVi+D13aRczyBC5bMrgZaInjcV7rk4P19cZ6LXCVt4EcbpoJ43gnToyE9j3HOR/+quU8PXT2mqagqBSgkJORkYI547jBOR6E9OtcjXLUs9TazT/AK9b/gaV3vjk3MpAzuIDdGPOQfRgMg/1FbkZu9ctLGw0+3mgiKmK9vnTYoG45EYPcjHThScDjkZUqRuqeXuWEghMnO3u0Z9cfeU9wffj0PQ0H9n6eqyGWNE2hwMFsHnj65/zzWeJfLG9r6nHmWsI/M2Y/D2m2Xhn7LHaRGDYRsKjn3+vv1ryLxVpGnWtxZpY2yRSM4UlM5xnp+hr3e7XOlBenFfP3ii+8rVl81PKZXEgBYHOGIb9cjHtXPVUuZW2PHw8knd9zO8T6XNpclzBOmHMG8D2Zcj9DWDosvlLaMrHKEnHY8kV6n8TLWKWz0jUYFzE8H2aUjOMr0/EgmvNvDWjy6le3enxtse2glmBAyZGA+VR9c/lWiiknE9DGy5uSr6r53PbPC0y3Wjs2dhdAyv/AHCDgkV5x41ieGdY3RUKyLICh+RlZlIYcnGcdOldl8K7lbjRRF1dCefr/wDqrnPH8cEczrbptjJUbTxtO7sp5UHOcdO47itKS91kYL+JJeRt+JYz/wAIfYS7s7twx6YArzWQf6bp/JBJkH6p/jXq/ixVj+HmjsM/O0hOfXp/IV47qR23lm4zkCQD/wAd/wAKyt769P0PSnUth3L+9/7ceyaHcAyNFkCOdFuE2nKkjCMVPXGAnHbkcdKz7C0ik8f6U5bdGbY3JHYMWZv54rlNI8QXFpBCWjLQht5GeGJHUfgR/nFa8N69h4j0q7uJFYxRpazhcZibaPlYdjhm4/2TXdGopOJ4mMouKnOOzS/M92jvQkIbOPSsPV7uWd8s5xjt6VE1wfJXnIqjezjYApG5uPpXQkeMyxorGa9Tc3Q5J9u9WtU13zrgW8GBHGcBR3/zmqUR+w6e8jDbJIOPYVz9pIXuWMmUwGdie2Wyf0FLzFbodTqksM+i3Mc+wq0TFWYcA4wDU+i30mmeHVk1QqkFpD5hbjJAGe3GSfzrnNJSTxHMXgDf2fbgupbgSsOM/QcY9+e1bTWp8Ra5Z6JIMWtqq3eoqOhA/wBVFx/eI3H2FeHiqixOJjTp9N30fl8jvoQ5Ytz2Om+HunvZeHEnuE2Xeoyvfzj0eU7sfgNo/Culoor2orlVkcE5ucnJ9SGS0t5J0nkgieaM5SRkBZTgjg9up/OuFuPh/cXfi+HWrvUNMPk3ou45oNJWG+2AkrA1ysnzR84IKZI4J716BRTJPFdc+FOsw+GprWy1WDUVs9LuNN06zFmIW2yzRSZkkaUhiBEB0UH2762qfCq71O9k1a58QqmvPeC5M1rbz21uFEAhCBIrhZAdozu83nuMcV6pRQB5tYfC2Cz0XxBYR3sEZ1XQ00VWitnItgBOC6+ZK7kEzA7S/wDAPmPZw+Gs4vio1mL+yjf/ANpmD7D+/wDP8ny/9dvxs742bsfLuxXo9FAHP6B4Zi0jwHY+GRMHjttPWwadIwm/EexpNuTgk5bGTyeprmIvhvdS6W1rqesWtxKNAm0COWKwMYWNwoWQgytlgF5AIB9q9HooA81sfAcq+O7i7k3ppMNhEIt20rNfGIwNcBQSVKwqqc4zuOOmaefhtPa6R4ftdH1e1trnTNHfRZJZ9P8AOjnidYw7iPzF2OWjBzlhyQQ1ej0UAeZWvwvm0vUYL/Rdajiu7aeKS3N5ZfaECJZR2pVgJELMRGGDArgkjBHXdtPCF5ZfDaLwxYa5LbXkUIiTUooirA79xO0MCAeQcMDgnBB5rsKKAPM/CHwvfQ9Wt9QvNYF/LFqU2pFWgkOWkt1hxulmkfI27tzMx7cYzUN58Lb2eztreLxCsQsNQub6wZLeeJkFw8jyJI0NxGz8yfKVMeAMENmvUqKAOC8L/Dqy0FdS84QXkF3pUOmNbRQsoCRmYuFaSR2w/ndGbjaOT2tfCjw5d+HfCsQ1hpJNau9s148rK7ghFRIyy8EpGiKSOCQSOtdnRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUyWRIonkldUjQFmZjgADqTQBzvjzXG0nSlgtZFTUr5jBbEkfJx80n0UfhkqO9R6FotnDZ2JhiVFhjVRhQN2B1P86yrPSH8VahNrWpRPFDIBHZROuHjgB4Y56M5y3qAVHauuhhitY1iiXaByeep9TXHOHtp3kvdR3c0aVJQi/e6k2QqKB161WZjJcbs/dqWQBQMnIIqDZtVjnGT+dbTdnY54oiMqiUoWAJyxPYdBz+dPGWhYHgjn3FQ6d5V3DerIu6JmMZOMA4HPP1yPwqil79imFpeMSWB8qY9JAP5MO9aUtY3NYw5tI7jL28c7oiwWVeV9GXPB/p9ceuK5TU4Y540hcBVyViLdI3/55H/ZPUHt9OK1takBfaSEfdmOTP3WPGD/ALLdD6fiKxnuRcWsxmQl4wUniPVlH/sy9c+lanr4anypSX9f1/Whxl/aHTwSgb7I2Rzx5TZ5U+gz+RweMkVJa3EkxWPhp40PlZ4E0fdD3z9OQQMdFrfutkc04ulEqbFF0VHLxkfJcKO5HRhXL3di2m3ZspH/AHbNvgkByFPb3wR6dvUgVm9D2qU/aLlluN1qVf7DkVdzRbl8snG6MlxkHHGOT9Dn+Flzy3h+ETTaiyMRLvbyl2/6zbxgH+9gEj1wRXU6srXui3Fyi/vUdPtMeRncG+8Md+v6/wCzXP6OgsJ9TsrkyBY7h0lCj5gQxw6+jA8+4yPrzS/iL0GtFZFu3wHJVtkL4DbT93nIYD1HUf8AAh6Z9M8OCWGysluAnmujN8nTBJI/TFec3ayR3bFWQXBAJMZwsm7lZF9A3B9mH5dhqXibTLe1sY9L3XWoGBFjsbZclPlA2ueiY498cgEVGITcVbuedmUrqPZnozRvPp+xCobtuOMmuD8Q6PBdRSW2qRLJEx4YABlPYg+opLjwa2q6cdR8WzG7umX91Ap2xWo9FAPXpznnuTxWDpms3OibbPXpZbzRnOLe9Kl3gP8AccDJI4ODyePwGNRXtZ6njQVrlHWoZoPD/wBgu1bfaYIkAJWSMA7XB+nX0OaofDqIt4xieNCT9kkDkDpggAn8wK9TthBq3h+eIyrNpc8LIZ42+XYQQfm7Y569O9ec33jHQ/C1rcDwlY/aJpD5Ru5ZCyMefu5JJHB/ujuM0uVvc7ninUouk1e1tf8AMo6ZrMnhPVtcsbaN3le7dLeNEDEKMsCAeOARknisrxLqTahKZbtZIriV0JWQKSeRgAjgjjgdhWx8PkurrWNU1XUUW4v54fMYleFVtvHAOBgjt2Gay/GSOMyFXEbyxuCRngtkc/j/ADrphZwdjowCfLKXkdx41dT8PdB2gg5l7+9eRXMbTapp0caF5HYoqAEkklQBxyfpxXba7qpufDun2h6QBz+Z/wDrVxryCLVbB9+wjJV+flORzxk/kM1yqV538v0OzEUnHDuL7/nI6C4lubC/lk3Sw3caCOBOPMSRvurxwmBltq9BxnODVzVPC8+l2ht7mR/tF5EJMscsZuZFY+52uv8AwPOKo3ltc2Wo2slwrRHzI38qbO/DhgXbPc9SPTH1Po3iy0hk0Se8jlYfZ3jliZwPmlHVSeoAIAx3FaRdncy5YyjytaPT8vzKnhDxLa3vh+zkmu4BNEojlVpRuyOhx1pZ/FFnHLugCz7SOQ3Ga87t/C4uJ2JJiimJlgcAlSuN2OM4IA6enP0gvPDksNvHcwSPgLlmyBg55xznqR/9cc1vLEN+R5UctlHdXsezPqq6xYpLCRvHyFf7p4PSsRkl1O+/suM+Vbkg3cnfaT8sY9Ce/tXAaF4gm0i6IujI8eDl06t9R/WvY/AmiFNHWa8JS8u5POZm7E9QPzx+FceOxkoUeWHxP+v+Ac7w0YVbvY172G18NadPdvI32OFAFRRhpT0VQPc4H410fgjRn0rSnmvOdTv3+1Xbejt/APZRwB7Vg2NuPEfjAI7M+maA4J3dJrojI/74B/M16BV5dhI0YudtWY4qq7KH3/p/mFFFFemcQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVynxS1K+0nwTd3WlXb2d559rEk6IjsgkuI0YgOGXO1j1BoA6uivJdU8c6h4K1fVtNu7ubxQsS2fkSGJVmhmnkdPJmNvGc8JvG2Itg42nINJd/FzUYY7WCPwdqT6rJFPO9o0V2MpG4UGPFqZDvyMGSOMDuRQB63RXnFv8AEe7l1jypNBWHTP7Wh0czSXZFyJpYY5VPkeXjA8wBvnyME4ODje1jxHqEXi2Hw/oum2l3dfY/t00l3etbIkRk2AJtjkLtkHIwAOMnkUAdTRXkQ+MVw9vqF7D4VvpNMgSdornE6KxikCbZHaARLu+bGySTkYODW9qHj690vW10XU9Ehj1i6aD+z4Ir7et0skjK53GMFTGq73GG4PBPWgDv6K818M+OtT1e6g03StNivLw/a55pNRvxAEijvZbdQhjgO8/uzxtGBt3MxOTy/jv4p3Fzo3ibTLG3NsW0u/nsNVsbi4AYwEKSGeCNc/N1ieQKRgnoSAe5UVzXjrxM3hqxtHt4Le6vbqfyYbWR5w0uFZm2LDDM7EBc4CYxkkjHPDyfFHVdb8N3k/hzRYYbhfD41gzXV5sEG5p0KhfKbeymDIyAG6HbjkA9doryO5+KOtaWmm2Nx4Zk1PVW02HUbhdPe4uN0bsVXZ5dsRvOxiQ/lqOAHPONx/H97HHeX8miRJodjqjabc3bXp8yMCURmby/LxsGQWywI56gZIB6BRXO6F4m/tLwkmvy6fcx2026SCKBWnllgLkRyBVXOXXa+0ZwG6mq3/CYzSD/AEXwp4ln4/59oos+n+tkX/63fFAHV1j61BLqVzBpw3LZnEt2399AfljH+8Rz/sqR/FWZ/wAJF4glP7jwVqUf/X1e2ifnslf/AD6U3+0fGUmTD4a0WHdyTcay4I9OEt2yfXn8aTGnY6UttJx34HtVaUEymubd/GUjDI8OWuT6z3GP/Ref89aJLLxeyGSbxBosI64g0aTI/F7k5/IVEi0zcu7jy3RmXKA8iqlxdCVvLt3jV3GFVucfhWNcaJrRi8y58W3qg8/6PZWiYH/A435/z70kXhWTYrSeJPEL71BO2WCHn/tlEn+HtWMY88tzRO3Q6ywtlsrGGBDuCryzclj1JPuTk1m69p63tq8TqxVvmyq5ZGHR19x+tZ3/AAhemMP9KvPEE47B9cvApH+6JQp/EVnX3gvw+9tI1vpUV1cw/MY7qR7guP8AgbHn369uK61oFJyUrxMK+S/sriW01OKRYyuGmbCoR/eBPT8fp71nSazY2hWS81vRLe6iPlSebqdvGJh/Cw3OMNj1q5NoXh9rYDStG0Wweb/UyQ6bAhWQcFWIQc84z16e4GFY6xqWnymFZWt7u2fGyMeWr+qkLjg/zwe+aG7H0NH6xWVkop/Mvtqmkyxg2Wr2jSwNvtzBuuBtb70REYbIPb/65qO+itr/AE1rYR6s5RgbZ4tGviEzyU3mEKQD0w3tjrTf7QummC/2jdPbXBMltLLIzFGHVG556dO/zDrim6jc4827bzFWX5Jwp5imU4WUH1DYB6Z3ZH3uJ3LVHEcy99L5f8H1/plEWhBYvbamzPB5c4+zQxbuMZ/ezJg9+eBgZxiuU1VmtPFckm2QLexLKQ7xMzMPlckwySJksueGJGexreuiqNHqOFYL8lyirgbTjPHTHIYeoOOzVyusKIZI3JH7i4BUr3SRf8VFc9VpWZ1UqdRPnnO9ulkjoraI3Pl23JOSYNo5II+aPHvgkD+8D2NdtYFprLTY8AuEI8wc71ydrZ91x/nFcroloLmWKISsJPMDIwOCQDnIPbhT+IU88A97pKq9+JAqLGDwAMACsMTK8VBdTjzCorqPbU6DWv3PhsZHROQa86tjEYxazgP5ob5SvBHXmvQ9av7HVdMI029troIdr+RKHCn0ODx+NeN+LbybTfs8zg7EkKv7dCP5GsqytUSPKou8WY2kaedW1e5gs1YRPuk8sZwTng457A81zOsKS8MS9GkPA74Feg/C9xEdTu2cxtHDJsfHQiMnP61xDW8l5relwRBy7vLjAzzheefTrTitU/U9hvlwklbt+LOr8Fqbme6iZ9h2DblC+eBwQOT9KqeOovJaOIusjK0eWBH94ccccdO5459KreBb4nWHCAMzLgZOF+p74qx43VVjjDyKZRKgZRgY+cHgDoDnP61tRTUJIWEektdLGRPKTHtyeKbo/wDyMVliBbiQoyxREHlyQFxyOckY9+vFV2O5j6UgEo1KyNs+yXZIVbOMEYI/XiuWn8R34u8qenl+Z2XhOzm1/wAQDUr52uLO0k3li2GmIIACZwcAAY74HPoLPinW/wC0r+UzTkWMKvciMnG+X5gmffO4AegB/i4r2GsppfhyPTGto7a4AxJNPEQ6twNoxyTwTtH4kda5yXS7uOyuL25cw2zjenmYZ5F5+uDx2x37VteyOZQV09/6/r7iaGCQ3ep3EDRmOHbA7A8FY1Cb15GSNoYY54q9c3hlsjDdR7Jkj8v7n3yp5Kt369u2M9KsaD5kGhvK90ka3bvK9vt4yOR7Y7DBrDupHmvbshjJGsFruUdQRAgLD0bOT75Oc5IKb0ua2cFFJb/1/mXNB0r+1fENpaOcRlg7/wC6DnH44xXveuBfDFlLqEbCdUi/dqcfNMcBF/EkV5T8KbCW68QTI4QOkSjzR935uQR7FRmvStSik1TxT4d0ckyRRynUbgnpsiwE/N+CPevPcPbYjlktrWfbq/zR5OLknO99LanY+ENF/sHw/a2Lv5twAZLiXvJKx3Ox/En8MVtUUV9ElZWR8/KTk7sKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqrqenWWq2MtlqlnbXtnLgSQXMSyRvggjKsCDyAfwq1RQBkQeGNBt9Gm0i30PS4tKmOZLJLSNYHPHLIBtPQdR2qtL4J8KzafBYS+GdDksYGZ4bZrCIxxs33iq7cAnuR1roKKAOZ0fwP4f0rXb/WYNNtpNUu5/PF1LBGZIB5SR+XG4UMqYT7uerN64rT1nw/o2tvA2taTp+oPbndCbu2SYxn1XcDjoOnpWnRQBhv4Q8NPfXN6/h7R2vLoETzmyiMkoJyd7bctnA6+lak1jaT3ltdz2sEl3bbhBM8YLxbhhtrHlcgAHHWrFFAGLeeFPDt9Hbx3ug6TcR28jywrLZxuI3dtzMoI4JYliR1JyajXwZ4XWe5mXw3oomuldZ5BYxbpQ/3w52/MG756963qKAKGtaLpeu2q22t6bZajbK28RXcCTIG9cMCM+9Ns9D0mxQrZaXY26mEWxENuiAxAsRHwPu5dzt6ZY+prRooA52TwN4Tktbe2k8L6E1tblmhibT4SkRJySo24GT1xVnXPDdhq3h/UtHZDaWmo7xcm0VY2k3n95k4IywyCcZwTyDzWzRQAyGNIYUihRUiRQqqowFA4AAp9FFABTXGVOOtOooAzpl2yD25qC+Z3hIQEgc/Wr13FuUleo5qlAyi1di3OeK56mnu9zaOupQQyX0ht4hgADex6KDnp6ng1ZupjYELOpe3Y5R/7vtTfDrlnvj8pHnYGB1+Rf8cfhWtcwpPEyzAFD1qsPG0bvqU5pSs9jLubgS2ha2+eRPmC9Cf/ANeP/wBXbmr++mUR6tpshZIxmeJuPlHU+2Dww/H2NnU4J9GnDoN9r/C3XHqrf57DvisjUL37JPHqNiQbWdsSox4STH8X1HB9eD2NdD2PQoUlvHVP+rGfrzwtK2oWa4sbkZuI8cwyDgvjuB0PsfTJrm9dRrtHugM3touZRnmaE8Zz6j1+h5zxrX062F6fITOnznDRMMhDjBU+uB9cqccbRWXqkclhNFc2bF41UvDu+YtFxvjb1K5APqCp7mobuexQXLa3y/yf9fkZ1rOrjyZWOyQCRXB+6f4ZB6EcZ71bkufMti8gXzoiI7uI8K642q/0x8p9iP7tZ9zbLFKsduT9mlUzWRI3Y7vEfUjrjuM/3hQL+PyPOABniGyVTzvhI5+uPw4Ge9Tfud3uz95L+v6/EST9zGVJYov8TjloznaW/wB07lPtvHYVyWvJsgv1G4LGkRTPX/WEj+ePwrpYpOGjxvUAyJgg5T+Ie+B83/AePvGsLxGhXT77J3BBBApHI5Z3BHsQO9Y1vhFU9yLv5/kd54Ht8aPLfSHAkBRQ2Aqhcb2B98AHp92m3moJr3l6do80g05Cxvr2MlVl/wCmSHvn1HXA6jNZuno+rnStB3vHYx2YvLxASDMC3EfrjPX2Irqra2F08dvAqw28XyqijaAPoK46krSv12Pnq03UqSk+5ymvWh0N4td0FPs4syqzWycLLCW5Xn/PfqOdrxlYxSL5rwrLbSqGww6itjxDoqjTrqBw5juImjbJ7EYyPeuX0nxOkOjjTvGMU9tNbr5cN4kDvHMg4ByoOCOM59vWnbmVnuYXs79CS6h0a08GXE1pFFZTRDG0Z/e+gPPXoAeayPCthZW0iX00yyX8ilYNrAogbGfq3aqfiLUtBvcWVhqE92Ih5q+VFgSOeNoZuFABOW56jAPIrlbnUrvSRutxbxSBinzRlzgg8HcSO3YD8KHFuy2Z0xdSVF2u4I0n0l7HxvHp0UjRW9w2VdThmRv4ByPdeoq54osbHTbYQ2iwx7MERqAcHPPPc8dePzrn477Urm7t7y4n8y7jTEZEaqqL/ugY/D/61S35L2NxNIzyEx5Jb5mk4ycDjCjufwFdCdlbudGCUopza6DF5Jpk9sbm8sI1PLMyAA4yTjj+dami2cV9OyStKF2bgYmt1Ocj/nvNEuOezE+2Mkak3h+zxE5nvkEUgfcZtK9xj/kId81y06cnqjvxWIpQi4Seuj2fe/YoXtuYG2PevNBasotyxJ2li3Cg9FOC34VpXcZvNQ06xnvi9gbcSNPIMEkdYyABwrAZAB5GeeKuyaXbzahHcg3rCNxKI2k0lxn+HOb/AAQFxwRzye+KlvrKwubqSSRL5JAfNVVudKXZ6nAv+hAX06e9a+zkc/1uho23a/Z6/gVtXuIGHzwvBa7N+2M4HlqD0AAwSFIye/PrXMWzT/bTNKoX7XB5oVcAKASoA9gBjn0rqJ9AjuPM3jUMBHYKr6WAuU5Yn7fuYAZPzE4GecVHDoEN1LawwyajLJFAIESOXSix+Zmzxf553dPaj2crO/6BLH0+eL1VvJ+fkdf8I45obG7uANytKY0GeVUDgj8Tiu9+HqDUde1/Wm3MiyLp9uW/hSMZfHsXOfwrmtKuZ/DuiSwr4c1qJBF5STyzaaqxueA3N769s10HhW+1Pw9oNrpsXgjxLMYgS8pl05TI5JLNj7WcZJPc1jgcNNVJVZ9emj/I8bGYmE+bl6/keg0Vyv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXrnlnVUV5z8QdQtYPGGj2viXWLvR/DUlpM/nxXj2Uct0GUKkk6MrLhCxVdyhjnrgCucb4hS6TcRWOiaraXlhCtt9jj1QSy32sCWZlfyX3L9zG3Ox+mSQOaAPaaK8dtPGvjS/msTbTeHYYb+XVFiElhM7QrZzMg3ETgOX28424689KryfEjxVeaSuqaamhwW62mjzPBcW0sjs9+UU4cSqAEL5+6SRxx1oA9qorx2/+I2uWDmy1K+8O6a8N7e20urXdtKLRzCkTRxiPzcrI4lPVz/q2wGJwFtPiJ4nuAl/JaaZa2Mc+kQz2UsEpuM3gi34k8wBShl4yhzjBx1IB7DRXEfELxVc6BqmjWceoaRo1rerO0mqatGXt42jCbYsCSMb33MRlxwhwD24q5+Ll9F46Gj2k2mX1oWuYWIt1ikR4rd5Qw/0p3ZGKcExIpU8Me4B7ZRXjer/ABE8Q6Zpml3N/feG9O+3aSdVie6tZvLmfbGRaRnzQWkJYnIycMoCHBJztO8Xawmr6xFqWp2vnS+JNOEekStNHdW0EzWY3ArMD5Q3su3ZsZ9xOQxSgD3WivFPCPii58U/FDw1c317pZnTT9UDabaxss+nnzbceXOxkbc5Cj+FMYPUEGtHxT8TrvSvidZeHbJ7OaB761sriCWBUlTzgPnRzcB3A3KciAr1BbNAHrVFeJN4s8TXkngPW9Q13Q9F07UZp0dHt5RDny3wsjGdQxbb8q4G1sctjmlZ/GDxJcf2g32DSEkhXP2SWaJZrVvtMcQWRFuXlYFXOWMUe07eCDQB71RXnN74o8TaZ4qs/Dd1Fp11f6k8UlldQ2skcIgUsbrepkY7kVVwdwBMqcdRXo1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUANb36Vy+qJcbhZWUqxyTNtVjglFHJYA9SB7EZIzXUkcHFZ5tgrySnG/lVJ7DjP5kfoKyqQ52jSnKxBpNlHpVrFbQg+Wi9++eSfcknNXpJAoO44GcZPSmRbWVSQCRx9KSZ4wCknG47f96tUraD3ZT1iOOWBobgHy5MDcP4T/n/CvMNVjn0u/mimiLWc48uVByH9v97oQe/1Bz31zcNExtJ8PHj5Ce49KxdThS9he0nG5ipWNh/y0HXafRh26YP1IqmtD08G3SfdM4wBFeazuGM0EiAq+OZIugfocsh4OQTjntmmabv8u4028dBLF+8hnbpnB2yem0jIb0GT/Dw6SNtkkMm1p4n82Jz/ABEjqR2V8EMOMMDnqBVK6ZpbaO9tWY3FqpZVYZMkX8Sn1xgnH+z6ECsttT2Frt1/PuUHUeS1ujNFGriSBicGCReo9sHg+mVJPy1l3Mnk3S3KLtRuJEx908bl/PBA9CtX9XaNZo54GLxTDJYnk8cEnpnAOfdS2ORVNv8AXCKUFklwCemc5wfqSePc5PSpOuk3fmI4pzZzqoGfKYSRtjPHUEZ/Dr1wM8CsjxEymxvvLGI/Pt3UeihX4B7gbsfhWmylo/JwDLDkISCNwznH65Hs3tVZLJL24WCRsQ3QEZyO3PP4cisqqfLobVYKUTqvDnkJ4g0KeJwTdaY1sMt0CBiT/wB9Lit/Wby50jwtqWoaeqPd28RkXcu4AZGSR7DJrH8J6TPo8umT60y3GnafHcIl3bfvDH5u0DzR1CgBuQD15wBXdRJBCrgGOa2mXGRh1dD6diMVzTjaSkfLVbqUlY8++HHxBufE00mi6+yS3TqXt5lQJuxyUYDjp047Vv69cNZeCtZmt1w620igj1Ixn9a4PQ/DEPg34gaY2p3MX2S4kk+xzbuMjhd4PIPzD2ziu/8AEOveHE0nULJ71JVMZjlFuN5yRwMj5c/U1c4++pLY54X5eXqeC+Ek83X7OPB+d8cVf8aRGK8uFI+7OenTvR4QjFrqttJuLFZQNw4zzj8ODW98VrN4fEOp7ELkz+YoHcFs/wAjSk05JnrYVN4WcPV/kZujRxeS8k+4WygeYV6sM4CL/tMRge2TjANa8GmtPaXE8qLGrp82OirwoUfTcPryaqaBpzNdeXcthYnw2OQp/iY/Tp9BXe20SJYGMgKoPmSoq5APKqvuQ0j5/wCuY9K6KMNOdnqRfsYL5f8ABPLtFDSWUIkBEioFYejDg/qDT7mDzYpof+eiFR9ccfrV2xQQa1ewkZVbgsBnqrYb+ZNT63afYtRZM5APB9R2NcE1yydjqp2lSUX2/wCAzK0yc/YzJlQG+cnjpjP8hTpfNks76dI3EsqhVBHIXhVB/ADNdv8ADGKwvRJpl7BDN9nuGVUkUHchORwfr+gr0HxN4K8PiyMpiaNiASUbaP8A69dSw0mrxe58881jH91WT926PEr2622bG22P9oHkfMckK4Ibj/dJFdp8N9AYXr6lPE0illCKAegxnH4cce9U4PD9nPrEVpE5aANvI2gMABx06DOPzr17ztP0bRo3hTZb20bSuCQWGBz/AC/WvJxs3G9C9np+J0YjGwrRUqet/wBLkNwh8ReMLDTkVls9PI1C7BH8ef3UZ/HLEegr0OuW+HljNDoZ1C+QLqGpyG7m4+6G+4n0C4H511Ne5haXs6aT3PnMTPmnyrZaBRRRXQc4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUTpVk2trq7Q51Bbc2qyl2O2MsGKhc4GSBkgZOBk8Cr1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZWv6jHpMEd1O2ImmjgxtLZeRwiDgHGWZRnp6+o1ar6hZW+o2U1pewpNbTKUkjccMDQNOzOP1PxEuma1apqEtsun6g3lW8mSrJKAP3cgJOc9VYY7LjOCdqadJYik5IB43f1/Dv+dce2jTad4ouLO7g1XVreeyKrd3aLJb+SD80J2gfMeMs/wAzY68VX0jxtpWoa2unQJPCZgz2+ACrooOWU9iCGBQgMMEEYxVHVTSep0N4u+SS0uycDlZMdP8AaHqOxH+RmSjy2e2uWJbopznPuOOvQ+9bN1E0kKxq4WaMh4nAyCMZ/EEZH046gVk3scV9ZBWQqWygGfutn7hPp6H39+WelRa0/r5nOeILYmZpOPtK8qVOPNBHI9twwPZtpHrXFreyRXaTQsHkU+fHgbd2Dlh9CDnjpjvs57dCbqI6Zdyf6SAWt5mJyw7qffI/PPTPHEagJra43sxSdGLqzDKhhy2fX175yw71lNdUerRjo0N1SCG2lkggffp1youbVxk7FJ6fVTgepwvTNVY4TJC9s67iil0I5yhPKj8efwNWpIt2LWHcsbs09oHOTGwyHjJ/AgnuVOOtT2O6VbeeKIO8LDMbfxgnbt/HgH0OO7VmtDppzShd6/1/VzPIaXZM/wA0yN5cucDcf/r7s+wceldLpvgu61ZTLcSvahpPMRAv7w8ENn+7nnjqMniuw8N6Lay3HneWhmK/M+3knp+B9+p754rtbWyjtIt5HIFc3tnV0prTueTi8xduSGh5XrWgz6E4vtAWSGeBNz224ssy9xhs8/oe/qMF/FN7o+kz6noFraTadcEtJazIzLbSnqy4IIU919ee5Nes684mjJK7SB1HWvJJo7jStZu7uCBLixmOLu0x99T1Yep7/ryazU+WVjnpTVWPJV+TPJNc1jUdcvDdalO8spzgdAvso7D2q/a2httBeSTJ+03CRjjkBQWP8x+VdNq3ha2eI3vh6UXenyESCH/lpCfTHcfj+dZHiRvKt7G0KsskSGRlbszZP8+K0lUvoOOGnSvOXT9dCPTYyrebG/zg5x6EdK77xbcQT3OlarG6vIbMTFQefMX5VB/4Fg/QVwulfuonZgd3PBHvx/OtmwW2WKX7c5LS2bT24B6HeVQH8A3/AH0D3rnu7tHZgUm7P+v6/QZ4EliEU8E5YzwszMveQnJI+jKT+K12l1IsOmvHuy4YuWB+8V+RT75dpT9K84spLjStQj1GBSZYSGaLOBIo5Hbt19+R3rq479ZtIs3tSjhE3gg/eRDkD2yxJxXoUqqnG52xi01CXT8V/X4nMSsIfERRWyskeP8AvhiB+akflXW+NbYSafpF8oA823Ctj1U4/liuLMDtKb8j91ayIhJ6neQgA/F1r0TVI2vPh3byd7S5aPn0Zc/0rjmr3fdF0K6nLR7Sa+9f5lP4VQWVz4pu7TULaGeK4tlkBccqynacEcjg+tegeJtHjt4RDaapeQQFh8sx+0IvUgBWwR0x97v3ry34ftOnjLTzayRLK8cseJAcHAz2ruvES6/dMUNoSxON0EwZQD/s8NjjqRxXdh5fu02fL5vTcMTJJb6lvwVpVtZ31zeyy/afPUxo2CoVQOQM56n3PQc1talYxarrGkaF5eUdje3eGPECHCoQOoZ8D/gP0qx4dgSGwsrBlxK20nj0GT+ufzq/8PYlvX1TxBw39oTeXbnOcQRfIuPTJBY/WvCwcfrWJlVlqr/1+FvvKb9jTutLL8f6u/kdkOKKKK+iPLCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGT+YYJPI2ebtOzfnbuxxnHavB/HPhKHQ57rUorTVLy9aA3GpXVtEYoVlyWEqOclCmWwI9xC/eDV73VXUrCDUrN7W7EhgfG4RytGWHoSpBx6joRwaCoycXdHnXg7xB/bVpLZ3C7LyzZYnkSRZE3lQ3yuuAQRg9AQT0HFXdR4WS5YE7VxdwgfeX/AJ6D3HX6VzF1bz2niCaysoYdF0vTJVH2GIfvJImP7uXOMCMsDwuTnO5gciuje8W5iS6icC4gG6UHgSRHgkj26/gRVns0PeSmtv6/r11MHWrdpiqrIpukAmilH/LRcja+ce4Vj9DxXP63GmpIs4XyZ5DsJPBjnU8Z9O4/E84AFdbd2sZjNquFRmLWjtyIZccxN/ssMj8SK5++VZbaaWRCqH93eKeTGRgBz6lcgN6qVPfFQz1KMtv6/r/M5GBlniCbvJfd8jE4Ecg4B9j8oUn/AGF7tWha3JtbyJ1LRR3vyMoP8e75lI7jg/Qiqt7GYbpjPvRy/lzqp5LDow/2iFPI/ijXHUVq+GLUanq0EZAYRvufYMDzF+Qt6YIII+mc8muao7QbNKskou+x6T4YBSSI8AN1rd1W/WJWUsMAZFR2ljHbQoUXbt4Ark/Edwz6myK3yjjBPcdK5FehTsfO6VJ3F1HUgWMWc54yfeuTuH3So4wJCMbV9en881pXCyO4WMHk8H29KntNCaWUM+7Oc5zxWXKbLQ5S6hfQpU1mxTHlsDdQclZF/vY9e59RXM/E7y7jxJ9rt+IrpN8ZXoOFIX8Mkfga7P4h6/Z+HQmnbBc3c0W1oV6KpBG5vz4HX6da5D7G+seEXkxtuNPcIR6L2OT16qP+Be1btWO7Dv21OUOvT70YWnyLLEqSTJEHbBdwx2evAHPr+dP1uUf23ElruMUcEMUYPUgDBP4nJ/Gn6JBFfTRW4nitndij+ZkDODxnoMEAc/3qu+KLea0m0WedVIihW1d14D7Tjrj8M1CRphU+W9vmdhqcFp4g8JJqNrEsWr2QUTBcL5kQGAceo+X8K8/jnWx3Qklba5Y7ADxHJ1KgdgTyPfIrqvD13v1hraAgrcZQqOhYj09D1HtWDrNn5d3dWj4QljtbrsYHgj6Gq5uSVz03Tai+Tdar/L0/roX5dKmHgS5uVkQRsvnyqVwQd2Vwfoq9h35rttHj+0fDTVxuACSRuPeuTvpLq58LRoscaRERptVuQVcBlKnnscEcY5ru9JhNn8NNTLYHnFR+orprJKyXY8TL3Llk5Kzc4/meZeH71dO8SaRdSSBEju1DnPRSDu/QV6Xfamus+JrCGymWWFnBDxtkbRktnHTIFeRTS/Z5EnU8wyow/wC+gP5GvZ/DFzY3uvTtp1nChwWMqwKshbd/EwAJ6nrmud1HDCzkic4pp4qL7nT+LZpNN0KeZVAuIIGhiZTyHc7VP5sPyrrvD+nrpWh2Fgiqot4EjIXpkDk/ic1yGsob6e0t7hCd99b5B9A4J/PFd/UZUk4Oa7/lp+h52KdoRj/X9bhRRRXqnCFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXB/Erx+fBmpaPZrb6Y51CG5mEuo6l9jjXyfL+RT5b7nbzOBgdK7ysHXvCuma9q1jf6mjzfZba5tBbtgxSxzhA4cEZP8AqxjBHU9ewBlRfEDToYoZdXU6cJNOs7820iyvdK1w7qsXlLGdzbkwArMxIOVAAJzNR+KOmwa5owgNy+j3UN/9pb+zLo3EUtu0A2+UE3qB5j7sp2HI5ya18Nk+xGfTL7ULrWIIbWCzlur1YjEIJnkjPmeRJkgSuvzI+4AA8ktS+D/h3JZ2sVz4hvpbjV86h5jQyKyYu3QvlvLXcwESYIVBkt8uMYANfwz46sPEPiTU9KsoLoparDJDdrbymGdJIlkDb9gReGGAWyw5FWLzxzoNnNqiT3F2E0tJHvJ0sLh4Idib2BlVCm4KQdu7PI4zUfhfwVa+Gr4T6bqOo+SbSC1ktZDE0cvkxiNJCfL3h9qjO1gp9Koax8M9I1nXr/VNSubyZry3mtZIVjt4l8uSMxkF0iWR8KTgO7AHnqBgAXxd4+s9HubCGzk8+Q3trFeRrazSukM6SshRUGWY+UcABj7cir0XxA8Ozi0+y3V3dSXQdkhttPuJpUCP5bGSNIy0eHBU7wvIIrIT4X2qyvcN4j199Qaa1mW8drYyRm3SRIwq+TsxiVs5U54PXJNnTfhzZ6TcQXekazrFjfhZFubuNoHe93ytMxlEkTLnezHKhSNxAwOKAIdI+ItnD4YTVPEwmtQbq8iaa2sLiWCNIbqSFWkdVZU4RSSzAZyeB01tS8c6FZ2dzIt9G00U1xaiN45R++hiaV1bajMFCLuLhSMEEZyM8vr/AMFfD2t2i211e6mIgtwuMW8n+unkmYr5kTbGDSsAybWxgEnFdBefDzRbrW9U1SRrtbnULB7CRVkGxAyBGlVSOJCiopbnhBx1yAXE8ZaSt9p9jcvcw3N95awO1lcC3kd03hEnaMRsSM8ZB4IwCCKTwt440DxTOsWiXc0zvbi6j82zmgEsWQN6GRFDgEgErnBPNc+nwk0NfE9nrn2vUHurSaG4jV1gbDRoEUeYYvNCYHKBwuSSADW74Z8E6b4el0eSymvHOl6YdKh851O6Isjbmwoy2UHIwOvFAFy88VaVZa7b6RePeQXdxIsMLyWM6wSSFSwRZ9nlFsA8Bs8EdRXOR/FPRLrWNBtdLh1G+s9WjkkjvIdOuigChSNv7rDj5sMQfkx82Kde/C7Rrzxsniea6vjfJdpeKhWBgrooUKJGiMoTA+4HC5JOM1ctvANjZ6f4ZtbDUdStToERgtpkMTPLGVCskgeMqQwUZIAPoRQAD4l+E/KlmbU3SCNUcSyWk6RyI0qxB42KASJvdFLISBuBJA5q8njXQiJt91PDJDLbwPDPZzRSh522xDy2QMdx44HY5xg45bS/gz4a0uKWGyeeOBmhKKltaI8YjnjnUecsIlYbolB3u2Rnvgjd1TwiNR+I+leIZhCttp9oyhVZt805JCF1xt2xq8u05zmU9MAkA6+isLWvDo1O8Fymr6zYShQuLO6Kpwcg7GBXPvjnvmqP/CNa5D/x6+NdYYdlura0lA/FYVY/iTQBZ8caM+raDeiwghOqiB47eVgocBsbkVyPk3AYz2OD2rySawtvBmpwX6T3WnWsqMywXjEeYSR98MT8/BQlevyt8w5HqI0/xpD/AKrxDolwo/huNIkDH/gSXAH/AI7+Vcr4r8GeIvEF213qVhoV3c+QsCSRahLamLaxcOm6CXa2Sc9mGAwO0UHRhq/sZXauivFeWdzaxXEEnmaReoMEf8siOO/QqRg5xgY/uGs7WHuba5l88L9qjHlzORhZl52P+Iyp9+vQVWUnR4r2KfSyqFzcSiLUoG2PwGb975QAP8XTkse5NTXFyZoIYpdO1oSwMY4j5ME58vIDRt5E0mSPlII5GB3JoZ7dPFQjbm/JnNXipcK3zMvlgRyOc58vI2Oe+UYAH6L612Pwwto4murmUr5pYR5+iqMfh0/4DXNyQRW9ytwTeRpnDJdaVewq6nhxuaHbj33HsSa0vDWraNYPPbS+INHj+fMYlvoonbAx912DA4C8Y42n1rnrRbjoa4zE0alK0Jo9Yv3KWQKcEc157fqbjUDltrMQSfp/n9K7SzvrfUrLba3NvdNtwPIlWTPH+yTXJvZTjVpDLBMqkd1OB2rlrJtnkUmjQ0ewEsxYkbMgjmrniW+t9B0S91KbaEtoiygjhm6Kv4kgfjU1jFtCKM4rz79oO+aDw/YafGTuvLgswH8SIOn/AH0yH8KVP3umgSvc8Uju5dQ1R7q+d57q4cs7nBJJPoQf/rV2WkanPpd0LQxifT3OHBjGAffaBwa5nR9PlikWTaC56LjJHvXb6D4T1HWLlQkTMc55GAKJyvK0T2cJh6kUqknyx8xniHwZcmZtR0WFms7j5lA+ZeR90+hHTPfFS6Romoap4et9FvbZ0aEmRWcE7WIGRx24Fey6Npa6Hpkcd7cLGNuCN3Wh/EOiWBZkKM44GOc1r7JdXYiOJ99ypQ5n+Hqed+DfAtzp+ow3d2CRE25V9TVvxP4Dlv7957dgpc5P1rrP+FgWqkhY1254q7aeMrCYYkQfXinyUmuW5Tr42EufkPPdP+HzwTLJdPlVO4j3/wA/yq34w1AWuiLpsDYhHLAdzXqMbWOp25NtKAcYxnpXmvj3w9PGCwBYdcilUpuEfdHg8Sq1ZKro07221PGNRX/Rpu4BU/jvGK92+FdhaLHHPauSzYZmd85IUEgcepP/ANevHZbKNhLb3O5VkG3cOqn1r2n4XWiWNjYotwsoKuzvn+LP+FcVSpakod5IM4oy9oqltLPXzNvxFO1rpcmpqCwtruKfGP8Almjjd/46Sa7hWDKGUgqRkEdxXLmKF7OdNQZI7DEkcpkO1SrA55PGKyPDfjnQNO0eHT7/AF2yur60zAUs5BdSOikhG2RbmGVC8EZzXRlrlyar+uv4ng4mzW+q/r9PxPQKK5EeNWuTjSfDHiW+z0Y2QtF/8mWjOPwp39o+Mrv/AI9vD+lWKH+O+1Jncf8AAI4yD/32K9M4zrKK5P8Asrxhd/8AH54msLNT/Dp2l/MP+ByyOD/3yKQ+CI7k/wDE28Q+JdRznIbUDaq2exFsIhj2xQBW+KfifUPDFloTaUYVk1DVEsZJJLCa9KIYpXJWGFld2zGBgHoTWZ4O+JEmpxWNhf6bc3OvTfaTJFYwiJY1hnSMmRJnDQttkjcoxJAJGS2Aeu1zwtpWuafYWeoxXLRWEqz2zQ3k0MscioyBhIjq+drMOTznmoNK8F6BpVx9os7FhcGKaF5ZZ5JnkWZkaTezsS5Yxp8zZPy4zigDmLT4w6BczX1slretfWvlKtrDNa3LzvJL5SIhhmdA2/AIdlwDk4HNQax8Q77RPE9xJqeiazFpMGjfbri0C2ryWu2Z1aZ2WUgjao+VGY4/hzmt23+GPhOC3khTT7ho2gS2US6hcyGKNHDosRaQmIKwBXZt2npir7eCNCktLu3uLe6uUu7NtPna6vp55JIGZmKF3ct1Zuc5GcA4AoAx/wDhYUKX11YwWGo6vfC7uIorWwt40cRQpEzuTJKAQPNQZypJYAJxmpbH4j6ZqEU11p1hqd1pNtbx3V3qKrEkNsjwLONweQOx8tlJCK2Nwq9f+AfDl8G86ymR2mknMkF5PDJukVVkG9HDbWVFBXO07RxT4/Anh6G6E9vZS2/7lLd4YLuaKCWNE8tVkhVxHJhML8yngAdhQBzGl/Gbw/qkEh0+zv7m5EtvEltBLazPIZ2KxkFJii8rgh2VlyMgVUufifKPE9u9rpmrzadDp2oNf6akdv58E9vNCrMxMgUhVZ/uuQd4wCcY6DVPhvplzplvYWd5qtrbx3dvclX1K6mwsLZCRFpcw5BxlCMcegrUsfA/h6yTbbaeVP2a4tGZp5Hd453V5dzFiWZmVSXJLcdaAMmT4n6HH4n0vRHSbzdSMQtpRPbEN5ke9cxCXzlGOMmMDPfkE894G+JssvhzTDrX2nU9VnsNNdYbW1jSS4uLkTHAYyKnSFiQVjChTy2cL11v8O/DNtqMF7BYzxywTR3KIt7OIhLGgRZDFv2FwqgbiuSByTSx/DvwvFYi0h01oolitoUMd1MrxrblzCUcPuVl8x/mBDHdyTQAzxt4o1HQ/Asmt2uj3C3yyQr9iuDEzpvlVDu2y7M4PGHPJGe9U9Q+JNrpyam15oWtx/2WsTX3ywH7P5iqyAkS4YncB8hbB68c10l14d0288Ovod4lxc6c67GWe6lkkOG3A+azGTIOCDuyMDB4qqPB2h/2dqdlLaSz2+pxrFefaLqWZ5lVNi5d2LZAA5znvnNAGbq/xBsrDXn0aHS9Vv8AUlvFslitVi+eRrY3GQXkUbQgOSSOfbmuf0/4nQ3njSCCAXk9rqOk2s9hpaxRi4adp7lZSckAbViG4l9o28HJGet0rwL4e0vUI760tJzex3BuxPPeTzuZTCYSxaRyWPlsV5z69eahPw88LkR40va8SRxxSLcSiSIRyPKhRw25WDyyHcCD82M44oA6yigcCigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPJvih4Kt57+XWrkSXkEzqHgkJ8qHCgDCDggkckgnnGQK8+gnS0uE083BaWJQ0csjgkqpIU5HOVGUY9cYbkkGvo7V9OttW024sL5Ge1nXZIgYruHpkc4/nXzZ4ssdD8O6vc6cB5I06dGWezs2wpC5AZlXaMq5VgT/F2AFI9vLsSrcsrJr8V/wAA3Irj5vOgfyY5yXK5KmKUE7gQOi8njtlwPu5rX0DVL8XEdnc3M8sSSMNkkhZWUqSAQeMgj8wfSuFh19Y9VgtZ4zHb3KQqshb52kYnY4TvgBAcHuM8MTXcaPb+ZfxOwBCn5h/dIzjHryMZ9MH+MVFTSD9D1azpyhKO9jrJfDWhahbSNf6Dot04PWewhk9f7ymuVtdG0ldTa3i09LeMDj7JLLbEf9+nX2/yK9DtVP8AZ54zmuQVVh1mSSUqqjLMTwFA6kn0rhlUnpZnz8acXe6L8Xh+AQvNHq+v2kagkudWmmCj1/fs/wBef5cVwuqyxa1qKQRahqmqQQErFNe21lKAT97biBXwcDq2Tx0wM6+pX934ruE0zTA6aap+Y4wZj6n29vxPt0ltZ6Z4RtVeXE11gkLjoa1hKbW+nc7qeDp0leqrye0V+bMC18GXcNsbz7TokKjHy3mlyq3/AH1Hcgf+Onp0FSx+Kr/SbdoANBZQOXge4ifPTIBjcH6Fh6ZHWue8UeKLjUJWMj8dAq9B+Fck0s11KscSvJI5wqqCST6ADvUSxCjpBHp0sqc1zYibt2vp+Ju614luL2UtLISc8DPSsCa/dz94813/AIZ+FWpagFn1qb7BA3PlgbpSP5L+OT6ivR9K+HvhrTlG3TY7lx1e5/ekn1weB+AqY0KlTV6F1s4wmG9ymua3bb7z5vN3IT96pYNRmjcfMeK+p00XS0TYmm2Sp/dECgfyrK1nwP4e1eJluNMt4pCMCa3URuPfI6/jkVbwclszmjxFBu0qenqeM+HfEskUq5cg/WvWLG9j1zSnt2ETTlT5ZfO0ntnHOPpXk3jvwNd+EpY7mCRrrTnOBNtwYz2Vh/Xofarng7W2jZFZjweuamnOVOXLM6MVQpYykq9Bk3ifRLnSJPMv2sFY84s9OLH3+eaV1P18sVm6Fqtvc3K2tzc6wYjxtW/+yg/harCB/kc167q9rFr2hFsAzKOvevBtVtH07UW2jG1uOKddyh8OiZz4GhSxlNxrXcl3bPX9J8JeG5UW8bSdOnlY5jmurf7RIpPP35Nzc/Wta9kn0iSLVLXcLWzXyrqyiHymEnO9EHAZevA5GR6Vj/DvUxqWlrB5g3bgGRj365H5V2ttF5iykjcDj6iuClKtGaTbf3nkV6aoTcJLY0bS5hu7aK4tZUlglUOjochge4qWuNaG68OvLf6TH9o05z5l1py/eRifmki9+5Tvzjmum0nU7PV7JLvTp0ngf+JT0PoR2Psa9qlVVRXOCpScfeWqLlFFFamQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeb/FbREkltdVELzzhlt0ZiCkJOQF246SEhSc53CMdCSPSKr6lZQajYXFndpvt50MbgHBwRjg9j79qDSlUdKanHofPd2sTeReqPMjZfmB6lTkE57H734gn0rqfCxaWdA7HfDwxBxvUjg/8AjwOPoP4AKq6tYvY3UnnIFYymG6jQYRZ8LllXoFcFJAPU7TgKaseFo9t9EiYGDtyWwChy2PflTj38w9xWVX+G/Q+qqVY18Pzx2/r8j0Z2itLB5p2VIkUsWY4AA715ZH9r8Wao0VsrpZs3zD+/z1Pt7Vt69d3PijUV0nTif7OiYCRh0lYf+yj/AD2q9qt1aeFdM+yWRX7UVxIwHSuXlT1eyOLDUnSs7XqS2XbzYt9eWPhXT/stoFNzt+Z8dDXmWuazJdSsWckmq2r6pLdSsWckk9Sa3fAXgi48TTi7u8waWjYdv4pCOqr/ACJ7e5rKUpVXyxPZhTpYGm61Z69WZXhTwxqXiq7KWaiOCM/vbh/up7e59h+OK928K+EtM8NwYsot9yww9xJy7f4D2FbGn2Vtp1qltYwRwQIPlRBgfX6+9WK7aVCNPXqfMY/NKuLdto9v8wooorc8wKKKKAIL21gvrSa1uo1lgmUo6N0YGvnLX9Gn8I+JZLKQs8P34JT/ABxk8fiOh9xX0pXBfGDQf7U8OG/hTN3p+ZcgctH/ABj8gG/4D71z4inzxut0erlGM+r1uWT92WjKfgfVhIgRj8rYFYHxN0QR3DTRj5X+YVi+Cb/ypVTNeneJYBqfh1Jdu504NYx/e07M9ar/ALHi1NbM8j8DakdL1qLzGZYycMQegr2vSdTt7qELBcRyyqcShJFJAPqAeCK+f71GtL9tuQQ1bnh5xP4ntlwESWJpVYSOpJH3wMHg98jFcXI5PTc6czwca371dj3aCPZMw3jnpWXqPhsSXzaho90+map1d4lBjm/66J0b68GuetfG+lpOkDXEokh/ds0gBywODnBJ657V2trcfa7eO4gkR1YAq8bBlYfUVdCXLePK9D5upTq0mpPS5kP4nuNI2r4nsGgQdb20DTQfiMbk/EEe9dFY3trf26z2NxDcQt0eJww/MUwgSDnBJPQGspvDWlyM8kVt9luD1ltHMD59SyEZ/HNdsK0723RztU5LXRnQUVzqWWsWrH+ztW+0ov8Ayx1CMN+UiYYfUhqtHVri1RTqenTRj+KS1P2hB+AAf/x2to1YyIdJ/ZdzYoqvZXttfQ+bZzxTx5xujYHB9D6H2qxWqdzNprRhRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlvFGkfbNUtStt5kN6jWtzIq5MZVWeKRv9kHzEPr5orjPFcsfhfTYrG4kSG5uQFa62crGRyob1O057AemRXrhGa5rx14Yi8TaUYTtFygOxm6EZBKk9ug57EdxkGKibi0juwWI9nNQm/duczY6hpuh+HQ9hLFJO6jy2Q5GPXPp1rzHX9UkvLmR3csWPJJ61Ne6LeeHYHimeQRow8+1YfPHngSJ6+4HBxwTjIt+E/Cd1r+sJFgi1G2SWZeVCEZBB75HT/6xrgqc07RSPp8LKjQUq05Xe9yf4e+DpvEV8txdKy6bE371+m8/3B7+p7D8K98tbeG0t44LaNIoY1CoiDAUDsBUWm2FtpljFZ2UQit4hhVH8z6n3q1XZRpKmvM+Zx+OnjKnM9lsgooorY4AooooAKKKKACmuqujI6hlYYIIyCKdRQB853Vi/hzxXdaexO2KTEbH+JDyp+uCM++a9Z0aYXOjyRk5BTOK5f43acIrzTNVjGGYG3kPrj5l/m3+RVzwTen7Eu7+7iuGC9nUcT6mtN4rBwrdevqjz3xrb+RfOQMc9ap+H79ba6srh8Ytp1Y/7jHa4/I5/Cul8fRB5GZVyetcHb7o5GVgdrAqfoa5Z+7M9qivbYdJ9js7Oyt7rxXq0N9HFcoiNJAzgNyF3cHrjgjHSvSfhfePcaFO0hDSC7cNgAdlPb615Nol2Y760us/vNhglHqOcH8ckflXovwjmVTq9rnLLOsxHpuXH/shrSM9VY8bM6HLQem1v1X+R6J5QDApweteT6x48vrP4qJbxSXC+GrS5h0u722MjQtPKrEyNcbNibHa3TaXH3244FevKuKpNo+mNaXFq2n2ZtbiRppoTCuyVydxZlxgknkk855rtVJdj5fmPNJfixJDpg1KbQYxa3VpPe2Ajv8AdLKkUiowlTyx5RO8EYLjsSDVXXfGXizTNS8cte2dnDYaTpEF4iWuoAzQFhcYZC9sVZmMahg2VTaCN+SK7jTrTwVda5q9jp1hoc2pyLnUlgtY2ZstnEzBcE552sc98Vr6n4c0PVbsXWqaNpt7dCJoBNcWqSOI2BDJuYE7SCQR0OTWnJHsK5z2h38niPxBqTw6PZxWFjdy2D6h9tZLtpIwAcRrH90k4GZASOcdKxNb+IF54f8AGttocMMOq2Ul5b2EkpefzbeWYDaHcQeSOqna0m8g5rvl8P6MutnWV0nTxq5G03wtk88jGMeZjd0469KiufDGgXWsLq1zoelzaqpVlvZLSNpgVxtIcjdkYGOeMCmoJbFc72ZxWlfEbV9Wj0NbPw3ax3OtLI9mlzqbImyIEyF2WFsH7u0KGJBJITFVfD/i3W9P8Ua1b6lZJc6dceI49OE39oM7WjvaQMEjjMeDGGyc7l5cnb1r0G98NaFf6ZDpt9oumXOnQndHazWsbxIeeVQjA6noO9TQaHpNvGqQaXYxIsy3AVLdFAlVQqvgD7wVVUHqAAO1UQaFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUtT0uy1OIR31ukwGcE8MueuCOR+FLpum2umweVZxlEwByxY4AwBk84A6CrlFKyvcrnlblvoFFFFMkKKKKACiiigAooooAKRiFBJIAHJJpssiQxPJK6pGgLMzHAAHc14p458bXHiK4fTdGZ49MBw7jhp/r6L7d+/pWdSqqauzsweCqYufLDbq+xq/EvxVYavDHpOmqLry5hI9wOUUjIwv97qeen17R6F+7tkRBjjoKy9A8PO4BZCT1rv8AS9A2RqSOlc0FKcuZnu1ZUMJSVGDObv8ATGvPvqeawLrwwFywQ5r1YWsaErwcVDc2iPGRgVcqKe5hSzKUNFseIXemyWcm+PPFbfw61pNN8VKLolYbxRbu391s/KT+OR/wLNbPiOXT7a/NizyXOoldwsbNPOuMf3mXIEa/7UhVfeucurWa23NMws1P/Lvp8p85h/00usAj/dhCf9dGrD2PK7t2R3VMbDFU3RjHmk+3T1Z65rPjLT9OvW0yzjuNX1tQCdP09RJImehkYkJEPd2X2zVP+wdf8Qvv8Ual9g088jSdJkZdw9Jrjh291QIOx3Cq/wAI9QsZ9CksrSytbKa3cmSO3QIH3fx+5PcnJJ5J5ru67oSUopo+UrUZUZunPdFTSdMsdHsI7LSrO3s7SMYSGCMIq/gKt0UVZkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcR8Vtck0zQRZWrFbu/zGrDqqDG4/XkD8fapnJQi5M2w9GVepGlHdnG/EjxXJr2oHRtKkJ0+JsSOp4mcH/0EH8zz6VY8H+FhgM4Hbtmqngjw2XKO6AsTnkV63awRWFsAABgVyU6bqPnmfQYvEwwdNYbDjLayt9PizwD6kVm6hq6x7lDfLWdrmrEscH8M1x17qDSFuTzWs6qWiOTDYGVV88zo7jXypYqkkrAEiOMruc9gNxC5PTkgepFZEtxq2r5GpX39k2Z62emS7p3HpJc4+X6RAf8AXQ1z8lwd3U80ou3XGDxWSrNHozyuM7a6HY6faadp9g1ppVpDaWxO5kiXG9u7Mert/tMST61j6taB1IAqPTdQONrGrNxMsqkUSkpLUKVF0JWjsc3ot7L4d1+C/hBKKdsiA/fQ9R/nvivfopEliSSNgyOAykdwa8F1GLdnAya9O+GGpNe+HhbSnMtm3l/8APK/1H4U8NK0nA586oc9OOIW60Z19FFFdh82FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUtW0uz1W28m+hWRQcqSOUPqD2q7RSavoxxk4vmi7MxbPS/7MXEQ8xR0IHOPf/61ZetakQpXccjt6V11RXFvBcrtuIY5V9HUGpcdLI6KeItPmqK549qVyZGJJOOtYsxZj3r2iXw1pErZeyTPszD+RpsPhfRoZFdLGMsOfmJYfkSa53Qk+p7VPOKMFpF/geS6RoV/q02y0hZhn5nPCr9TXb6f8PYhEPt92xbusIxj8T1/Ku6ijSKMJEiog6KowBT60hQit9TixGcV6jtD3UccfAOnqv7m5ulb1Yqw/QCs248DX0bf6NdQyqP72UP5c/zr0OiqdGD6GEMyxEftX9TyubwZq5fHkoy+okX+prpfBHh+90a5uJLkIscqAbQ+TkHjj8TXX0URoxi7odbM61am6crWYUUUVqeeFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view of a schematic drawing of the carotid arteries, vertebral arteries, and intracranial vessels and their relationships in the neck and brain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Uflacker R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4874=[""].join("\n");
var outline_f4_48_4874=null;
var title_f4_48_4875="Expected reduction CHD";
var content_f4_48_4875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Expected reduction in coronary heart disease (CHD) and stroke due to lowered diastolic blood pressure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Diastolic blood pressure reduction, mm Hg",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        CHD, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Observational studies",
"       </td>",
"       <td class=\"subtitle2\">",
"        Clinical trials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-6",
"       </td>",
"       <td>",
"        20-25",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Cook, NR, Cohen, J, Hebert, PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155:701.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4875=[""].join("\n");
var outline_f4_48_4875=null;
var title_f4_48_4876="Clinical Aeromonas spp";
var content_f4_48_4876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Aeromonas species associated with human disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Species name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Occurrence in clinical specimens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disease association",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. hydrophila",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Wounds, septicemia, gastroenteritis leech therapy, peritonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. veronii biovar sobria",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Wounds, septicemia (including \"primary septicemia\"), gastroenteritis, leech therapy, peritonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A caviae",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Gastroenteritis (esp. pediatric), septicemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. veronii biovar veronii",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Gastroenteritis, septicemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. jandaei",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Wounds, septicemia, gastroenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. schubertii",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Traumatic aquatic wounds, septicemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. trota",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Gastroenteritis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Amy Horneman,&nbsp;PhD and J Glenn Morris, MD. Data from:",
"     <br>",
"      1. Martin-Carnahan A, Joseph SW. Aeromonas. In: Bergey&rsquo;s Manual of Systematic Bacteriology, 2nd Ed, Brenner, Krieg, Staley, Garrity (Eds), Williams and Wilkins, Volume 2, Springer-Verlag, New York 2005.",
"      <br>",
"       2.&nbsp;Janda J.M, Abbott, SL. Human pathogens. In: The genus: Aeromonas, 1st ed, Austin B, Altwegg M, Gosling PJ, Joseph SW (Eds), John Wiley &amp; Sons, Ltd., Chichester 1996. p.175&nbsp;&nbsp;",
"       <br>",
"        3. Figueras MJ. Clinical relevance of Aeromonas. Rev Med Microbiol 2005; 16:145.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4876=[""].join("\n");
var outline_f4_48_4876=null;
var title_f4_48_4877="Sxs signs childhood cancer";
var content_f4_48_4877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms and signs of childhood cancer mimicking normal childhood illnesses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom/sign",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Generalized malaise, fever, adenopathy",
"       </td>",
"       <td>",
"        Lymphoma, leukemia, EWS, NBL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Head and neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Headache, nausea, vomiting",
"       </td>",
"       <td>",
"        Brain tumor, leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Febrile seizure",
"       </td>",
"       <td>",
"        Brain tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Earache",
"       </td>",
"       <td>",
"        STS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhinitis",
"       </td>",
"       <td>",
"        STS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epistaxis",
"       </td>",
"       <td>",
"        Leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pharyngitis",
"       </td>",
"       <td>",
"        STS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenopathy",
"       </td>",
"       <td>",
"        NBL, thyroid, STS, lymphoma, leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Thorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Extrathoracic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Soft tissue mass",
"       </td>",
"       <td>",
"        STS, PNET",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Bony mass",
"       </td>",
"       <td>",
"        EWS, NBL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Intrathoracic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Adenopathy",
"       </td>",
"       <td>",
"        Lymphoma, leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Abdomen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        External: soft tissue",
"       </td>",
"       <td>",
"        STS, PNET",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Internal: diarrhea, vomiting, hepatomegaly, and/or splenomegaly",
"       </td>",
"       <td>",
"        NBL, lymphoma, hepatic tumor, leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Genitourinary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hematuria",
"       </td>",
"       <td>",
"        Wilms' tumor, STS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trouble voiding",
"       </td>",
"       <td>",
"        Prostatic or bladder STS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vaginitis",
"       </td>",
"       <td>",
"        STS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peritesticular mass",
"       </td>",
"       <td>",
"        STS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Musculoskeletal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Soft tissue mass(es)",
"       </td>",
"       <td>",
"        RMS, other STS, PNET",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bony mass/pain",
"       </td>",
"       <td>",
"        Osteosarcoma, EWS, NHL, NBL, leukemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EWS: Ewing's sarcoma; NBL: neuroblastoma; NHL: non-Hodgkin's lymphoma; PNET: primitive neuroectodermal tumor; RMS: rhabdomyosarcoma; STS: soft tissue sarcoma, including rhabdomyosarcoma.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Malogolowkin MH, Steuber CP. Clinical Assessment and Differential Diagnosis of the Child with Suspected Cancer. In: Principles and Practice of Pediatric Oncology, 5th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4877=[""].join("\n");
var outline_f4_48_4877=null;
var title_f4_48_4878="Recurrent AF after amiodarone propafenone and sotalol";
var content_f4_48_4878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    The rate of recurrent atrial fibrillation is lowest with amiodarone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Canadian Trial of Atrial Fibrillation randomized 403 patients with at least one episode of atrial fibrillation (AF) during the prior six months to low-dose amiodarone, propafenone, or sotalol. After a mean follow-up of 16 months, the likelihood of being free from recurrent AF was highest with amiodarone (65 versus 37 percent for sotalol and propafenone) and the median time to recurrence was longer (&gt;468 versus 98 days).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Roy D, Talajic M, Dorian P, et al. N Engl J Med 2000; 342:913.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4878=[""].join("\n");
var outline_f4_48_4878=null;
var title_f4_48_4879="Mallet finger PI";
var content_f4_48_4879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mallet finger",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 334px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFOAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5gopaKkBKKWgUAFLRRQIKKMUtABRRRQAUCiigBcUlLSUgCilFFABRRRTAWg0CigApaKKAFpppaSgBcUUCigAoxRS0AAopaDQIbQaWigYlFL2oxQAUhpcUUAJRilFBoEJRSmkxQMSlFFKKAEopaKAEooooASilooAQ0pooNACUUUUAIaKKKAGUUUooGJS0UUCEpQKKWgApaKKQCUUtFABigCilpgGKQ0tFAABRilooAMUmKdQKAEop1JQAlApaUUAJikp1BoAaKXFKKXFADaKdikoAQUUopcUAMop2KSgAFGKUUuKAEpKdikxSASiloxTEJS0UUAJRS0UAIaKWgigBtLRiigYlKKMUGgApKWigBKMUUUAIaAKWkoAZS4pQKeiM5+UE/SkMYKKvQ6XeT/6q3kI9cVdi8Nai/wDyxI+pqXNLdlKnJ7Iw6XFdGnhHUG/hVR7mr0HgmV8eZcqPZVzUurBdTSOGqS2Rxwor0GHwHF1kuJG9gMVbTwDakZ3TEeuan6xA1WBrPoeZ4pa9Jk8A2xXMcko96yr7wJdRqWtpVf2bihYiD6ilgq0ehxYpav3+k3tgf9JgZR6jkVRxWyaexzSi4u0kNpcUUtMkSiloFABigUZooAWiig0AJQKWlxQAgopcUY5pAAopaQCgAzRRRQAoxRmkpcUAJQBSHrS0AFKKbThQAtJS0lACUUtGKAE70AUYpaAEpKdRigBKQ040lACUUtFADaU0GimISiiloGIaKKWgBKKWigDtLDwtCcGZi3rXRWek2Foo2QqSO5FaQsyT3xQLQg9M15kqkpbs9yFCMdkRbo1HygAe1OWRn4iTNW4dPzy3J9K1LSwGRlQBWbZuomZa2DyndM2fbtWpFYoMccD0rVit41XpTwgB46nsaTZpFFA2wA+UKAfzphh+YApzjoKvSLh8FefXPFNSIscKCo7tipvc1WhTlgYrtJYf7IFVmtwqksv4GtcoiDJdmb0xzUJCfxjj070DRhXOnxXEJVo1wexrgvEfgyWPdPYKCvUoD/KvVWiWR8KAg9+ajktECkMSSfStIVJQd0YV6EKqtI+eJonhkKSoyOOoIqM17D4j8M2mooWIZJezY5rzTWdEutMlIlQtH2cDg13066n6niYjCTparVGVRiiitjkEpwFJS0AFLSU7HFADaWkpaBhS0gpaACkFLSUAKRSYpTSUAKMUtJRQAhFLigigUCExSgUtLQA0ijFKaKYCUAUUA0hhiil7UUxDaO9OpKQCUUtFACUU6koAaaSnGkFACEUU6kphYTFIadQaAG5opcUjUAfQbQk4xwKlW2Cj1NaCxhiAD830qeKLBO75q8U+juU7a0yASDmr8cIjXDH5e4HWpUU44yP9mnMjZAZQh7Uyk7kecHKRg/j0qOTDL8iHOeTnk1c8sqdqqSx5+buaVoi2FB5/ix0+lFikygjSDIaNcD+92pXZ84eXC+uP6VofZSflGDj1HSkFuA21FDHuTRYdzPCIMH5+e54poECMWUMW/wBo1oNbMzgJkt79BTX09g3IJc+h6f4UahczHlDycIoPY02admOAigj0GP51pNYBR82DjuO341A+nuSCAQvqw4o1C5mOplHzBM96zb+yhnjZJVV1PBBFb8+muSMqCe2KqtYzRyAEBc/3qadhNpnk3iHwmEZ5bBW9dhrjJonhcpIpVh1Br3+6si39/dnpXN6/4VivELvEVk7MuOK6qeItpI86vg1LWGjPI25OaSuh1HwtqNmcrC0kY/iUf0rElt5Ijh0ZT6EYrqjOMtmebOlKG6IgKDS0VoQNApaKU0gG0tAFKRQAlLiilpgNxSgUtApCExRS0UwEoxTgOKKQDaeBSUoNABikIp2aQmgBhFGKXNApgJiilpKACiijFACUUtGKACkpaDQA0mkFKRS4pAIaSnYpCKAEpKU0uKYCUhpaSgD6lSDKjjaPbvVuG3XA9PepAgHPpUvUDIrxj6LchjjYPkkgHv6CnoqlywPA6HFSORg7T14ApUZYxskXK5yR/wDXplpDOVA5+c9cdhUkMOc+/emhMMSOA3b0qyjCFB3PYUirdhJI/LPlrneRz7U9YlRVC9T1JFLEAMscbick05pgmDtyewouLyEVI4VLdAe5HJpAhaIOygRZ4XPX6+tM37syS8t2JPH4CnRMXO58kDoKVwsNcbmXByOyqMBfzpksHm8Fto6cHcauhWfH8I9AtJJCXJDMcd8U0SY8kCKx2lnI9RVeW3XqWRj/AHRk4rYkjRV25YnNQG3GRwqnuRzRYsyXhLA4O0Y6McVA1v8AKFKgKeeT1reMDYIAD/7RGagMfOAVU9wFqQsmc9PYx7SoUPnrkdPzrG1Hw7ZXCjzogxz6Zx7V2rwktx9MEZzTJrUtgpjK9QOKpNoORdTyvUvAVrIpaAvESf4TmudvfBdxZqSiJcH0ZiD+Qr22W3GMnK/XtVWe0SVdgUMRWsa811OeeEpy6Hz3d6cYm2yxfZ5PQtkH/Cs6WNo3KuMEV7zquhwSoFkt1kB5xt61xeteDzIC1n8uD9x66IYpPSRxVcBJaw1POBRitHUtKu9Pci4hZVzgNjINUMc11KSlqjz5RcXZiYoxTsUhFMkbilAoxS0ABFJilFLQMaaSnYoIoENpRRijFMApaMUtADaBS0UgGmlAoIpcUAJijFLijFADcUUuKQ0wGminUmKACkNKaKAG0GnUhoASindqSgBKSnU3NAH1t3wAcDrkU7b1O4dOlNQlpMngZ60/ADEsc1459GIq/vOf4R2pWyfvZxmiEDY5xyTUvG5U6qozSLuBwqbvwFRO/wC9VQenJFNu3IwqdWPenRw7EyxO88k0nq7D2V2TNM2cDj0AFIEctk5ye/epYIc+1WzEq7vm4HrVKBHNbYzfKbeC+SSepNaMEY2Dgn8KYssPnLjhQOcHk1e85X5CqP0p8gSbEAVVGEwSO561UcmN2OG3dBjpVqWdVXIA4GKqW67wzFu+B70WCHdixjzASCC2ec1H5eWIAA9/WrCoEODgA+1N3AgE9B1GKLF+hFsKj5TyTzimNCOPkXJ/WrWckNgjd09qcFwN3XHNFhFWO1H3m7+nGKaYSucKAa0Qo6gDafWo5Mb2XAPpmpsK7Mt4Qc7hn1qA2aqwKjB9a1yuTyAMcGkMAHGOR+tKxVzEmtS6E7R9KpS2CsQdoroZVG45GDiontxt+XqOeaVh3OQvNHikZlljVlYdCMiuT17wnaz2zFLZVccBkGDXqb2oK59OKqT2YOSOQexpqTjsZShGWjR40PAUAg3tcTFvbArJ1fwVeWyCSyb7RHjJHRh/jXtkFmAzIVwoPUis7VLBhMphBEZ+9WscTNO9znlg6T0sfPDI8ZKuhUg4IIoNfQVxotvc25hkgidGHTaDWE3gbRbcb/s7PIeiFj1rpji11RxywMvss8aor2g+AtOuRmWDy89Ahxioj8NNLIO37R9fM4qli4EvBVFseOUYFeuH4Y6ergm4uSvcZH+FK3wz08odktx9Sw/wp/WqZKwdU8ixzQRXscXw00sYybiT/geM1bT4c6MBzA7H3c0vrcClgKrPEwKCM17mngXSYlwljG3+9kmtvTfCtlCgKWkK+g2CpeLXRGiy6XVnzisTtwqMT7AmnfZ5RwYpAev3TX0+mhQR5PkoPouKgn0q2B5iHHtU/XH2LWXX+0fMhXB5yDQRzX0VqXhrTr6IrPaRMCOpXkfjXlvi7wPLpwe407dJAOTGeWUe3rWlPExk7PQxq4GdNXjqcKTRSlcHBoxXUcI2jFKVoxSAbikNOxSUAJigilAoNMBvNBFKKWgBuKMUtFADSKMUppQaAPq2BuAAeKkdstmM8+9UgxWQKQQKkJ2s2M9OK8Y+l5S1bylR86ng+lSRtvcuvQ9ahtnO0YPNTxj5WI6nk1SQaIqE77/GeE/nWkm0AZ6VziXflXE7Sfe3d6sxaks8mFPAqYtBUi2dAsyIMKRUFzexBsyHg1lSynGVkX88Vl3H2icMFUtjritHImEVfU6iwuInycKQa1Y4WZS0WDxkiuBsb5rdQkgII4rorTWV2gbiDTUkx1E+hrXAYRt+7+Yc8CqkLleQcZ5x2qQalvjI3A8EUuEmiBGA4GOKfoKMml7w55jjpUUc3mPsY8LzVacSRHbzis8XLJdYY+1SaxV0dIWVvvcjtSBt2AByBz6CshLlnkVAfl7kVqWuBgZoYNWRYU5wBnPepDGPl4yD6d6YW2vnHHanb/mDchvWoJEVQG2kDBFK/TYeT1BqRpCV24989aHhLYKjOewosBWnUHawweMmlRVfpkU7aeh+lJHGSx3EgnpSKtoV5YNjnB4Peq4h+cjn6VpyqHJ3cY/KoJEBHHUVLEZb2xErn1qGa2zwRkVqt975x7Z9acVUrQkBy81vIJQkY2Ec5FWbLSwZTJIMn1Na/wBmG/OOverUSADAHNCQ2l0M42aDAAqYWY24CYq8sQB9fYVIoyT1/CqFy3MiSzA6gfSkFmAPu8VrGPI6YFIseSVPX0osNRMuKzHIxhacbZAdoBPsK05EdRxgD6VXkQlhtBx9etFhqNyi0SqwOCF71Org52KBTmiwTnr6Um1U47niixTig3Z4c4omgRwMU8w/MBnccZ4o24XAB4PrTsTyroZ8yKhIwc1k39sJVbKgg9q6G5jDAnaR9DmqEsfHHIpNDS0PBvH/AIeaxumvbeMCFz84UdD61xlfRXiKwhvLV4yAcjBB714Lrentp2oywEEKDlfpXdhqvMuVni47D8j549TOPFNJpxpCK6zzxM0maUCgigBKKMUGgAAxSUvakoACKMUUtADSKCOKCaMmgD6muAUUNnn1FQ+Y2RuBOeOO9LcP8uCeQatQQgIX5Oe9eQo6n0vNZakSyqkeCeasRXSeXjNVrhcFsD5elQvCpjyufwqiklLcxdZlCzSspHIyeaqaDcbbcHJJbnJo1yPETA5YscCrul2EUNuhHXHSslHqaTaSsXoFedxzha1YotigIMe5qG1AVeQBU01wiJyw4q46HM9Svc2UbOG6nufeq7WEicpVyxu0kmLH7nTOKs+arg46Zo0Y7SRlxSNG4V9w+takFyEXIcfSoLgRyLgrk+orMeObJEQZvai9itzda88wcms3U3XHmLwRWYzXC5DKy4qGW7ZAROCVPf0p810Wl2Nixul8pdx+aty2uOAT0PSuDt7oRzBg2UJwp9K6WzuvMUbSCvemgkdGs4Kgg5B6Y7VOHBTrzWMk2MAcD9KsxzFRycj2pWJNaKQA8f8A6qtx4cdeD3rIgnBI5wfercTlRgHr2NFiC5PCoBIIyeM1UBKkhgxHap1lUqTkjFRMSWABxik4lxfcRvn+VQf8KWSIquTT4fkOScjtT2O8jP3fSpcRtlbYXGMCm+VjAH5VbRlQ4FNZgp3EZ/z0pqIlLUqPGIgC+M5wV71dtbXzIFYD5mH5Vn386uofIH0q3Y3P+jop529M9qpFv4blgWuPm5wAPTOfSnrB8o2Ak/yNRSXGcc59+9Oiu+Dubg+/Gf8A69PQzbYixBnbaMt0x6VDMmx1b+LvjsKVrgeYWjO2P1Peq9xc/L8v5mhouEm2WJXTAUkkcHkc0yRkCttBHpVNZS/GR/SnMCwxyPYClc0skOLKzP8AKMngZ7VVusJguR6gA5p87rFkgYHUZrAvr4NII1PLdaTdiormehtWk3y7mY4Pf2q6Iiyqwzh+Pr61iWcvAx2rVhuymPLx0HUdMf8A6jVR2InvoPmQoDuXJ9Aeaz3jDN0xnsa1hm6YYAUkknAxikubXyx0xxSaIUrHL6vZq0Z4IYCvJfHOitNC0qLmSPkH29K9yuIc5DLkVx/iDTwyuNudw6UotwlzIU4KpFwkfOrcU01t+KdP+w6ixAwjnOPQ1ikV6kJKSuj5yrTdOTixBSEc04CjFWZjcUmDinEUh6UAMANLilFLigBvelIpKXmgYgGaMYNHOaDQI+lbxiGU56mtWCTdEFz2rDaXdOiyZyDzWhCxjUDt2NeV1PpnHQdMw8wjt3pkjiNDmlmO4rjr3qvfDbCS5x7UhnLa7eqLmIE8bs1Ystdgkb/WKFTjr3rh/Et+0usGGFuQNv0re8O6RahUaRQzHk5oUdByaudL/bZl+S2RpD/sirljZXN0we7ban9wGrVhDDGoCKoH0rSjdIz8vpU8q6k8/ZFqysIAoG3H0qa406AMNrsARk1nS6gqDAbFRNq42jDE496bcRxjJ6mxDYW4P32I7kmpGggAKgsBWD/a4680HVC4xEjsfYUc0QdKRrPFEylWTIHc1i6lbQknjC+9Ae8fnyyoPqcUPatIP38hP+ytO9+hPLyvc47VLfy5G+ztx121DpOtyWrCKbI+tdRfaajLlVAI71j6joaXCLsOGA6jqKRomram9ZaqsgyG5PetKG7PUjA9RyK8xZrvTJtsgLIDw1bWn6wXxh8N9cUXIlG2x3guBkEHaexHSrovGVecH36iuRttSLcOBz3q79sO4FCQMZ54NFyL66nSi6ztwOPTrVtZyyjGMnr7Vy8eoqRjj3zV6G/AOMgcU7l3N/zhwM9O1P8AO4HOGrDF6OvvxmpDeNknOAaBM1ZHbcWJBPqKjmmymAaz2u8oemKqy3mFxnmgcVcku5Sqnb3NWrafEQNYN3fKI+eTT0v1SPGeMZFBpPY6Bp2cAJ+eacJ1QANtJHbPFYUN8Nvp9ake6Dj5eTT0Mr9zWNyGbOc03c85KjgdzVCEqpBlbn0BqxJfRxoeQOOlAnK2xdjkjgUdziopL0bjg8Vg3Gpbh8pHFVXvlxy2c0i13Zf1O9IRjniuUt7zz9RZmPyr8oqTVr7903OK5bTNQT7eyhx9/FQ1c1jOyPTrViE6nFXIXA61i2N1uhUZ6VOJyW6irWw4+8dNb3ZU/L/n/Oat/azMVVh1/Qdf61zEUzEYrStJiMeuKomVNbmrOgdjswR7Vh6pab15HJGa3rOcJ8xAJzxn8KS6iSbggAdDjtyR/UUWuZJ8rPBviHou6N5drZVSRgc5FeVnivqDXrAMD8oJHIBGa8e8c+EDbb76xQ7fvSRgdPcV0Yeaj7rPPx9ByaqROAzSg0EU0DFdh5Qp9qXtTcU7FADDQDS4pMc0CDvS8UEUlAC0hxik6UpHFAz6JiUtdASbcfWthYOApzjHHeuatJWlnU7uPU10ULMiDcxJ9BXl7n1UotEMp8lxu4wawvFeqpbWMjlvuqTW3fTrJAQwww7mvHfiNrYLiyi4zy9Sk5PlRM7RXPLoZmlO13fS3EnLMc12+lzlAoHSvP8AQLpFG0kZrrbO6AwQa0mraGdN82p2sN+yqMZqf7TcS8Jxnua5mC+K9+K17e9UqOawaNuWxqRxO5xLKW9h0rStFSMDai/lWPDNv6HBq/bztnDAZoTSFI1otmPuL+Qqyrgfwr+VZYmPGKk8845IqlIixdeTd0GBUUmMjJqobgE8v0qvPeKmfm/M07iL0pGMrjIqvsHm7lPX0rCvNdihyPNXd6A5rNXUtWnbdZWskkXqRilcdtNTpriwiuVfegIzXK6lorWshazOQOdrf0qwdQ11CWFgwPpmqk3iKeHi/s5Yz3IGRSuRr0KsV7LA22QMh9G6fnWhb6oy45wO9Z02saZeAq0igns3BFUZkaL5rScOp7E5p2EdcuopIOoU1PFeurA7sj161wo1FUIWUFGHer1vqWBlXDfjRYd0jtU1FlPfFWo9VXHLYrjF1oIMOPzpH1aCT7rAH0p2YtGdm+pcHBqpJfllIJrlBqAPRuKel+pBBeixd7bGreahhCpJ3dqRr/dDjknFczqV6ODuHBqlLrawocsDVKLZMqiR2NtqbFCrv04q9Bq0MYyz5P1ryO58ShJmKNwfeq8niOV/uMAPrVqjI53iIdz2iTxBEi8OD+NZlxr4kJzJgdMCvKV1KWY5knVR9a0ra5iIG+7/AAxQ6LQo14nfLq28AJk0kt/tG55FA9BXIR6hAowbk4qnqOsWkSE+Yzkdt1T7NmjrxWpr6/r6xwPhua5LQNRlk1LcMdeR3rA1XUpL2Xj5UHQCoNOums7uOZex5rpjQtF9ziljb1FbZH0Pot4GRSTjjmt1ZkwSDXnvh7U4bq3Rgw5HY10ENwQeGNclrHrwnfVHWJchU+XH5VatpWY8Vzcd1uAGcGtSwm+TJ6nmg06G/DOUIG7ircVyeeOv+f6ViRzKynNWY5ARmmmJxTLWoYlHA7n8O4/mfyrntQgWZdpX5gNuSeGHvW4XDHluSap3KK2Rxik+6IcE1Y8J8deGW0+Vr6yjP2Rjl1H/ACzP+Fcb1FfQWuQuwcH94pBBRuQwrxLxDp40/UXSMYhf50HoPT8K68PWcvdlueNjcN7N88dmZPNLzTiKSuo4BD0pBTsUUAJSEUc0tIQ00ZNLikNMD3nRhvkUdcV1YCpHyAAP51zXh2P5QwGQK6GV1MRGcV5S2Praj1M/UpFWFs9MZr568b3AuPEM+3op217T4qvvsljK5I4XivDJrG4ubiSfBYsxJNa0Lc92cmMUnTtHqO020lcbo81swPdwYBUkVe8NW+xAGHNdULSN1GUH5VVR6k4dWRy8N7dcDYa0ba/ukxmNsVr/ANmoD6fhU8enyY+Rl/KudnYnYqW/iFogA8b/AJVfj8TxkD91Jn1xUcmlykcsg/Cq8Gj3E1wFSYKncgVNgvFmqnifjiCUn6U4+IppTtitXZvc1t6R4ftlVfMUyN6tXTWmi20abliQfQUrXE+VdDgE/tq94igEQPc1ftPCN7dHN/duQf4UOK76KyjwMcVZEWzv+lNKxDl2Od0vwlp9phlt1Z/7zcmt6GyRF2hAAPQVZiBDVMDVXsc8k2ym1qpXG0Vj6rpVvMCJIkYH1FdIw4qpcx5FHMyVGx5fr3gi0uVZoV8tjXmPiHQ9Q0WVjG8iqO6mvou4j+U8Vxviu3jlt5FdAciqjJImabPAv7ev4yVkdZAP761LH4gYHJjKH1Q1Br9qsF7KqjGDWRXeqcJK9jzHWqQdrnVJ4lOMF/zWpB4ghb7+0/jXIUUewiNYqZ2P9vQj7r4/GmN4kC9HzXI0UewiDxdQ3b3X5JhhSxrLlvJpOrkfSq1FaKCWxjKrKW7FLZOSc/WkooqjMXJpdzDufzptFAEnmyf32/Omlmb7xJ+tNopWGLRSUtMRr6HrMumzDkmLPI9K9R0TVVvYlkgcH2JrxetPQ9Wm0u6DoSYifmXP61z1aPNqtztw2KdN8stj3WBmZA3Stayn+XbnkVxOja7FdWweNwVatqC+XAIPNcLVj3YTUkdbFcAD5j+FWYbgdAa5Rb1SmQ3NXba+BA5qbmq2OkE3oajkmPc4rMF4McEVHJdDHJ5ouJkl828Me/Y15H8QI1F1FIOGyQR6+9ej3t7sjOCK8p8X3wu77apBC8nHrW1BNzTR5+Na9m7nPk0UcUvGK9E8IbS0HpSAUAGaVcUmKOlAAetIaXvSGgR9BaFIEhITjBNXbq4CRkk81jafLs3gYA3Gq2tagIoHYnAArypPQ+rtzM5bxtetdTJaxnOTk4o0rShFbguvJFGiafJqF493KDtJ4zXWi1CJginHRFtJuxyz2nkvujXA7itK1lBQeoq/NagjpWHfObOQkfdovfQiVPl1RtGZCvzVCbkJyh4rPs3e8XKKcetTS6VcMpMbEVL3HFXWhZhne5fDHCV0ekwLgHFcjZ+baFUnBBB6+tdbo0oYDmo6lqOlzprYpGoyKvw3acAVRgUSRDNSxWw3ZGcfWqVwSi9zSjk9OlOLHHXOfao441VCeePenAYAwSD702YySuWI2GAOhqQdOuag3YHPNSRk7qkxaHk80yccZqUL+dRTAlcGgmxlXPQ+lcxr6AwOSOvFdPecHiud1sDyWPfFMUkeA+MrcRX75HWuTbGD612/jtQJy3+1iuHkHznHSvRoO8Tx8SrTY2koorc5wooooAKKKKADNLSUUALSCiigBaKSloAKKKMUAFFFFAFzT9QnsZN0LHHdexrqtO8VKQFkJVveuJorOdKM9zeliJ0tmepW2uhsHIP0NadtrK56149HNJGQY3ZSPQ1bTVbtBjzMj3rCWG7HdDMrfEj2WLWV7tTZtcUAnI/OvIl1m67sKlXUJpRh5Dio+qst5lHsdjrXiNnVo4DljxmuUdmZiTyTyTTVbNPIrpp01BaHn168qzuxlJ2pxFBFaGA3NLRjmkC0AFJingcUY4oAZSU7FGOKAPW7O7AVjnPJqldLJq18ltHnywcuRVKyMsz+XEMsxwBXe+GNFFrFucZduSa8q1z6iU1EfpunfZbdVUYAFSS25zk9K3JEAAUDGKrXMRI4pyZVLuzDuIcLkVy+p25ubpYQOp5rsLhWC4zxWVp9r5mou5HTgVm3qdHQm06wS3iVVXAA6VqR25PbirsVsBjA5qyIcY9KRmY9zpcdxGQyispYJ9MmyctD6+ldn5Y280j2iyJgqCDSsNStuVNMvlkjGDmtiCdAOeK5650mWBjJZfK39zsab9pnhUfaI2Ujv1FNStuS4p7HVtJuX5CRmgs2OTWJaagjoMMDWkswmXg9aG7kONiZJyXHNaVt8wyBmsyIKp7H2q7EWQDGdvpQjOduhcA9PyqvORyc4xUyzrt4/Oq03zEmqsY6mddYboa57VeUYV0NyuAc1gaqBsJoQpHifxEiwzFR0rz1+TXqvxAhDRScc15qLfctd+GfunlYtWnco0Vaa2PaozAw7V0nIQ0VIYm9KTy29KAGUVKsLHtUyWjE80XAqUuDWitn608Wi0AZeDSYrW+yLQbFcUAZNOAJrS+xCnpZgUgKMUBanPAQK1EiC02WLIoAxXXBptW7iIg1VIxTASiiigAooooAKmik2moaWgDUglBq2rZFY8DnIrSgbK0hk2eaM0YFFACMOaM8Uu2mkUAKDQelIaKYAKXIxSDpSUgPafDunx211IxALZ4z2ru7QoqgelcU1wLW8LbTtbuK6DT71HXOcg15XNofRyi+a5ssM5Yc1G8fyEmovPBTg9TUySbl5OeKm5qmZF4u3PHSo9CtwxaQjqau6lzHtUctxVjT4PKgCjtWd7s2b0LIQL0HWlYcDpTiRsyTzmlmcGMbaomOgxsMMDr1p0cwVQOKhdtqgk1A5GeKdymky+1zGxpj+XMhBwc+tUigAyO9IH2cCk5EcqWwiaTb5fYu09cg0+1tntnIYs6Z4JqRJ8c5p/2wgHBBzUNIHJlhnKMO3GQKtR3PmLjBGPesbzi0gzzV+GZVPzIeelaImUTSt2Bb5xUk77U46VVhmRgB3FE8oYYyaZjJakF02Rgd6wtSXIOa1p2fHA4rMugChJpEs818bwB7WQ45IryyPhiD616341YLbvjpivJR/rW+tduF2Z5mNWqY8gUpQHtSilzXYcJH5a+lKIlI6U6ngcUgIwijsKd9Kd2oAAoABSjFJjNG0igAxTh0puDmnAUAJjNKFpQCaXkdaAGHNHWndaQigCKWIMKzriAgnitgHiopIw46UAYLKQabWjPbHnFU3iZe1AiKilINFMBKKKUAmgB8X3q0rc1St4yTWjFHikBNzRS44pKBig0jUpFIKAAim1JgYpMcUAMxRilo60Ae9XdvubJHAqgheCUeWevatyTLKaznizcqB6147Pp07lqC7ygVuGrXs5gygetY11a/JlfvCmWV40LhZMg+tS9xrVHSeUGl3HtwKsNhVxWMt9nGGqb7WCPvVKKSZcdwp7/jTJZuAKpNcZNMacGqNC8zZQYpg+Yc1VE3HWnrKMU7EuRZDYGKrOcMcmk83nFMZ8jrQ0TzWEZnJ9qFyGpVJC54pFkG485oUQcy3B245qyHXpg5HNZs1wEAPApDeqoHzE5qjNzNqKcAZBpZLktyD+Nc3Hf4kYdu2ac2o9iwxQRJ6mzJcr03ZrK1O6CRMQaz7vUUjQsHHFcfr3iAurKhwB1NNRbMZSMvxfqPml1zxXBx/M7EdzU+uag0jkBslqqWhyK9ChDlR5eJqc8rIsjilNFIK3OYUA0+mc0oNIBaACaQ0q5oAUCnDmkpRQAAU4im0Z9aAHUGmlqUHNAB1oPFKOtKaAGjpRminDgUANK561G0Kt1FTUbaAKMlmp6VC1j6VplaMUgMr7Cakjscda0ScUhzimBBHCqmptvHFJ0NHNAAV4pNuBS80hBxQAoORSEcUDilJoAZyKMjFOzTcUAGR6UopdoxS7R2oA+hZwUBY4wKhtUPmb3GWPQVoS25b5nHHYVHgKw46V459KmrEVwfl6HNVZbQTJyOetXJhnkdqbb5bIHpUvUa0Rg3EU9t8wJZBSwXjMvWtuSMMpDDqK5+7hFnKSR8hP5UkaxqFyO4ZiBVlGyKyI7yMHjFWVvUI4PFWkDmai8jrTxmsxb1PWg6gBxnFMxczSc4phlwPesmTUlB+9VSfVUB+9TsZuob7zHBBPFVftYTd8w/OuWutbQZ+esW78QbQcNVqDZnKqkdtdahuU8jjmqTatHt/wBYPfmvPLnxG5yMk1my6wzNlQfpWiotmEsVFHo82tKsh2tkYrOvNbfrEfzrhLjXpAuFXms2fVrmXPzYFaRw7e5jLGJbHYX/AIiYghn59Aa5u/1dpc859AKxnldz8zE0yt40VE5p4iUx7yNJJuY81oWR4FZq9a1LNeK1MC2Bk0p4oAAoPNIBM+lLyaAOafQAwCnqPWjiloAXjNJkCmHg0bsnpQA8HikHJoHIpygCgA2Zp3AGKM0jD0oAOlHNJj3pc0AAoIFIeadjigBnNO696COKMYFAAM07FJk0ucUAJig5oLcUgJNADG4NKDS9+aXHegBM8UUYpOPSgAI5oKmjjNLmgBhWjFL3pDQAuDijJxS5wKaOaAPpl2Lck5FVzxuNS53cDrUcnGMnFeQz30yvJ0IzjNRxfIq+oqbb3PWq0j1JonfQkkYcgnGDWbfhbiFkIB7VO7cEsOTVZ3AQ9OaLXK2OUu7KWNj9nc7v7prIuNSuLIkToy11UjAThvQ1V1pIZoDuUHI9KcfMyqNrY5ZvE4HG6on8SkjrXM+JLMQS74shT6Vg+Y/9413QoRkro82pipRdmd2+vk5+f9aoz64efmzXJeY39403J9a1VBIxeJkzoJ9Wkk4U4qlJM8nLMazQxHc0vmN61ooJbGTm3uXfqajllVRgcmqu5j1JpKdiBXYscmkoopiCilVSelWIbVm6jigBtvGWataFQqCo4YRGKnGfSgYUCkxSjigBwpwGaaKcDikAYp3akBo70AAUd6CoB4pecUUAGKcAAKQUGgA6mlx70ClFADPrSnpxSHrTkPHSgAUEijGKCeaTORQA6kLcUoHFNZcd6AAH0pC3tSinEA9KAGhvajd6CndDQMUANDClLDFNxk04gYoAaSKTIo60negBRjvSkU3Gadg44oAQAUhApQDSYoAOaAuaO9BNAH0gJMDryaafXPNRBgDx07mlclvu15DPfsRyO3rTPLAG5utOwq9TkimM5bgDrSL1K0o3sQOg71mXzYUgVsSjahA61gaox5C9TQVF3Mxp85JPTiqOrXgEIGeaZfsbdPQ9TXPvcm7usZ+Qda0hG7Ma07EOqW/2iE5HUVxdzEYpWU9jXoUjIykcYFcbrUe65JQcGu2k7Ox5VdXVzKoqTyW9Kctu57V0HKQUuKupZnHNTJbKBzQMz1jY9BT1t3PatRUUDgU4AUAZotHNSJZ4+9WgOKTNICGOBVHSp1HoKVRTwMDgUAIPenUdqQAmgAzQacFpcUANGB1oyDTsA0oXFACACnDGKGA4pAB2oAKUAYoC80beetAB/OlAo24Oc0v40AGDRjikJPSjtQAYzQBik57Uc0AOKZpFTmkBY05aAA8UmCe1OI4pVyBQA3AHalyKUnJpMc0AIcU3FPYZoAA60AMFKBx1owMmg4AoAMUhTFKCCetBoAYOKfuyOKaRnjNLtwOtAA2KacilC+9I6nqKAEzSGl2kc0nNAH0RHgjAGMd6exHAWqqy/KAOp6AVKp8oEk/N/KvKaPfJHQIvzYz1xUanAzjBNKp43P36D1qGWYCpHciu2wOOprMnh2q0knU9BWuqDHmSdO1Yms3ShWORihqwKRxfii4CJJ9K5S3mKjjljVvxPfebOUU96boluGYPJ+ArrowtHU4a9S8rImjguZVG75VNUNYt1gdV611DsqjAxxXI6/cCS8CjtWsfi0Oer8JU2j0p4AFNU8UueK6DlHDmjFNGaeDg0AAXFLjnikJzQM5pAOxkUoHFJmlAoABxSgmlGAKMigBSaXOKaeRQOaAH544pM0nNLQAZpc8U3GTS7cUALnnmlUjNAI9KBQA4Glx70zNLuoAeOtGKbnvShvagANAyaXcMdKduAFAEbAinK2R0phYE805W9KAFI44FNGQaduxS53UAAJNFI/AwKRT60AKTijdmlwMUm3NACg8U0mnFcU3bzQAje1N+tPIzQRigBnQ0uM8040g4oAacCkGTTjzSCgBR2pCeevFB600igBxGaRuOlKvSgn1oA92WRI8Acmpg4Ub3OSegrGhdsbic0ye8Ydq8pnupmrNdqoyT9KrecCfMkOB2FZnmkjzG5x2rG1bV5FBCg0WGb2p62Nu0MOmOK4jxBroCFVPNZOo6nJgnnJrnZ5Xmfc5zW1OjzO7OatiFBWQ7e08+5jnJrctZfLQVhwnaatG52IWIJxXW10Rwxl1ZrXV8IoGZj2rkzKbi6LnuaS9u3uG5JC+lLZR85NVCFtTOc+YvAcCnCmmnDkVZAYp1N70o60AKBS4pQOaDQAqilwaQH0pNxoAcQQM0KCTQCcUobmkA7bS7aaGp244oAXHFKq8U3cRShjQAHiimmlHNAC4xThim4xS49KAACjGaToacT2oAQ0ozTcHPWng4xQAnXjFL7UpOKN2e1ACFOaXbjtRvOacz8UAN4J5pTj1pKSgAP1pSKXHFAA60AN5o5J4peuaTFADjnijjvTSDjOaCM0AOXmmuPenKpAxmmsDnrQAgyBxTcnvT8nFIM0ANDUueaCKFPPNACZ5oPNAOSaO9ACHpTSOaex44po9aAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A \"mallet finger\" is a finger injury that makes the finger tip stay bent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_48_4879=[""].join("\n");
var outline_f4_48_4879=null;
